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Abstract 
Thrombin-activatable fibrinolysis inhibitor (TAFI) prevents the breakdown of 
fibrin clots through its action as an indirect inhibitor of plasmin. Patients with 
abdominal aortic aneurysms (AAA), in common with a number of cardiovascular 
diseases, display an altered fibrin clot structure, with denser clots that have 
smaller pores and an increased resistance to lysis. Murine studies have 
implicated a potential role for TAFI in AAA disease. This study aimed to 
investigate the role of TAFI in human AAA, and to complement this with an 
investigation into the effect of TAFI inhibition on AAA development and 
progression in-vivo. 
By measuring the plasma levels of TAFI zymogen, activated and inactivated 
TAFI, and the TAFI activation peptide in plasma samples, and using clot lysis 
assays to determine in-vitro TAFI activity, this study indicated increased 
turnover of TAFI in patients with AAA. Further to this, it was determined that the 
delay in lysis previously demonstrated in patients with AAA could be corrected 
through the inhibition of TAFI.  
Inhibition of TAFI in-vivo resulted in a decrease in mortality in the Angiotensin II 
model of AAA. The site of action of the inhibitor determined the effect on AAA 
formation, however, with inhibition of plasmin-mediated TAFI activation resulting 
in a decrease in AAA formation rates, whilst inhibition of all active TAFI resulted 
in an increase in AAA formation rates.  Delayed TAFI inhibition following the 
formation of AAA had no effect on AAA progression.  
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This study demonstrated evidence of increased TAFI turnover in patients with 
AAA, whilst in-vivo studies indicate a role for TAFI early in the development of 
AAA disease.  
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Cardiovascular disease is a major global health problem, accounting for almost 
a quarter of all deaths, or 160,000 deaths per annum, in the UK alone (BHF, 
2014). Despite technological and scientific advances in the prevention, 
diagnosis and treatment of this disease, its prevalence continues to increase 
both in the western world, but also in developing countries. One type of 
cardiovascular disease which remains poorly understood is Abdominal Aortic 
Aneurysm (AAA). The multi-faceted pathogenesis of this condition has meant 
that research into potential medical interventions for AAA have hitherto failed to 
make any significant advances, with surgery remaining the mainstay of 
treatment. Even with advances in surgical technique, equipment and materials, 
such that endovascular intervention has now replaced the need for open 
surgical repair in almost all cases, surgical intervention of any kind continues to 
carry significant risks of morbidity and mortality. Changes in coagulation and 
fibrinolysis are common to many cardiovascular diseases, although the 
aetiology of this remains poorly understood; in many cases, whether such 
changes are cause or effect is yet to be fully determined. In line with all 
cardiovascular disease, the fibrin clot structure is altered in patients with AAA, 
and they show increased resistance to lysis (Scott et al., 2011). This thesis aims 
to further explore 1) Why fibrinolysis is altered in patients with AAA, 2) The 
specific role of the fibrinolysis inhibitor Thrombin Activatable Fibrinolysis 
Inhibitor (TAFI) in these changes, and 3) The potential for new therapeutic 
interventions affecting fibrinolysis in treating patients with AAA. 
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1.1 Abdominal Aortic Aneurysms 
An Abdominal Aortic Aneurysm (AAA) is a permanent, localised dilatation of the 
descending abdominal aorta, exceeding the normal diameter by more than 
50%, or being greater than 3 cm (Johnston et al., 1991). It most commonly 
occurs in men over the age of 65 years, and affects up to 1 in 25 men in this 
age group (Collin et al., 1988, Ashton et al., 2002). In the UK, men over the age 
of 65 years are the focus of an abdominal aortic aneurysm screening 
programme, which was rolled out nationally in 2014, and invites all men to have 
a single ultrasound scan of the abdomen during the year of their 65th birthday. 
Interestingly, the detection rate of AAA in this screening programme has thus 
far been lower than anticipated, with a prevalence of just 1.4% of all men 
screened (NAAASP, 2014). This may be a reflection of broad lifestyle changes 
in the UK population, that is, decreasing smoking rates, and the increasing use 
of secondary preventative medications for cardiovascular disease, such as 
aspirin, antihypertensive medications, and statins. In fact, a recent 
observational study of AAA patients identified an apparently protective effect of 
both Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin 
Receptor Blockers (ARBs), with a reduction in mortality in patients taking either 
medication, and a decrease in the need for surgical intervention in those taking 
ACE inhibitors (Kristensen et al., 2015). Despite lower than expected detection 
rates, the screening programme remains cost effective (Glover et al., 2014), 
and so looks set to continue. This is because the implications of ruptured AAA 
remain serious and significant. The natural history of an untreated AAA is 
rupture, the risk of which increases significantly with increasing size (Brewster 
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et al., 2003). There are no medical treatments which can be used to prevent 
AAA formation, or to halt or slow progression once an AAA is established. 
Currently, the only management available is surgical intervention, which is 
offered electively once the AAA reaches the intervention threshold, dependent 
upon anatomy and pre-existing co-morbidities. The current intervention 
threshold is set at 5.5 cm, where the risk of rupture each year exceeds the risk 
of mortality from elective repair (Filardo et al., 2012). AAA rupture occurs when 
the stress on the aortic wall exceeds the wall strength. Ruptured AAA is 
associated with significant morbidity and mortality, with two thirds of patients 
dying before they reach hospital, and a mortality rate of 40-50% in those 
admitted for emergency treatment (Dillavou et al., 2006, NAAASP, 2014). 
Despite the introduction of the national screening programme, ruptured AAA is 
still responsible for over 6000 deaths per annum in the UK alone (NAAASP, 
2014). 
There are a number of established risk factors for AAA, including smoking, 
hypertension and male gender. Unlike in ischaemic heart disease and stroke, 
diabetes mellitus has been shown to be protective against AAA (Lederle et al., 
1997), although the mechanism by which this occurs is not fully understood. 
There is also a strong suggestion of a genetic component, with a proportion of 
patients having so called ‘familial AAA’, recognised in those patients with one or 
more first degree relatives also affected by the condition. The incidence of 
familial AAA has been shown to range between 8% and 18% (Kent et al., 2010, 
Larsson et al., 2009, Linne et al., 2012), with the risk of siblings of patients with 
AAA developing an aneurysm being anywhere between two and five times that 
of the general population (Blanchard et al., 2000, Salo et al., 1999). The exact 
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mode of inheritance has not been established, and although a number of 
candidate genes have been investigated, no individual gene has accounted for 
the apparent familial presentation (Sandford et al., 2007). Genome wide 
association studies identified the genes for low-density lipoprotein receptor-
related protein 1 (LDLR-1) and sortilin-1 (SORT-1) as being of potential interest, 
but these alone do not explain the incidence of AAA in the general population 
(Bown, 2014, Bown et al., 2011, Jones et al., 2013). Clearly, AAA disease is 
complex and multifactorial, and is likely the result of the interplay between a 
number of factors, both genetic and environmental.  
1.1.1 Pathophysiology of AAA 
How and why AAA formation is initiated in not understood. Histologically, there 
is degradation of the tunica media, with elimination of elastin and collagen, 
along with smooth muscle cell loss (Thompson et al., 1997), infiltration of 
lymphocytes and macrophages (Rizas et al., 2009) and neovascularisation 
(Thompson et al., 1996).  Matrix metalloproteinases (MMPs) and other 
proteases are derived from macrophages and aortic smooth muscle cells, and 
are secreted into the extracellular matrix. This proteolytic activity promotes the 
deterioration of the elastin and collagen which normally gives the extracellular 
matrix of the aortic wall its structure and strength. Increased expression of 
collagenases MMP-1 and MMP-13 and elastases MMP-2, -9, and -12 (Annabi 
et al., 2002, Curci et al., 1998, Knox et al., 1997, Mao et al., 1999, Reeps et al., 
2009) have been demonstrated in human AAA, and their role in AAA 
development have been further explored using animal models (Pyo et al., 
2000). Another mechanism of interest relates to inflammation and immune 
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responses. An extensive transmural infiltration by macrophages and 
lymphocytes is present on aneurysm histology, and these cells may release a 
cascade of cytokines that subsequently activate a number of proteases. The 
trigger for the influx of these leucocytes is not known, although it is 
hypothesised that elastin degradation products within the aortic wall may act as 
a chemoattractant (Ailawadi et al., 2003).  Deposition of immunoglobulins into 
the aortic wall has been demonstrated, and is thought to support the theory that 
autoimmune reactions could contribute to AAA formation (Brophy et al., 1991, 
Jagadesham et al., 2008). Another area of focus in understanding AAA 
pathogenesis relates to the biomechanical stress on the aortic wall. The 
reduction in elastin and increased deposition of collagen in the wall of the 
aneurysmal aorta results in a stiffer, less distensible vessel (He and Roach, 
1994). The stress on the aortic wall is not only related to diameter, but also to 
asymmetry (Vorp et al., 1998), likely due to an increase in the turbulence of 
arterial flow. The presence of an intra-luminal thrombus also has a significant 
effect on the wall stress, altering the stress distribution, and has been shown to 
have a ‘cushioning’ effect on the underlying aortic wall (Wang et al., 2002). The 
intra-luminal thrombus is discussed in more detail below. A schematic 
representation of the processes involved in AAA development can be seen in 
Figure 1. 
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Figure 1. The Pathogenesis of Abdominal Aortic Aneurysm 
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A. The structure of the normal aortic wall, with the three main layers (intima, media and 
adventia). A well-organised structure of collagen, elastin and vascular smooth muscle cells are 
present. 
B. Following insult or injury to the endothelial layer, either as result of, or in combination with, 
established risk factors for AAA, leads to the recruitment of macrophages and lymphocytes into 
the aortic media, and the production of pro-inflammatory cytokines. Activated macrophages, as 
well as producing inflammatory cytokines also produce pro-MMPs, which are activated to MMPs 
in the extracellular space. These MMPs are responsible for elastin and collagen degradation. 
Over a number of years, elastin degradation, elevated wall tension as a result of hypertension, 
and wall strain due to turbulent flow result in progressive aortic dilatation. Smooth muscle cells 
and fibroblasts in the aortic media promote some repair, resulting in the laying down of a 
disorganised collagen network, but overall smooth muscle cells become senescent and 
numbers deplete due to apoptosis.   
C. The structure of the aortic wall in advanced AAA disease. The medial layer is thinner, with 
apoptosis and senescence of vascular smooth muscle cells, elastin breakdown and disordered 
collagen deposition. Inflammatory cells remain present within the wall, indicating a potential for 
an autoimmune element to AAA disease. 
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1.1.2 Intra-Luminal Thrombus 
Larger aneurysms are often accompanied by the presence of intra-luminal 
thrombus (ILT) (Vorp et al., 2001), with thrombus being found in 75% of AAA 
(Wang et al., 2002). Historically, it was thought that the presence of ILT may 
serve as a protective mechanism against rupture, as it has been shown that the 
presence of an ILT alters the wall stress distribution and decreases peak wall 
stress (Inzoli et al., 1993, Mower et al., 1997, Wang et al., 2002). Aneurysm wall 
that is covered in thrombus has been shown to have decreased tensile strength 
(Vorp and Vande Geest, 2005), and histologically is thinner, with a reduction in 
elastin fibres and vascular smooth muscle cells (Kazi et al., 2003).  The ILT is 
not a static structure; it is biologically active with constant remodelling of the 
luminal surface. In-vitro studies show active secretion of proteolytic factors, 
which although more active at the luminal surface, are still thought to contribute 
to the breakdown of the underlying vessel wall (Folkesson et al., 2011, Houard 
et al., 2007, Fontaine et al., 2002, Coutard et al., 2010). High levels of both 
plasmin anti-plasmin complexes (PAPs) and D-dimer, a plasmin mediated fibrin 
degradation product, are found within the ILT, the concentrations of which 
increase with proximity to the luminal layer of the thrombus, indicating ongoing 
remodelling of the luminal surface (Houard et al., 2007). A positive association 
has been demonstrated between ILT thickness, levels of smooth muscle cell 
apoptosis, levels of MMPs, and decreasing numbers of elastin fibres within the 
aneurysm wall (Koole et al., 2012). Increased concentrations of the 
plasminogen activators (tPA and uPA) have been demonstrated in AAA wall 
compared with normal aortic wall, and plasmin itself is a key activator of MMPs, 
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suggesting that production of plasmin by the ILT could be directly responsible 
for the activation of MMPs within the aneurysm wall, leading to increased 
breakdown of collagen and elastin, and acceleration of aneurysm expansion 
(Carrell et al., 2006).  In addition, the ILT is thought to have further indirect 
effects on wall weakening, through local hypoxia related to thrombus thickness 
(Vorp et al., 2001). Observational studies have reported significant associations 
between the size of the ILT and both the rate of expansion and the risk of AAA 
rupture (Wolf et al., 1994, Stenbaek et al., 2000). In addition, a faster growth 
rate of the ILT itself is indicative of a higher risk of AAA rupture (Stenbaek et al., 
2000). These findings, however, are merely the result of clinical observational 
studies; the mechanisms behind the association between ILT and AAA rupture 
have not been fully explored. What is clear, however, is that as the ILT is 
usually found at the point of rupture of an AAA (Simao da Silva et al., 2000), 
any biomechanical protection on the underlying wall offered by the ILT is far 
outweighed by the negative impact related to the increased proteolysis and 
hypoxia it is responsible for. 
The main constituent of the ILT is fibrin, which is produced as a result of the 
coagulation cascade, in association with platelets, erythrocytes, leucocytes and 
neutrophils. Both macroscopically and microscopically, the ILT has three distinct 
layers. The luminal layer, which appears red, and is the main location for 
protease activity; the medial layer, which is white/yellow in colour; and the 
abluminal layer, which is dark yellow/brown. A continuous network of 
interconnected canniculi transverse from the luminal to the abluminal surface, 
and thus allow for the progression of proteases and other substances through 
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the ILT (Adolph et al., 1997). The ILT itself is also fluid permeable, with fluid and 
other small molecules passing through the thrombus network. 
1.2 The Coagulation Cascade 
Thrombus formation is the end point of a series of enzymatic reactions and 
protein interactions, commonly referred to as the Coagulation Cascade. Prior to 
formation of fibrin within a clot, primary haemostasis, resulting from the action of 
platelets, occurs, with the formation of a platelet plug. Secondary haemostasis 
refers to the formation of a fibrin scaffold, which is required to stabilise the 
platelet plug. This is achieved through the production of thrombin. In-vivo, there 
are two pathways which ultimately result in the formation of thrombin, and thus 
the cleavage of fibrinogen to fibrin. The ‘Tissue Factor pathway’ or the ‘Extrinsic 
pathway’, is the main pathway for the initiation of blood coagulation. Activation 
of the tissue factor pathway generates a ‘thrombin burst’, which ultimately 
results in platelet aggregation, fibrin formation and stabilisation, and the 
inhibition of fibrinolysis. The second pathway is the ‘Contact Activation’ or 
‘Intrinsic pathway’, which begins with the formation of a primary complex on 
collagen by high molecular weight kininogen (HMWK), prekallikrein and Factor 
XII (FXII). 
1.2.1 Primary Haemostasis and the Initiation of Coagulation 
Following injury to the vessel wall (either mechanical, chemical or electrical), the 
endothelial cells surrounding the damaged area are activated. Upon activation, 
P-selectin is released to the endothelial cell surface from the Weibel-Palade 
storage bodies (McEver et al., 1989). Vessel wall injury also activates platelets, 
with further P-selectin released to the surface of the platelet from within the 
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alpha-granules. The receptor for P-selectin, P-selectin glycoprotein ligand-1 
(PSGL-1), is held within the membranes of neutrophils and monocytes. Binding 
of P-selectin to its receptor thus aids the localisation of platelets and leucocytes, 
and thus thrombus formation, to the site of injury (Polgar et al., 2005). Alongside 
the release of P-selectin, von Willebrand Factor (vWF) is released from the 
body of endothelial cells and the α-granules of platelets. vWF has two roles in 
the initiation of coagulation; firstly, under conditions of high shear stress (as is 
found in arterial flow), vWF binds to platelet membrane glycoprotein Ibα and to 
connective tissue (collagen) exposed in the subendothelial matrix, thus 
supporting adhesion of platelets to the site of injury. Secondly, vWF binds to 
platelet glycoprotein IIb/IIIa, which enhances platelet to platelet aggregation. 
Tissue Factor is a transmembrane glycoprotein expressed on stromal 
fibroblasts and vascular smooth muscle cells. Tissue factor is exposed to the 
blood when the endothelium is disrupted and the blood comes into contact with 
these subendothelial cells. When Tissue Factor comes into contact with 
circulating Factor VII (FVII), it binds FVII, which undergoes auto-activation, and 
an active TF-FVIIa complex is formed. This complex then activates Factor X 
(FX) to Factor Xa (FXa). FXa then converts prothrombin to thrombin. This small 
amount of thrombin then propagates further thrombin generation in the 
amplification phase (Monroe and Hoffman, 2006).  
1.2.2 The Amplification Phase 
The trace amount of thrombin produced during the initiation of coagulation 
causes further activation of platelets, as well as Factors V and XI, to FVa and 
FXIa. vWF circulates in the plasma in complex with Factor VIII (FVIII). Thrombin 
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produced during the initiation phase of coagulation releases the FVIII from the 
vWF, and activates it to FVIIIa. Factor VIIIa binds with FIXa on the platelet 
surface, and this complex, in the presence of calcium, activates additional FX. 
FVIIIa-FIXa along with calcium are referred to as the ‘tenase’ complex. 
1.2.3 The Propagation Phase 
 The formation of the ‘tenase’ complex leads to large-scale generation of FXa, 
which binds to FVa to form the prothrombinase complex. In the presence of 
calcium, this prothrombinase complex results in the ‘Thrombin Burst’ which is 
responsible for the conversion of fibrinogen to fibrin. The thrombin produced in 
the propagation phase continues to activate platelets, FV, FVIII and FXI, and 
thus results in further thrombin generation. Furthermore, thrombin activates FXI, 
which through activation of FIX further contributes to thrombin generation. 
Thrombin also activates FXIII and Thrombin-Activatable Fibrinolysis Inhibitor 
(TAFI) (further discussed below), which, through different mechanisms, both 
result in stabilisation of the fibrin clot.  
1.2.4 Contact Pathway 
The contact pathway of coagulation was previously thought to be of little 
physiological relevance, as deficiency of the initiator of this part of the 
coagulation cascade, Factor XII (FXII) causes no bleeding phenotype (Ratnoff 
and Colopy, 1955). However, mice deficient in FXII do show defective thrombus 
formation, and show resistance to thromboembolism compared with wild type 
controls (Renne et al., 2005), implying that this pathway does hold 
pathophysiological significance. The contact pathway is initiated when FXII 
comes into contact with collagen, or other negatively charged substances, 
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underlying the endothelium in the damaged blood vessel wall. FXII is 
autoactivated to FXIIa, which subsequently activates Factor XI (FXI) to FXIa. 
FXIa activates FIX, which, along with FVIII from platelets, activates FX. This 
part of the coagulation cascade also forms an important link with inflammatory 
pathways. As FXII accumulates at the blood vessel surface and becomes 
activated, it also activates XIIa dependent prekallikrein. Kallikrein cleaves 
HMWK to release bradykinin, a potent inflammatory stimulus.  
Following activation by the contact or tissue factor pathways, the coagulation 
cascade is maintained in a prothrombotic state by continued activation of FV, 
FVIII and FIX, until it is down regulated by exogenous anticoagulants or by the 
fibrinolysis pathways. A summary of the tissue factor dependent coagulation 
cascade is shown in Figure 2. 
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Figure 2. The Coagulation Cascade – Initiation, Amplification and Propagation of 
Coagulation 
A. Initiation 
Exposed collagen and subendothelial proteins trigger the adhesion and activation of platelets. 
Tissue Factor, expressed on the surface of stromal fibroblasts and vascular smooth muscle 
cells, comes into contact with circulating Factor VII (FVII), FVII is activated, and together they 
form an active TF-FVIIa complex. This then activates Factor IX (FIX) to Factor IXa (FIXa) and 
Factor X (FX) to Factor Xa (FXa). FV is slowly activated by FXa, and, by the amplification and 
propagation phases, the Fva and FXa bind together to form the prothrombinase complex. 
B. Amplification 
The trace amount of thrombin produced during the initiation of coagulation causes the further 
activation of platelets, FV and FXI, which then activates FIX to FIXa. vWF circulates in the 
plasma in complex with Factor VIII (FVIII). Thrombin produced during the initiation phase of 
coagulation releases the FVIII from the vWF, and activates it to FVIIIa. Factor VIIIa binds with 
FIXa on the platelet surface, and this complex, in the presence of calcium, activates additional 
FX. FVIIIa-FIXa along with calcium are referred to as the ‘tenase’ complex. 
C. Propagation 
The formation of the ‘tenase’ complex leads to large scale generation of FXa, which, with FVa 
forms a prothrombinase complex. The prothrombinase complex, in the presence of calcium, 
results in the ‘Thrombin Burst’ which is responsible for the conversion of fibrinogen to fibrin. The 
thrombin produced in the propagation phase continues to activate platelets, FV, FVIII and FXI, 
and thus results in further thrombin generation.  
Adapted from (Wisler and Becker, 2012). 
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1.3 Fibrinogen  
Fibrinogen is the third most abundant of all human plasma proteins, secondary 
only to albumin and the immunoglobulins, and has circulating plasma levels of 
2-4 mg/ml under normal conditions. Fibrinogen is an acute phase protein, and, 
in response to pro-inflammatory agents such as interleukin-6 and other 
cytokines, expression is upregulated, gene transcription is increased and 
circulating plasma levels become elevated (Dalmon et al., 1993, Lane et al., 
1991). High plasma levels of fibrinogen are associated with cardiovascular 
disease (Danesh et al., 2005, Scarabin et al., 2003, Tatli et al., 2009), stroke 
(Danesh et al., 2005), peripheral vascular disease (Bartlett et al., 2009) and 
pulmonary embolism (Klovaite et al., 2013). Previous work from our group has 
also found elevated levels of fibrinogen in patients with AAA (Parry et al., 2009).   
Despite multiple studies demonstrating a link between high fibrinogen levels 
and cardiovascular disease, whether this association represents cause or effect 
remains a subject of debate. In fact, a recent multi-ethnic meta-analysis failed to 
show strong evidence of a causal association between circulating fibrinogen 
levels and cardiovascular disease (Sabater-Lleal et al., 2013). 
1.3.1 Fibrinogen Structure and Synthesis 
Fibrinogen is a large glycoprotein of 340 kDa, and is comprised of two identical 
subsets, each consisting of three polypeptides (Aα-, Bβ- and γ- chains), 
supported by a total of twenty-nine disulphide bonds. The six chains all 
converge in the central part of the fibrinogen molecule, the E-region, where the 
cleavage sites for thrombin are located (Henschen et al., 1983, Weisel and 
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Medved, 2001). Away from the central E-region, the Aα- Bβ- and γ- chains 
intertwine and form alpha-helical coil structures, which expand outwards and 
connect the E regions to two D-regions. The D-regions contain the binding 
pockets which are important in polymerisation of the fibrinogen molecule (Yang 
et al., 2000). Unlike the Bβ- and γ- chains, which end in the D-region, the Aα-
chain continues, and protrudes beyond the D-region, forming a long flexible αC 
region of over  350 amino acid residues (Tsurupa et al., 2009). The structure of 
fibrinogen is shown in Figure 3. Fibrinogen is primarily synthesised in the liver, 
where the chains are assembled rapidly in the endoplasmic reticulum, 
producing a complete molecule in as little as five minutes (Redman and Xia, 
2001).  
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Figure 3. The Structure of Fibrinogen and Convesion of Fibrinogen into Fibrin 
Fibrinogen consists of two identical subsets, each containing an alpha, beta and gamma chain. 
The molecules all converge in a central E-region, which contains the cleavage sites for thrombin 
(Fibrinopeptides A and B). The chains extend out of this central E-region through a coil-coiled 
region to the D-regions, where the beta and gamma chains reach their C-terminus. The alpha 
chain extends beyond this D-region, as the alpha-C chain. Thrombin cleaves Fibrinopeptide A, 
which exposes a binding site on the E-region which is specific for a binging pocket in the D-
region, allowing fibrin(ogen) molecules to come together in a staggered protofibril, with each E-
region bound to the D-region of two fibrinogen molecules. Cleavage of Fibrinopeptide B results 
in the exposure of a second binding site, and is associated with the release of the αC regions, 
the lateral aggregation of protofibrils molecules and fibrin fibre formation. Adapted from Bridge 
et al. Thromb Haemost 2014 (Bridge et al., 2014b).  
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1.4 Fibrin Clot Formation 
Soluble fibrinogen is converted to insoluble fibrin by the thrombin cleavage of 
two fibrinopeptides A, and two fibrinopeptides B, from the Aα- and Bβ-chains 
respectively (Cilia La Corte et al., 2011, Yang et al., 2000). In brief, this exposes 
polymerisation sites, results in a change in solubility, and causes the fibrinogen 
molecules to polymerise and form fibrin fibres. The first fibrinopeptide to be 
cleaved by thrombin is fibrinopeptide A, which exposes a binding site on the E-
region which is specific for a pocket in the D-region γ-chain. Due to the 
configuration of the fibrinogen molecule, with one central E-region and two 
peripheral D-regions, one fibrin molecule can bind to two other fibrin molecules, 
which in turn each can bind to another fibrin molecule and so on, producing a 
fibrin polymer, or protofibril, comprised of staggered and overlapping fibrin 
molecules. This is illustrated in Figure 3 (Ariens, 2013, Cilia La Corte et al., 
2011, Blomback et al., 1978, Weisel, 1986). The cleavage of fibrinopeptide B by 
thrombin occurs at a much slower rate compared to the cleavage of 
fibrinopeptide A. Cleavage of fibrinopeptide B exposes a second binding site in 
the E-region (which is specific for a different binding pocket in the fibrinogen D-
region β-chain), and also results in the release of the αC-region, such that this 
region of the fibrin α-chain becomes available for intermolecular interactions. 
These actions facilitate the lateral aggregation of the protofibrils into fibrin fibres 
(Weisel, 1986). 
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1.5 The role of Factor XIII 
Whilst the majority of the blood coagulation proteins are serine proteases, factor 
XIII (FXIII) is a transglutaminase, which, when activated, plays a vital role in 
stabilising the fibrin clot. This is achieved through its ability to covalently cross-
link fibrin, both to other fibrin molecules, and to proteins involved in the 
prevention of fibrinolysis, such as alpha-2-antiplasmin (α2AP). FXIII consists of 
two A subunits, which contain the active site of the enzyme, and two B subunits, 
which protect the hydrophobic A subunits. The activation of FXIII is a two step 
process. Thrombin first cleaves a 37 amino acid activation peptide from the 
FXIII-A subunit, before calcium induces dissociation of the B subunits, exposing 
the activated FXIII-A and producing the active enzyme (FXIIIa) (Ariens et al., 
2002) (Figure 4). Once covalently cross-linked by FXIIIa, fibrin clots have 
increased density, reduced pore size and thinner fibres, and increased 
resistance to lysis (Hethershaw et al., 2013). FXIIIa cross-links the α- and γ-, 
but not the β-chains, of fibrin. γ-Chain cross-linking occurs first, soon after 
protofibril formation, and affects fibre density (Duval et al., 2014). Cross-linking 
of the γ-chains occurs within as little as 5-10 minutes, with isopeptide bonds 
forming between Gln398 or 399 on the γ-chain of one fibrin molecule and 
Lys406 on the γ-chain of another (Purves et al., 1987, Spraggon et al., 1997). α-
Chain cross-linking increases fibre tautness, increases clot stiffness and 
reduces clot deformation (Duval et al., 2014), and, by reducing the accessibility 
of the coiled-coil regions to plasmin, plays an important role in the regulation of 
fibrinolysis (Gaffney and Whitaker, 1979, McDonagh et al., 1971, Mutch et al., 
2010b). There are many residues involved in α-chain cross-linking, with Gln221, 
Gln237, Gln328 and Gln366 in one α-chain binding to Lys208, Lys219, Lys224, 
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Lys418, Lys427, Lys429, Lys446, Lys448, Lys508, Lys539, Lys556, Lys580, 
Lys583, Lys601 and Lys606 of another (Lorand, 2001, Sobel and Gawinowicz, 
1996). Inter-chain cross-linking between the γ- and α-chain also occurs (Lorand, 
2001). Other proteins that can be cross-linked into the fibrin clot by FXIIIa 
include α2AP (Fraser et al., 2011), plasminogen activator inhibitor-2 (PAI-2) 
(Ritchie et al., 2000, Ritchie et al., 2001, Ritchie et al., 1999), and TAFI 
(Valnickova and Enghild, 1998), which serve to help stabilise and maintain the 
fibrin clot structure. α2AP is cross-linked to Lys303 of the fibrin α-chain primarily 
via one major site, Gln2, but also three minor sites, Gln21, Gln419 and Gln447 
(Lee et al., 2001). PAI-2 is cross-linked via Gln83 and Gln86 (Ritchie et al., 
1999). TAFI has three known amine acceptor sites (Gln2, Gln5 and Gln83) 
(Valnickova and Enghild, 1998), but the receptor sites on fibrinogen have not 
yet been reported. 
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Figure 4. The Activation of Factor XIII 
FXIII consists of two A subunits (shown in red), which contain the active site of the enzyme, and 
two B subunits (shown in blue), which protect the hydrophobic A subunits. Activation of FXIII 
occurs in a two stage process; thrombin cleaves a 37 amino acid activation peptide from the 
FXIII-A subunit, before calcium induces dissociation of the B subunits, exposing the activated 
FXIII-A and producing the active enzyme (FXIIIa).  
Modified from (Ariens et al., 2002) 
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1.6 Fibrinolysis 
Plasmin, generated from plasminogen by the action of tissue- or urokinase-type 
plasminogen activators, is the main enzyme responsible for lysis of the fibrin 
fibres in human plasma. The presence of fibrin enhances the conversion of 
plasminogen to plasmin by providing a catalytic surface to which both tissue 
plasminogen activator (tPA) and plasminogen bind. This co-localisation of 
plasminogen with tPA, to the C-terminal lysine residues of partially degraded 
fibrin, increases the catalytic activity of this reaction by over 1000-fold, with 
fibrin acting as a co-factor in its own breakdown. Fibrinolysis is largely inhibited 
by the inhibition of plasmin, which occurs directly, by α2AP, and indirectly, 
through the inhibition of plasmin generation, by plasminogen activator inhibitor-1 
(PAI-1) and TAFI. The fibrinolysis pathway is shown in Figure 5. 
Changes in the fibrin clot structure are associated with changes in rates of 
fibrinolysis; denser clots with smaller pores and more closely packed fibres lyse 
more slowly than clots with larger pores and more loosely packed fibres. The 
delay in fibrinolysis rates in densely packed clots with thinner fibres is likely due 
to a combination of mechanisms, including reduced permeation of the 
fibrinolytic enzymes into the centre of the clot, as well as reduced binding of tPA 
and plasminogen to densely packed, thin fibres (Longstaff et al., 2011, Mutch et 
al., 2010a). 
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Figure 5. Fibrinolysis 
Plasminogen is converted to plasmin through the action of tissue plasminogen activator (tPA) 
and urokinase-type plasminogen activator (uPA). Plasmin is the main enzyme responsible for 
the lysis of the fibrin clot. Fibrinolysis is controlled in-vivo through the inhibition of plasmin, which 
occurs directly, through alpha-2-antiplasmin (α2AP), or indirectly, though plasminogen activator 
inhibitor-1 (PAI-1) and thrombin activatable fibrinolysis inhibitor (TAFI). Adapted from (Bridge et 
al., 2014a).
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1.6.1 Fibrinolysis and AAA 
Whilst the presence of ILT is more often associated with large aneurysms, there 
is evidence for a systemic change in clotting in patients with AAA. A potential 
connection between fibrinolysis and early AAA development was highlighted by 
studying fibrin degradation products. Higher levels of D-dimer (a plasmin-
induced fibrin degradation product) were found in patients with small AAA 
compared to controls, suggesting that increased plasmin generation and 
fibrinolysis may be present even from the early stages of the disease (Parry et 
al., 2009). In addition, plasma levels of plasmin-antiplasmin complexes (PAPs) 
have been positively correlated with AAA expansion rates in patients with small 
aneurysms (Lindholt et al., 2001). The plasma levels of fibrinolysis proteins 
appear unaffected by treatment, with patients undergoing endovascular repair 
continuing to display high levels of thrombin-antithrombin (TAT), prothrombin 
fragments 1 and 2 (F1+2), and D-dimer up to 5 months after intervention (Bailey 
et al., 2013b). Patients undergoing open repair, however, did not continue to 
display high levels of these markers, suggesting that the ongoing presence of 
the ILT within the aneurysm sac, even when the aneurysm is stented 
successfully, continues to fuel the AAA related hypercoagulability observed in 
patients prior to intervention (Bailey et al., 2013b). 
1.7 Thrombin-Activatable Fibrinolysis Inhibitor  
Thrombin-activatable fibrinolysis inhibitor (TAFI), is a zinc dependent 
metalloprocarboxypeptidase with a molecular weight of 56 kDa (Bajzar et al., 
1995), and is intimately involved in the regulation of fibrinolysis and the 
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maintenance of thrombus stability. Identified in parallel by a number of groups, it 
is also known as plasma pro-carboxypeptidase R (Campbell and Okada, 1989), 
pro-carboxypeptidase U (Hendriks et al., 1990), and pro-carboxypeptidase B 
(Eaton et al., 1991). The TAFI pre-propeptide is a molecule of 423 amino acids, 
and is synthesized by the liver and by megakaryocytes. The two pools of TAFI 
show differing glycosylation patterns, confirming that the platelet TAFI is not 
synthesized by the liver, but is instead produced within the megakaryocytes 
(Mosnier et al., 2003). After removal of the secretory peptide, the proenzyme 
contains 401 amino acids, and circulates in the blood as an inactive zymogen. 
The majority of the TAFI in blood circulates within the plasma, with a small 
amount (<0.1%) being carried in platelets (Mosnier et al., 2003). TAFI is 
released from the alpha granules of platelets upon platelet activation, and is 
thought to complement the TAFI already in circulation, particularly in arterial 
thrombosis (Schadinger et al., 2010).  
The normal concentration of TAFI antigen in human plasma is between 4-15 
µg/ml, or 73-275 nM (Colucci and Semeraro, 2012). Antigen levels can also be 
expressed as a percentage compared with pooled plasma of healthy subjects 
(which is assigned a concentration of 100% or 1 unit/ml). Levels of TAFI are 
normally distributed (van Tilburg et al., 2000), the variation in levels between 
individuals is wide, ranging from 41-259%, although individual variations are 
narrow (Chetaille et al., 2000). TAFI acts under a threshold dependent 
mechanism; that is, once TAFIa levels reach the minimum threshold level 
(estimated to be approximately 8 units/litre, that is, approximately 1% of the 
total plasma antigen concentration), fibrinolysis essentially ceases until they fall 
below the threshold level again (Leurs et al., 2004). With such a low 
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concentration of TAFIa required to actually prevent fibrinolysis, it is possible that 
the thrombin burst generated during the propagation phase of coagulation could 
be sufficient to activate enough TAFI to exceed the threshold level.  High levels 
of TAFI (resulting in TAFIa concentrations which are persistently above the 
minimum threshold value) may lead to a hypofibrinolytic state, and an increased 
risk of thrombotic disease.  
1.7.1 Activation of TAFI 
TAFI is cleaved at Arg92  by either thrombin, thrombin-thrombomodulin (T-TM) 
complex, or plasmin, to yield the active molecule, TAFIa, and an activation 
peptide (Willemse and Hendriks, 2006). More recently, in-silico analysis has 
also revealed a second thrombin cleavage site at Arg12. The significance of this 
cleavage site has not yet been fully elucidated, although it has been speculated 
that cleavage at Arg12 may accelerate thrombin-mediated TAFI activation (Plug 
et al., 2014). TAFIa cleaves lysine residues from the C-terminal ends of partially 
degraded fibrin, eliminating the plasminogen binding sites involved in the fibrin-
enhancement of plasminogen to plasmin conversion by tPA,  thereby inhibiting 
plasmin generation and fibrinolysis (Bouma and Mosnier, 2006). This is 
illustrated in Figure 6. As a result of in-vitro studies, the major physiological 
activator of TAFI was, until recently, taken as being the T-TM complex, due to 
its 1250-fold higher catalytic activity compared to thrombin alone (Bajzar et al., 
1996). However, in-vivo, thrombomodulin is localised to the endothelial cell 
surface, and as such, activation of TAFI by T-TM could only occur on the 
surface of intact endothelium. As a clot forms and extends into the lumen of the 
vessel, away from the endothelial surface, other activators of TAFI are likely to 
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come into play. Indeed, recent work with monoclonal antibodies specific to TAFI 
have demonstrated that plasmin itself is a significant TAFI activator both in-vitro 
and in-vivo (Vercauteren et al., 2011, Mishra et al., 2011).  
Human TAFIa has a relatively short half-life in plasma of around 8-10 minutes at 
37°C, although until activation, TAFI is relatively stable. The stability of TAFIa 
certainly seems to be largely temperature dependent, as the stability of TAFIa 
increases to approximately two hours at room temperature, and at 0°C it is 
almost completely stable (Boffa et al., 1998). Murine TAFIa has a markedly 
reduced half-life of 2-3 minutes (Marx et al., 2000b).  
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A 
 
B 
 
Figure 6. The Life-cycle of a TAFI Molecule and The Role of TAFI in Fibrinolysis  
A - Following release of the secretory peptide (SP), TAFI circulates in the plasma as a 406aa 
zymogen. The intact TAFI zymogen is activated by thrombin, thrombin/thrombomodulin and 
plasmin. The zymogen is cleaved at Arginine 92 to release the active molecule (TAFIa) and the 
92 amino acid activation peptide (TAFI-AP). The active molecule is then inactivated through a 
conformational change in the dynamic flap region of the TAFIa molecule, before being further 
cleaved by thrombin. B –TAFIa cleaves the C-terminal lysine residues from partially degraded 
fibrin. In doing so, it removes the binding sites for the co-localisation of plasminogen and tPA on 
the fibrin clot. This co-localisation is responsible for increasing the catalytic activity of the 
tPA/plasminogen reaction 1000-fold. Thus, the action of TAFI results in the decreased 
conversion of plasminogen to plasmin, and thus inhibits the plasmin-mediated breakdown of the 
fibrin clot. Adapted from (Bouma and Mosnier, 2006). Electron microscopy images courtesy of 
Dr Cedric Duval, University of Leeds.  
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1.7.2 TAFIa inactivation 
TAFIa is inactivated by a conformational change, and is then cleaved at position 
Arg302 into an irreversibly inactivated molecule (Bajzar, 2000). Confirmation 
that the inactivation of TAFIa is the result of a conformational change rather 
than proteolytic cleavage came from studies of a TAFI mutant resistant to the 
secondary cleavage by thrombin (Arg302Gln mutant), that, following activation, 
displayed the same half-life as the wild type (Marx et al., 2000a). When the 
crystal structure of TAFI was first determined in 2008, it revealed a highly 
dynamic region consisting of amino acids 296-350 (Marx et al., 2008). This led 
to the hypothesis that the flexibility of this region induced a conformational 
change that subsequently eliminated the enzymatic activity of TAFIa. More 
weight was added to this theory through the study of TAFI molecules with 
mutations in this region. The naturally occurring polymorphism of TAFI, 
Thr325Ile, results in an increase in stability, with the half-life of the 325Ile form 
being double that of the more commonly occurring Thr325 form at room 
temperature (see below) (Brouwers et al., 2001). In addition, by creating point 
mutations in the region of amino acids 300 to 330, TAFI variants with 
significantly increased half-lives compared with the wild type protein have been 
produced (Ceresa et al., 2006b, Marx et al., 2004). Until recently, it was thought 
that the stability of the TAFI zymogen was related to the relationship between 
the activation peptide and the dynamic flap region of the TAFIa molecule. Prior 
to the cleavage of the activation peptide, these two regions lie in close 
proximity, and thus the activation peptide could stabilise the flexible region, and 
in doing so protect it from the conformational change that results in TAFIa’s 
inactivation. It was suggested that this stabilisation was the result of 
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hydrophobic interactions between Val35 and Leu39 in the activation peptide 
and Tyr341 in the dynamic region (Marx et al., 2008). However, this has 
recently been disputed, following studies of another TAFI mutant, which focused 
on the activation peptide itself rather than the dynamic flap region. The 
activation peptide of TAFI is made up of 92 amino acids. The first 73 form a 
globular domain which shields the catalytic domain of TAFI from large 
substrates. The remaining 19 amino acids link this globular domain to the 
catalytic region. A mutant of TAFI which lacks the globular domain, but not 
amino acids 74-92 resulted in a molecule that was able to react with small 
substrates in a similar way to activated TAFI, but which maintained the stability 
of the TAFI zymogen. It was only when the remaining 19 amino acids of the 
activation peptide were removed that the mutant became ‘destabilized’ in a 
similar way to active TAFI. It has therefore been suggested that it is actually not 
the interaction between Val35, Leu39 and Tyr341 that stabilises the TAFI 
zymogen, but instead the ‘connecting region’ of the activation peptide, amino 
acids Arg74-Arg92 (Plug and Meijers, 2015, Zhou and Declerck, 2015). A 
pictorial representation of the activation and inactivation stages of TAFI is 
shown in Figure 6. 
1.7.3 TAFI and inflammation 
Aside from its effects on fibrinolysis, TAFIa also exhibits anti-inflammatory 
properties. It inactivates the anaphylatoxins C3a and C5a, thrombin cleaved 
osteopontin (OPN) and bradykinin (Campbell et al., 2002, Myles et al., 2003, 
Shinohara et al., 1994). The action of TAFIa on these substrates is similar to its 
action on fibrin, that is, it cleaves C-terminal lysine residues from C3a and C5a, 
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and C-terminal arginine residues from thrombin cleaved OPN. The cleaved 
products have a much lower inflammatory activity than the uncleaved 
substrates. This suggests that TAFIa is involved in a homeostatic mechanism, 
whereby TAFIa, once activated by thrombin, is able to regulate thrombin’s 
inflammatory activity. C5a is a potent chemoattractant for neutrophils (Marder et 
al., 1985). Excessive C5a can have a negative effect, contributing to 
immunoparalysis and the dysregulation of coagulation and fibrinolysis. C3a and 
C4a are also generated when complement is activated, although their potency 
as chemoattractants are much lower than that of C5a. The role of TAFIa in 
relation to inflammation has previously been thought to be only relatively minor. 
Any activity it did have towards inflammatory substrates was largely masked by 
those of the only other known plasma carboxypeptidase, carboxypeptidase N 
(CPN). However, it is now known that TAFIa cleaves C5a, OPN and BK with an 
8.7-26 fold higher affinity than CPN, and this suggests that TAFIa does play a 
significant role in attenuating inflammation (Campbell et al., 2002, Myles et al., 
2003, Shinohara et al., 1994). This is supported by studies in a number of In-
vivo models. TAFI-/- mice develop a much more extensive C5a induced 
alveolitis than wild type mice (Nishimura et al., 2007). In models of rheumatoid 
arthritis, a primarily autoimmune disease, TAFI-/- mice develop severe disease 
which is abolished by the addition of an anti-C5a antibody (Song et al., 2011). 
Even in models of osteo-arthritis, a predominantly ‘wear and tear’ condition, 
TAFI was shown to be protective against joint destruction (Lepus et al., 2014). 
In human studies, patients with severe rheumatoid arthritis (RA), an auto-
immune inflammatory condition, were less likely to carry the TAFI 325Ile allele, 
and those with the 325Ile allele had a lower risk of developing the most severe 
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RA (Song et al., 2011). The majority of research into the links between TAFI 
and inflammation have focused on C5a as a substrate, as it is cleaved by TAFIa 
with a higher affinity compared with C3a. However, a recent study of a murine 
model of intra-abdominal sepsis in the TAFI-/- mouse revealed an important role 
for C3a rather than C5a, having shown an unexpected survival benefit in TAFI-/- 
mice compared with wild type controls, that could not be attributed to either 
increased C5a levels or enhanced fibrinolysis. The authors hypothesised that in 
TAFI-/- mice, the C3a is able to override the negative effects of excess C5a, 
exerting a greater protective effect, and causing an overall survival benefit. 
Differences in the effect of TAFIa in inflammatory disease in-vivo may be 
related to the site of the insult, and be related to the differing patterns of the 
receptors for C3a and C5a. C3a receptors are only found on peritoneal 
macrophages, with its primary role residing in the activation of peritoneal 
macrophages in order to limit dissemination of intra-abdominal infection. In 
contrast, C5a receptors are also expressed on neutrophils and other cell types, 
and thus lead to a widespread increased inflammatory response, which in the 
absence of TAFIa is allowed to propagate unregulated, and thus has a negative 
effect (Shao et al., 2015). 
1.7.4 Polymorphisms of TAFI 
The gene for TAFI is located on chromosome 13 locus q14.11 (Boffa et al., 
1999). Two naturally occurring single nucleotide polymorphisms that result in 
amino acid substitutions have been identified. The first lies at position 147 
where alanine is substituted for threonine (allele frequency 0.32-0.41) (de 
Bruijne et al., 2007, Morange et al., 2005, Verdu et al., 2008), although 
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functionally there appears to be no difference between the two genotypes (Zhao 
et al., 1998). The second lies at position 325, in the area of the gene that has 
been shown to be related to thermal stability (Boffa et al., 2000). Here, 
threonine is substituted for isoleucine (1040C/T, rs1926447), with an allele 
frequency of 0.28-0.30 (de Bruijne et al., 2007, Morange et al., 2005, Verdu et 
al., 2008). Unlike the Ala147Thr polymorphism, this Thr325Ile polymorphism 
results in a functional change of TAFIa, significantly prolonging its half-life due 
to increased thermal-stability (from 8 to 15 minutes in plasma at 37°C) and 
increasing anti-fibrinolytic potential by up to 60% (Schneider et al., 2002). 
1.7.5 TAFI and Cardiovascular Disease 
Other physiological inhibitors of plasmin, specifically PAI-1, are associated with 
an increased incidence of coronary artery disease (Scarabin et al., 1998), with 
polymorphisms that result in increased plasma PAI-1 levels being strongly 
associated with an increased risk of MI (Gong et al., 2012). The association 
between PAI-1 levels and MI may not be entirely genetically determined 
however, as PAI-1 plasma levels are also determined by insulin resistance 
markers, such as obesity (Juhan-Vague et al., 2000). In contrast, plasma TAFI 
levels are only minimally influenced by traditional CVD risk factors (Boffa and 
Koschinsky, 2007). A number of studies have investigated associations 
between TAFI levels, the Thr325Ile polymorphism and cardiovascular disease, 
most commonly focussing on coronary artery disease and stroke (de Bruijne et 
al., 2009, Fernandez-Cadenas et al., 2007, Kamal et al., 2011, Kozian et al., 
2010, Morange et al., 2005, Segev et al., 2004, Tassies et al., 2009, Zorio et al., 
2003). There is significant variability in the reported findings of these studies, as 
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is discussed in the following paragraphs. The reasons for some of this variability 
may be related to the difficulty in accurately measuring TAFI levels in plasma. 
Enzyme-linked immunosorbent assays (ELISAs) for TAFI use antibodies 
specific to TAFI or TAFIa. However, due to its intrinsic instability, measuring 
TAFIa in such a way is complicated. Also, many of the antibodies used for such 
ELISAs are unable to distinguish between TAFIa and TAFIai (Heylen et al., 
2011). The majority of ELISAs are not able to distinguish between the different 
TAFI Thr325Ile isoforms (Schneider et al., 2002). Assays to target TAFI activity 
are also variable and not without problems, specifically due to the interaction of 
other plasma carboxypeptidases in these assays. One vital component in TAFIa 
measurement relates to the processes around sample collection. Samples 
should be collected onto ice to minimise sample degradation, and centrifuged at 
4°C. The choice of anticoagulant is also important, as EDTA may interfere with 
TAFIa activity (Stromqvist et al., 2001). 
1.7.6 Coronary Artery Disease and Acute Coronary Syndromes  
Despite multiple studies, there is still no clear consensus as to the role of TAFI 
in coronary artery disease (CAD).  
Elevated total TAFI antigen levels have been correlated with both an increased 
risk (Kamal et al., 2011, Santamaria et al., 2004), and a decreased risk of CAD 
(Brouwers et al., 2003), whilst a number of studies have failed to show any 
relationship (Morange et al., 2005, Paola Cellai et al., 2006). For activated TAFI 
(TAFIa), there is also no clear association; low levels have been found to 
correlate with an increased risk of myocardial infarction (MI) (Meltzer et al., 
2009) whilst other studies have associated increased TAFIa levels with acute 
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MI in a young population (Zorio et al., 2003) as well as overall population levels 
of cardiovascular disease (CVD) (de Bruijne et al., 2009) and cardiovascular 
death (Tregouet et al., 2009).  
The Thr325Ile polymorphism of TAFI has been investigated as a potential 
marker of ‘high risk’ patients with CAD, but with conflicting results. Early studies 
suggested there was no difference in the genotype of patients with myocardial 
infarction (MI) (Morange et al., 2002). Since then, a number of studies reported 
‘high risk’ genotypes which seemed to vary with age (Zorio et al., 2003),(de 
Bruijne et al., 2009),  nationality (Morange et al., 2005),(Kamal et al., 2011), and 
disease sub-type (Tassies et al., 2009). A recent large meta-analysis of genetic 
variations in TAFI in all cardiovascular disease, CVD, (specifically 19 studies of 
Ala147Thr consisting of 4977 CVD patients and 8082 controls, and 15 studies 
of Thr325Ile consisting of 4890 cases and 8311 controls) found that there was a 
25% increase in the risk of CVD in those who were homozygote for the 325Ile 
allele compared with Ile/Thr and Thr/Thr, but no significant associations 
between the Ala147Thr polymorphism and CVD incidence were found (Shi et 
al., 2014).  
1.7.7 Stroke 
The association between ischaemic stroke and TAFI appears less controversial 
and more clearly delineated. The risk of ischaemic stroke is associated with 
increasing levels of both total TAFI and TAFIa (Jood et al., 2012, Ladenvall et 
al., 2007). In acute stroke, patients have significantly higher levels of TAFI at 
admission compared to controls (Rooth et al., 2007), with neurological deficit 
worsening as levels increase (Montaner et al., 2003). After the onset of acute 
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stroke, TAFI levels decreased over the first 72 hours, and then increased back 
to the baseline level by day 7, a pattern that became increasingly pronounced 
with stroke severity (Brouns et al., 2010). Furthermore, patients have been 
shown to have baseline TAFI levels that remained persistently higher than 
controls even at three months post-stroke, suggesting that the TAFI elevation 
does not merely represent an acute phase reaction (Leebeek et al., 2005, 
Santamaria et al., 2003).  It has been shown separately that thrombolysis in the 
treatment of stroke resulted in a decrease in TAFI levels, whilst high levels of 
TAFI prior to thrombolysis have been correlated with a decrease in 
effectiveness of re-canalisation (Brouns et al., 2009). Possession of the 
isoleucine allele at position 325 was associated with both the incidence of 
stroke and lower age at onset of first stroke (Kozian et al., 2010). In addition, 
when thrombolysis of the middle cerebral artery was attempted, patients with 
the 325Ile allele were more resistant to re-canalisation (Fernandez-Cadenas et 
al., 2007).  
1.7.8 TAFI Inhibitors 
Although there are no known physiological inhibitors of TAFI, there are a 
number of naturally occurring inhibitors. These include potato tuber 
carboxypeptidase inhibitor (PCI), leech carboxypeptidase inhibitor (LCI) 
(Reverter et al., 1998) and tick carboxypeptidase inhibitor (TCI) (Arolas et al., 
2005). These inhibitors have a biphasic effect on TAFI activity; at low 
concentrations they cause prolongation of clot lysis, whereas at high 
concentrations they cause an enhancement of lysis (Schneider and Nesheim, 
2003). This biphasic effect is thought to be due to a TAFIa stabilizing effect at 
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low concentrations (Walker et al., 2003). The potential correlation between TAFI 
and thrombotic CVD has lead to interest in TAFI as a potential therapeutic 
target for the treatment of atherothrombotic disease, with a number of potential 
molecular targets affecting TAFI activity identified (Gils et al., 2005). A series of 
imidazolepropionic acids were designed that exhibited high potency and 
selectivity against TAFIa, without affecting other circulating carboxypeptidases. 
These proved effective in rabbit models at an intravenous dose of 100 
µg/kg/min, resulting in increased thrombus dissolution (Bunnage et al., 2007). 
Further developments, giving rise UK-396082, lead to the characterisation of 
this inhibitor in rat models and humans (Owen et al., 2010). UK-396082 entered 
phase I clinical trials, but its development was discontinued in 2011 for unknown 
reasons. UK-396082 is a direct inhibitor of the active catalytic site of TAFI. Its 
chemical structure is shown in Figure 7. Another compound from Astrazenaca, 
AZD9684 (2-(6-aminopyridin-3-ylmethyl)-3-mercaptobutyric acid), progressed 
into phase II clinical trials, but its development was discontinued in 2007.  More 
recently, nanobodies affecting various aspects of the TAFI pathway, from 
activation of TAFI by thrombin-thrombomodulin to the action of TAFIa, have 
been developed with the ongoing aim to develop a pro-fibrinolytic drug (Buelens 
et al., 2010). Substrate specific antibodies to TAFIa have been developed 
(TCK26D6 and TCK11A9), which in in-vitro functional assays are able to inhibit 
TAFIa when fibrin is used as a substrate, but not when osteopontin is used as a 
substrate (Semeraro et al., 2013). These antibodies have been developed to 
target specific areas in the TAFI activity cycle. MA-TCK26D6 modulates TAFIa 
by impairing the activation of TAFI mediated by thrombin and plasmin. It 
specifically prevents the interaction of TAFIa and fibrin, but has no effect on 
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other small proinflammatory substrates, such as osteopontin (Semeraro et al., 
2013). 
 
Figure 7. The chemical structure of UK-396082 
UK-396082 is an imidazolepropionic acid, which is a known inhibitor of active TAFI (Bunnage et 
al., 2007).  
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1.7.9  TAFI and AAA  
The only study specifically focussing on TAFI and AAA in humans was a small 
cohort based study of patients with AAA which showed that the activity of TAFI 
was significantly lower in patients with AAA compared with control subjects 
(Dubis et al., 2014). The main association between TAFI and the development 
of AAA has been inferred through work in the TAFI knockout mouse (TAFI-/-). In 
a study by Schultz et al (Schultz et al., 2010), animals underwent porcine 
pancreatic elastase (PPE) infusion into the abdominal aorta. TAFI-/- mice 
developed AAA sooner, and produced larger aneurysms which were more likely 
to rupture than their wild type controls. By day 3 post PPE infusion at a standard 
concentration of 15 units/ml, 66% had ruptured AAA, compared with no ruptures 
in the wild type AAA mice. Such changes were not apparent in TAFI-/+ 
heterozygote mice.  
Furthermore, this group provided evidence for the role of plasmin in AAA 
development and rupture, as when TAFI-/- mice were given tranexamic acid (a 
potent inhibitor of plasmin formation from plasminogen), AAA formation was 
reduced and rupture was completely abolished.  
Whilst murine models have been used extensively for the in-vivo study of TAFI, 
it is not clear how applicable findings related to murine TAFI may be to human 
disease. The amino acid sequence of mouse TAFI shares >85% identity with 
human TAFI, and includes conservation of the residues involved in 
glycosylation, zinc binding, substrate binding and substrate specificity 
(Hillmayer et al., 2006, Schatteman et al., 1999). In order to be able to better 
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model the effect of TAFI inhibitors on human TAFI in-vivo, transgenic mice 
which are devoid in murine TAFI but express human TAFI have been generated 
(the hTAFI mouse). These mice show delayed lysis time in whole blood 
rotational thromboelastometry (ROTEM) studies compared with the TAFI-/- 
mouse, but an increased lysis time compared with the wild type mouse with 
mTAFI. In addition, male hTAFI mice express hTAFI at 3.5 fold higher levels 
than female hTAFI mice (Mishra et al., 2014). Whilst the reasons for such 
gender disparities in this model are unknown, this is akin to the gender disparity 
reflected in other cardiovascular murine models, including the Angiotensin II 
model of AAA (see below). 
 
1.8 Murine Models of AAA  
Three main murine models of AAA have been described in the literature. 
Daugherty and Cassis have provided a useful review of these models 
(Daugherty and Cassis, 2004). A brief summary of the main features of each 
model is given below.  
1.8.1 Elastase Infusion 
This model involves infusion of elastase into the infra-renal segment of the 
aorta, and is based on the role of elastin degradation in AAAs. Originally used in 
rats (Anidjar et al., 1990), it has since been adapted for use in mice (Schultz et 
al., 2010, Pyo et al., 2000). In this model, the murine aorta is exposed, and a 
cannula inserted at the iliac bifurcation. A ligature is applied proximally (distal to 
the renal arteries) and distally (at the bifurcation itself). PPE type 1 is infused 
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intra-arterially (at a dose of 4-5 units/ml), at a constant pressure of 100 mmHg 
for 15 minutes. The ligatures are then removed and the arteriotomy closed with 
a single suture. The infusion itself causes an immediate and sustained dilatation 
of the aorta due to the mechanical effects of the procedure. By day 14, mice 
infused with elastase show destruction of the elastic lamellae, and the presence 
of inflammatory infiltrate (mainly macrophages) within the adventitia (Daugherty 
and Cassis, 2004). 
1.8.2 Calcium Chloride 
Initially developed in rabbits, application of calcium chloride to the arterial wall of 
hyperlipidaemic animals promoted the formation of AAA (Freestone et al., 
1997). Adapted for use in mice, this method involves either placement of a 
gauze swab soaked in a calcium chloride solution, or direct placement of a 
concentrated solution (0.25-1 M), onto the infra-renal aorta (Chiou et al., 2001, 
Longo et al., 2002) for up to 20 minutes. This model also leads to structural 
disruption of the medial layer and inflammatory responses, but without any of 
the mechanical effects that are seen in the elastase infusion model (Daugherty 
and Cassis, 2004). 
1.8.3 Angiotensin II Infusion 
Subcutaneous infusion of Angiotensin II (Ang II) at doses of 500-1000 
ng/kg/min, via subcutaneous osmotic mini pumps, into either LDL receptor -/- or 
ApoE-/- mice leads to the production of suprarenal AAAs (Daugherty et al., 
2000, Zhang et al., 2012). This animal model is the only AAA model that also 
displays the sex dimorphism displayed in human AAA; that is, male ApoE-/- 
mice are up to 4 times more likely to develop AAA on infusion with Ang II than 
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females (Zhang et al., 2012). The pathophysiological mechanisms involved in 
aneurysm formation in this model have been studied by examining the aorta of 
ApoE-/- mice between days 1-56 post Ang II infusion. Within days of initiating 
Ang II infusion, there is macrophage accumulation in the media of the aortic 
region prone to AAA formation. Between 3-10 days, there is medial rupture, with 
dissection and dilatation of the aorta leading to haematoma/thrombus formation 
and subsequent inflammatory responses. This model of AAA formation is 
consistent with activation of an inflammatory response and the stimulation of a 
proteolytic cascade (Saraff et al., 2003), which then contributes to elastin 
degradation within the aortic wall. 
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Since its discovery over 25 years ago, Thrombin-Activatable Fibrinolysis 
Inhibitor has become a focus in the investigation of fibrinolysis in cardiovascular 
disease. Whilst a lot is already known about TAFI, there is still much to be 
established, both at a molecular level, and in relation to disease states. To my 
knowledge, there are only two previous studies that have investigated TAFI in 
relation to human AAA. The first measured TAFI zymogen levels using a 
commercially available ELISA kit in a small number of patients with ruptured 
(n=10) and non-ruptured (n=17) AAA. The validity of these results is uncertain, 
however, as the results quoted for TAFI levels in both groups were extremely 
high (in some cases >50 μg/ml), and fell outside the reference range of the 
ELISA (as quoted by the authors) of 12-20 μg/ml. No control group was 
included, and it is therefore unclear as to whether these values are a reflection 
of extremely high TAFI levels in patients with large AAA, or an error related to 
the assay (Hobbs et al., 2007).  The second study to date compared TAFI 
activity in plasma from patients with AAA (n=32) and control subjects (n=45), 
and, using a commercially available chromogenic assay, found a reduction in 
TAFI activity in AAA patients compared to controls (Dubis et al., 2014). The 
experiments described in the following chapters aim to further identify the role of 
TAFI in AAA. This will be achieved through the use of both samples from 
humans with AAA, as well as in-vivo models. 
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1.8.4 Hypothesis 
TAFI plays a role in the development and progression of AAA, and contributes 
to the alteration in the lysis of fibrin clots that has been demonstrated in patients 
with AAA. TAFI stabilises clot formation, and through the control of plasmin 
generation, regulates local proteolytic activity at the site of the aneurysm, as 
well as contributing to the systemically increased cardiovascular risk in this 
group of patients.  
1.8.5 Aims 
1. To investigate TAFI levels, TAFI activity and TAFI polymorphisms in 
patients with AAA in relation to AAA size, growth and clinical outcome. 
2. To identify other proteins, aside from TAFI, which are involved in 
fibrinolysis and may contribute to the altered fibrinolysis seen in AAA. 
3. To study the role of TAFI and TAFI inhibition in an in-vivo murine AAA 
model, and investigate fibrinolysis in plasma and aortic sections from this 
model. 
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Chapter 2 Experimental Design, Materials and Methods  
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The Assessment of the Role of TAFI in Human AAA 
Given the evidence for a delay in the fibrinolysis in plasma samples of patients 
with AAA, and a link between TAFI and AAA formation in the porcine pancreatic 
elastase infusion model of AAA, a series of experiments were designed to 
establish if TAFI could be important in the regulation of lysis in patients with 
AAA.  
2.1 Collection of plasma samples from patients with AAA 
A large case-control cohort study of AAA patients and their controls, the Leeds 
Aneurysm Development Study (LEADS), was used to provide samples of DNA, 
plasma, whole blood and tissue for the study. The inclusion and exclusion 
criteria, as well as the study protocol, consent form and patient information 
sheet can be found in Appendices 1-3. Ethical approval for this study was 
granted by the Leeds East Research Ethics Committee (approval number 
03/142). Patients were recruited and their samples collected by a senior 
research nurse, Mrs Anne Johnson. 
2.2 Blood collection and the preparation of platelet poor plasma 
Free flowing venous blood was collected from the antecubital vein of the non-
dominant arm of AAA patients and their controls. Ten millilitres of blood was 
collected onto cold 0.1 M sodium citrate (9 parts of blood to 1 part of citrate), 
and then centrifuged at 4°C at 2,400 g for 20 minutes. The plasma supernatant 
was divided into 500 µl aliquots, flash frozen in liquid nitrogen and stored at -
40°C until analysis. 
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DNA was extracted from whole blood. For this, 6 mls of blood was collected into 
a BD Vacutainer® K2EDTA, and stored at -20°C until DNA extraction.  
2.3 Normal pool plasma 
For the optimisation of a number of assays, and also for the provision of a 
standard in the TAFI and TAFI-AP ELISAs, normal pool plasma (NPP) was 
used. This was produced by the collection of free-flowing venous blood from the 
antecubital fossa of the non-dominant arm of 25 healthy individuals. Collection 
of the NPP was approved by the Leeds NHS Trust Research Ethics Committee 
(HSLTM/12/045 and HSLT/09/020). Blood was again collected onto 0.1 M 
sodium citrate (9 parts blood to 1 part citrate), centrifuged for 20 minutes at 
2,400 g to separate plasma, which was pooled together to create a mixture of 
all 25 individuals’ plasmas. The plasma mix was then again divided into aliquots 
(0.5-1 ml) before being flash frozen using liquid nitrogen, and was stored at -
80°C until required.  
2.4 Measurement of TAFI antigen levels in plasma 
Enzyme-linked immunosorbent assays (ELISA) were used to measure the 
plasma levels of intact TAFI (zymogen), TAFI activation peptide (TAFI-AP) and 
activated and inactivated TAFI in combination (TAFIa/TAFIai). The levels of 
TAFIa/TAFIai were measured using a commercially available ELISA kit 
(Asserachrom® TAFIa/TAFIai, ref 00616, Diagnostica Stago UK Ltd). Levels of 
intact TAFI and TAFI-AP were measured using ELISAs developed by the 
laboratory of Prof Ann Gils (KU Leuven). For these ELISAs, antibodies 
developed in KU Leuven were used. Plates were coated with MA-T12D11 (a 
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monoclonal antibody specific to the activation peptide of TAFI). For the intact 
TAFI ELISA, another monoclonal antibody, MA-T30E5A2-HRP was used as the 
secondary antibody. For the TAFI-AP ELISA, monoclonal antibody MA-T18A8-
HRP was used as the secondary antibody. MA-T18A8 is also known to bind to 
the activation peptide. The site of binding of MA-T30E5A2 is not known, but 
during the development of these ELISAs, it was shown in combination with MA-
T12D11 to preferentially detect the intact molecule, and not react with either the 
activation peptide or the activated TAFI (Ceresa et al., 2006a). The 
configuration of antibodies for each of these ELISAs are illustrated in Figure 8. 
Detailed protocols for each of the ELISAs used are described in the following 
sections.   
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A 
B  
Figure 8. Antibody configuration in the TAFI and TAFI-AP ELISAs 
Each well of a high-protein-binding plate is coated with a coating antibody which is specific to an 
epitope on the protein of interest. After an incubation period, each well is filled with a blocking 
buffer containing high protein levels, which bind to the remaining plate surface rendering it 
inaccessible to further protein binding. A plasma sample is added to each well, and the protein 
of interest binds to the coating antibody. Excess plasma is washed away, and a further 
antibody, specific to a different epitope of the protein of interest is added (Secondary Antibody, 
conjugated with HRP), and this binds to the protein already caught by the coating antibody. This 
conjugated antibody reacts with a peroxidase substrate to give a colour, which is proportional to 
the amount of protein in the plasma sample. 
A – Antibody configuration for the intact TAFI ELISA. Plates are coated with MA-T12D11, which 
then binds to the activation peptide of TAFI present in the plasma sample. The secondary 
antibody MA-T30E5A2-HRP preferentially binds to the intact TAFI zymogen, so only intact TAFI 
zymogens are detected. 
B – Antibody configuration for the TAFI activation peptide ELISA. Plates were coated with MA-
T12D11, which binds to the activation peptide of TAFI. The secondary antibody in this case, 
MA-T18A8-HRP, also binds to the activation peptide, so only the TAFI activation peptide is 
detected. 
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2.4.1 TAFIa/TAFIai  
Levels of TAFIa/TAFIai were measured using a commercially available ELISA 
(Asserachrom® TAFIa/TAFIai, ref 00616, Diagnostica Stago UK Ltd) according 
to the manufacturer’s instructions. In brief, plasma samples and the high control 
were diluted 1:100 in dilution buffer. The low control was diluted 1:200 in dilution 
buffer. Samples (200 μl) were added to each well of the pre-coated microplate. 
Samples were incubated for 1 hour at room temperature, before the plate was 
emptied and the wells were washed five times using the wash buffer provided. 
Anti-TAFIa/TAFIai-peroxidase conjugate (200 μl) was added to each well, and 
was left to incubate for 1 hour at room temperature. The wells were emptied 
and washed five times, before 200 μl of tetremethylbenzidine, TMB, was added. 
This was left to incubate for exactly five minutes before the reaction was 
stopped with the addition of 50 μl of 1 M sulphuric acid, H2SO4. The absorbance 
was measured at 450 nm OD using a Molecular Devices SPECTRAmax Plus 
384 plate reader (Molecular Devices LLC. USA). 
2.4.2 TAFI and TAFI-AP   
For both the intact TAFI ELISA and the TAFI-AP ELISA, the initial protocol is 
the same. Nunc-Immuno™ Maxisorp™ ELISA plates (Thermo Fisher Scientific 
Inc.) were coated with 200 μl of MA-T12D11 at a concentration of 4 μg/ml 
diluted in 0.01 M phosphate buffered saline, pH 7.4 (PBS, achieved by 
dissolving 5 tablets in 1 litre of distilled water, P4417 Sigma-Aldrich Co. LLC.). 
Plates were incubated for 72 hours at 4°C. After 72 hours, the wells were 
emptied and blocked with 300 μl per well of an albumin buffer (PBS containing 
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1% Bovine Serum Albumin, A8531 Sigma-Aldrich Co. LLC., BSA). The plates 
were incubated for two hours at room temperature. The wells were emptied, 
and washed four times with 300 μl of PBS buffer containing 0.002% TWEEN®-
20 (P9416 Sigma-Aldrich Co. LLC.) using a BioTek MultiFlo automatic plate 
washer (BioTek Instruments Inc.). The wells were completely emptied by 
blotting onto absorbent paper, before being prepared for storage. Prior to 
storage, the wells were filled with 200 μl of mannitol-saccharose solution (100 g 
mannitol and 20 g saccharose per litre dH2O), incubated for 2-4 minutes and 
then emptied completely by blotting on absorbent paper. The plates were 
covered in foil to protect them from moisture and light, and stored at -20°C until 
needed. 
2.4.3 Intact TAFI ELISA  
Immediately before use, the plates were allowed to reach room temperature, 
then washed four times with 300 μl of PBS containing 0.002% TWEEN®-20.  
Plasma samples were collected and stored as described above. Plasma was 
diluted 1 part plasma in 160 parts PTAE buffer (0.01 M PBS containing 0.002% 
TWEEN®-20, 0.1% BSA and 5 mM Ethylenediaminetetraacetic acid, EDTA, 
E5134 Sigma-Aldrich Co. LLC.). The addition of EDTA was made in order to 
ensure inactivation of any TAFI in the sample via interaction with the zinc 
molecule present in the active site. Serial dilutions of this 1/160 sample in PTAE 
buffer were performed to give four concentrations for each plasma sample 
(1/160, 1/320, 1/640 and 1/1280). On each plate, two standard samples were 
included in order to test for inter-plate variability of the assay. These were a 
normal pool plasma sample, produced by pooling the plasma from 25 healthy 
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subjects, and a sample from a single healthy control (ABJ60). These standards 
were diluted to the same concentrations as the plasma samples to be tested 
(1/160-1/1280). Each plate also contained a standard curve, produced using 
purified TAFI (Enzyme Research Laboratories, Swansea, UK) diluted in PTAE 
buffer. The first point of the standard curve was diluted to 100 ng/ml, and then 
serial dilutions were performed to give a total of six dilutions (100, 50, 25, 12.5, 
6.25 and 3.125 ng/ml respectively). A final well containing just PTAE buffer was 
used as a blank. Either plasma sample or standard solution (180 μl) was added 
to each well, and the plate was incubated overnight at 4°C. On all plates, equal 
numbers of samples from patients with AAA and control subjects were included. 
A sample plate lay out is shown in Figure 7. 
Following overnight incubation, the wells were emptied, and washed four times 
using a 0.01 M PBS 0.002% TWEEN®-20 buffer. The wells were emptied 
completely by blotting against an absorbent paper. The antibody MA-T30E5A2-
HRP was used as the capture antibody for intact TAFI. It was diluted 1/8000 in 
PTA buffer (0.01 M PBS containing 0.1% BSA and 0.002% TWEEN®-20), and 
170 μl of this solution was added to each well. The plates were incubated for 2 
hours at room temperature. Following incubation with conjugate, the wells were 
emptied, and washed four times using 0.01 M PBS 0.002% TWEEN®-20 buffer. 
After washing, the wells were again completely emptied by blotting on 
absorbent paper.    
To produce a colorimetric reaction, 160 μl of a substrate solution containing o-
Phenylenediamine (OPD) was added to each well. To prepare the substrate 
solution, a 20 mg OPD tablet (P7288 Sigma-Aldrich Co. LLC.) was dissolved in 
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30 mls of 0.05 M phosphate citrate buffer, pH 5.0 (containing 7.30 g Citric Acid, 
251275 Sigma-Aldrich Co. LLC. and 11.87 g sodium phosphate dibasic, S7907 
Sigma-Aldrich Co. LLC. in 1 litre dH2O). For every 30 mls of substrate solution, 
12 μl of 30% hydrogen peroxide, H2O2 (H1009 Sigma-Aldrich Co. LLC.), was 
added. The plates were then left to incubate for 45 minutes at room 
temperature. The plates were covered in foil during the incubation period to 
protect them from light. After 45 minutes, 50 μl of 4 M H2SO4 (320501, Sigma-
Aldrich CO. LLC.) was added to each well to stop the reaction. The absorbance 
was measured using a Molecular Devices SPECTRAmax Plus 384 plate reader 
(Molecular Devices LLC. USA) at 492 nm OD. The TAFI content in the plasma 
samples was calculated using a standard curve generated by plotting the 
absorbance against the concentration of TAFI in the known standard TAFI 
samples. A sample standard curve is displayed in Figure 9. 
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A 
B 
Figure 9. Intact TAFI ELISA 
A – Sample layout of ELISA plates for the intact TAFI ELISA. A standard curve was produced 
using purified TAFI at known concentrations (column 1).  Two standards were run on each plate 
(NPP and ABJ60), each at four concentrations between 1/160 and 1/1280. Twenty plasma 
samples, ten from patients and ten from controls, (a-t) were run on each plate, again at four 
concentrations between 1/160 and 1/1280. 
B – Sample standard curve for the Intact TAFI ELISA, with known concentrations of TAFI 
plotted against absorbance at 492 nm OD. 
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2.4.4 Production of the TAFI-AP standard 
A sample of TAFI-AP standard was provided by Prof Ann Gils, from the 
Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven. A stock of 
TAFI-AP standard was then produced in our laboratory using purified TAFI 
(Enzyme Research Laboratories, Swansea, UK) following her protocol, and this 
stock was compared to her original standard for TAFI-AP levels. Purified TAFI 
(final concentration 3.75 μg/ml) was incubated along with Calcium (CaCl2, 
C1016 Sigma-Aldrich Co. LLC., final concentration 5 mM), Thrombin, (Human 
Thrombin from Plasma, 605190, Merck Chemicals Ltd., UK, final concentration 
16 nM) and Thrombomodulin (Rabbit Lung Thrombomodulin, RP-43135, 
Thermo Scientific, USA, final concentration 15 nM), in a water bath at 37°C for 
exactly 13 minutes. The dilution buffer contained 25 mM HEPES (H3375 
Sigma-Aldrich Co. LLC.), 137 mM NaCl (BP3581 Fisher Scientific, US) 3.5 mM 
KCl (10417460 Fisher Scientific, US), 3 mM CaCl2 and 0.1% BSA, pH 7.4. After 
13 minutes, D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone (PPACK, 
sc-201291, Santa Cruz Biotechnology Inc.) was added to a final concentration 
of 30 μM in order to stop any further TAFI activation. The solution was then 
aliquoted and stored at -80°C until needed. This standard (from here on referred 
to as KB13), was compared to the standard prepared in the same way and used 
as a standard for the TAFI AP ELISA at KU Leuven (S13). Two standard curves 
were prepared on different plates for each standard using the ELISA protocol as 
laid out below, and they were compared to ensure the similarity of our standard 
(KB13) to the original standard (S13). These are shown in Figure 10. 
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Figure 10. TAFI-AP standard production 
KB13 was produced using the method for generation of the activation peptide standard provided 
by KU Leuven. This was compared to the Leuven standard (S13) in the TAFI-AP ELISA at a 
range of concentrations between 0-20 ng/ml. 
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2.4.5 TAFI-AP ELISA  
Plasma samples were collected and stored as described above. Plasma was 
diluted 1 part plasma in 40 parts PTAE buffer (0.01 M PBS containing 0.002% 
TWEEN®-20, 0.1% BSA and 5 mM EDTA). Serial dilutions of this 1/40 sample 
in PTAE buffer were performed to give four concentrations for each plasma 
sample (1/40, 1/80, 1/160 and 1/320). On each plate, two standard samples 
were included in order to test for inter-plate variability of the assay. These were 
a NPP sample, produced by pooling the plasma from 25 healthy subjects, and a 
sample from a single healthy control (ABJ60). These standards were diluted to 
the same concentrations as the plasma samples to be tested (1/40-1/320). 
Each plate also contained a standard curve, produced using KB13, as 
described above, diluted in PTAE buffer. The first point of the standard curve 
was diluted to 20 ng/ml, and then serial dilutions were performed to give a total 
of six dilutions (20, 10, 5, 2.5, 1.25 and 0.65 ng/ml respectively). A final well 
containing just PTAE buffer was used as a blank. 180 μl of either plasma 
sample or standard solution was added to each well, and the plate was 
incubated overnight at 4°C. A sample of how the plate was laid out is shown in 
Figure 11. 
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Figure 11. TAFI-AP ELISA 
Sample layout of the TAFI-AP ELISA plate. A standard curved was produced by diluting the 
activation peptide standard KB13 to a range of concentrations between 0-20 ng/ml (column 1). 
Two standards were run on each plate (NPP and ABJ60), each at four concentrations between 
1/40 and 1/320. Twenty plasma samples (a-t) were run on each plate, again at four 
concentrations between 1/40 and 1/320. 
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Following overnight incubation, the wells were emptied, and were washed four 
times using a 0.01 M PBS 0.002% TWEEN®-20 buffer. Wells were emptied 
completely by blotting against an absorbent paper. The antibody MA-T18A8-
HRP was used as the capture antibody for TAFI-AP. It was diluted 1/8000 in 
PTA buffer (0.01 M PBS containing 0.1% BSA and 0.002% TWEEN®-20), and 
170 μl of this solution was added to each well. The plates were incubated for 2 
hours at room temperature. Following incubation with conjugate, the wells were 
emptied, and were washed four times using 0.01 M PBS 0.002% TWEEN®-20 
buffer. After washing, the wells were completely emptied by blotting on 
absorbent paper.    
To produce a colorimetric reaction, 160 μl of a substrate solution containing o-
Phenylenediamine (OPD) was added to each well. This was prepared as for the 
intact TAFI ELISA, described above. The plates were then left to incubate for 45 
minutes at room temperature. The plates were covered in foil during the 
incubation period to protect them from light. After 45 minutes, 50 μl of 4 M 
H2SO4 was added to each well to stop the reaction. The absorbance was 
measured using a Molecular Devices SPECTRAmax Plus 384 plate reader 
(Molecular Devices LLC. USA) at 492 nm OD. The TAFI-AP content in the 
plasma samples was calculated using a standard curve generated by plotting 
the absorbance against the concentration of TAFI-AP in the standard TAFI-AP 
samples.  
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2.5 TAFI activity levels – Functional TAFI Assay 
TAFI activity was measured using a modified version of the functional TAFI 
assay developed by Guimaraes et al (Guimaraes et al., 2005). 
For the initial experiments, plasma samples prepared as above were diluted 
sequentially in TAFI-deficient plasma (Enzyme Research Laboratories, 
Swansea, UK). Diluted plasma samples (100 μl) were added to the wells of a 
Greiner bio-one microtitre plate containing 25 µl of the reaction mix, composed 
of human thrombin (0.5 units/ml), rabbit lung thrombomodulin (0.6 units/ml), 
recombinant tPA (Technoclone GmbH, Austria, 0.10 µg/ml), CaCl2 (20 mM), 
and where stated, Potato-Carboxypeptidase Inhibitor (C0279 Sigma-Aldrich Co. 
LLC.), PCI (30 µg/ml), in 50 mM HEPES buffer, pH 7.4 with 0.1% BSA. 
Concentrations refer to the final concentrations in the assay solution. The plate 
was then immediately placed in a pre-warmed (37°C) incubation chamber of a 
Molecular Devices SPECTRAmax Plus384 plate reader (Molecular Devices 
LLC. USA). The optical density at 405 nm was measured every minute for 150 
minutes. For each plasma sample, a control with PCI was included.  
Lysis time (LT) is defined as the time point corresponding to a 50% decrease in 
optical density. The TAFI-related retardation of fibrinolysis was determined for 
each sample by subtracting the LT in the presence of PCI (LT+PCI) from the LT 
in the absence of PCI (LT-PCI). This is illustrated in Figure 12.  
A standard curve using the known dilutions of normal pool plasma was used to 
determine a sensitive range for the determination of TAFI-related lysis 
retardation in future experiments. The dilution which gave the most sensitive 
and reliable results in these initial experiments was 1 parts plasma to 9 parts 
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diluent. For the screening of multiple plasma samples, Tris-buffered saline 
(TBS) was used as the diluent, containing 50 mM Tris-Base (BP1521, Thermo 
Scientific Ltd.), 100 mM NaCl, pH 7.4. Compared to TAFI-deficient plasma, 
using TBS as the diluent seemed to give more consistent results, especially 
once a lower concentration of thrombin was used (0.5 units/ml vs. 3.3 units/ml 
as per the Guimaraes et al. method).  These curves are shown in Figure 12. 
TAFI-specific anti-fibrinolytic activity was calculated by determining the ratio 
between TAFI-related retardation to lysis time (min) and TAFI antigen levels 
(μg/ml) as determined using the ELISA. 
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A 
 
B 
 
Figure 12. A functional assay of TAFI activity in plasma 
A – Turbidity/lysis assays were performed for all samples in the presence (light green) and 
absence (dark green) of potato carboxypeptidase inhibitor (PCI). The time from the point of 
maximum absorbance (MA) until the time when MA reduced by half (or the time to half lysis) 
was measured. The difference in the time to half lysis in absence of PCI compared with the 
presence of PCI (red dotted arrow) represents the TAFI-related retardation to lysis time.  
B – TAFI-related retardation to lysis time in samples of known concentrations of TAFI (0-1 
unit/ml) generated using normal pooled plasma. The green squares represent the assay 
conducted as per Guimaraes et al., using TAFI-deficient plasma as a diluent and thrombin at a 
final concentration of 3.3 unit/ml. The green circles represent the assay performed using a 
modified protocol with TBS used as the dilutent and Thrombin at a final concentration of 0.5  
unit/ml. 
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2.6 Turbidity-Lysis in patients with AAA 
Previous work from our group has shown that there is a significant delay in the 
lysis of clots produced using the plasma of patients with AAA when compared 
with control subjects (Scott et al., 2011). In order to establish if this difference 
could be attributable to TAFI, serial turbidity lysis experiments were performed 
using plasma from patients, in which TAFI was inhibited using PCI, and 
controls, in which additional TAFI was added in order to enhance the effect of 
TAFI on lysis time. 
Plasma samples were collected and stored as described above (Section 2.2). A 
sample of patients with large AAA (aneurysm diameter > 5 cm), (n=32) and 
control subjects (n=32) were selected at random from the LEADS database. In 
each well of a 96-well Greiner bio-one microtitre plate, 25 μl of plasma was 
added to 75 μl of TBS. Fibrin clot formation was achieved by the addition of 50 
μl of an activation mix containing thrombin (0.2 units/ml), CaCl2 (7.5 mM) and 
tPA (41 ng/ml). Concentrations shown are the final concentrations per well. All 
samples were run in duplicate. The absorbance was measured at 340 nm OD 
every 12 seconds for 250 minutes using a ThermoScientific MultiSkan™ Go 3.2 
spectrophotometer (Thermo Fisher Scientific Inc. USA).  
The experiment was repeated with the addition of 30 μg/ml (final concentration 
per well) PCI to the AAA samples, and the addition of purified TAFI (Enzyme 
Research Laboratories, Swansea, UK) to the control samples. TAFI was added 
to a final concentration of 15 µg/ml in the plasma (the upper limit of normal in 
human plasma), so that all samples had an excess of TAFI of 15 μg/ml over 
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their original TAFI concentration. Again, 50 μl of an activation mix containing 
thrombin (0.2 units/ml), CaCl2 (7.5 mM) and tPA (41 ng/ml) was added, and the 
absorbance was read at 340 nm OD every 12 seconds for 250 minutes.  
All samples were then repeated with the addition of Thrombomodulin (final 
concentration per well 0.6 units/ml) to the activation mix.  
2.7 TAFI Thr325Ile, Alpha-2-Antiplasmin Arg6Trp and Arg407Lys, and 
tPA Polymorphisms 
These four common polymorphisms of proteins involved in fibrinolysis were 
investigated in a large sample of patients and control subjects (n=602 and 
n=490 respectively).  DNA was extracted from samples of whole blood using a 
commercially available kit (QIAamp Blood Maxi Kit, QIAGEN). DNA was 
extracted from blood with assistance from a laboratory technician, Mr Fraser 
Macrae. A full protocol can be found in Appendix 4. 
The DNA concentration in the resulting solution was determined using a 
Nanodrop (ND-1000 Spectrophotometer, LabTech International), using the 260 
nm/280 nm absorbance ratio and 2 µl of solution. Each 6 mls of blood yielded 2 
mls of 70-200 ng/μl genomic DNA. All samples were diluted to 10 ng/µl using 
DNA and RNA free Tris EDTA buffer solution (93283, Sigma-Aldrich Co. LLC.), 
and stored at 4°C until genotyping.  
TaqMan single nucleotide polymorphism (SNP) Genotyping Assays (Life 
Technologies) were used for each of the polymorphisms (TAFI Thr325Ile 
rs1926447, α2AP Arg6Trp rs2070863, Arg407Lys rs1057335 and tPA 
7351C→T rs2020918). The probe was added to TaqMan Genotyping 
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MasterMix (Life Technologies, Thermo Fisher Scientific Ltd.) in a 20:1 ratio 
(henceforth referred to as MasterProbe). MasterProbe (2.7 μl) and 2.2 µl of the 
diluted DNA (10 ng/µl) were added to each well of a 384 well plate. Two no 
template controls (containing only MasterProbe) were included on each plate. A 
Roche LightCycler480 (Roche Diagnostics, Burgess Hill, UK) was used for 
programming the real time polymerase chain reaction, PCR, with each 
programme consisting of 50 amplifications to 95°C. End-point genotyping was 
used to determine genotype frequencies. Correct genotype was called in each 
plate with an accuracy of 96-100%; samples which were not called successfully 
on the first attempt were subsequently repeated. In addition to the no template 
controls, random samples were repeated on each plate to ensure reproducibility 
of the results. Only samples for which all four genotypes could be determined 
were included in the final analysis.  
2.8 Histological Examination of the Intra-Luminal Thrombus of patients 
with AAA 
Samples of ILT were collected from patients with AAA undergoing open AAA 
repair, according to the protocol of the LEADS study (see Appendix 1). Sections 
of full-thickness ILT were collected into normal saline (NaCl 0.9%) and kept on 
ice for transportation. On arrival in the laboratory, samples were transferred into 
a 4% paraformaldehyde solution, and incubated at 4°C for at least 24 hours. 
After a minimum of 24 hours, these samples were dehydrated using a 17 hour 
programme (detailed in Appendix 7) on a Leica TP1020 tissue processing 
carousel (Leica Microsystems) and embedded in paraffin (Sigma-Aldrich Co. 
LLC.). Blocks were sectioned using a Leica RM2125 microtome (Leica 
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Microsystems) into 5 µm sections, and collected onto slides (4951PLUS4 
Superfrost™Plus, Thermo Scientific Ltd), left to dry at 37°C overnight, and 
stored before staining. Slides were stained with Martius Scarlet Blue in order to 
study the fibrin composition within the ILT. Details of this method are described 
in Section 2.22.5. 
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Inhibition of TAFI in a Murine Model of Abdominal Aortic Aneurysm 
A murine model of AAA was used to further investigate the molecular 
mechanisms underpinning the role of TAFI in AAA. An overview of all the mice 
used in the study is displayed in Figure 13. 
All murine studies were carried out within UK Home Office Regulations under 
Project Licence 40/3523 (Dr S Wheatcroft) and Personal Licence 70/25000 
(Miss K Bridge). 
  
Figure 13. Overall Murine Plan 
In total, seven separate experimental conditions were included; these groups are shown on the right hand side, with the numbers used for each condition 
displayed within the outline of the mouse. The different treatments included normal saline infusion (NaCl 0.9%), Angiotensin II infusion, TAFI inhibitors UK-
396082 (delivered via subcutaneous mini-osmotic pump) and MA-TCK26D6 (delivered via intravenous, IV, injection). In later experiments, AAA development 
was monitored using ultra sound scanning (USS). IVC = inferior vena cava, IV = intravenous injection. 
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2.9 AAA formation in the Angiotensin II model of AAA 
At 12-16 weeks of age, male Apolipoprotein-E knockout mice (ApoE-/-) 
backcrossed onto a C57BL/6 background, and maintained on standard 
sterilized laboratory diet and water, were administered subcutaneous infusions 
of Angiotensin II (A9525 Sigma-Aldrich Co. LLC.) for 28 days via mini-osmotic 
pumps (Alzet® model 1004, obtained from Charles River Laboratories, 
Germany), based on the method designed by Daugherty et al (Daugherty et al., 
2000).  
Initially, in order to optimise the experimental protocol and gather information 
about AAA formation rates using the Angiotensin II model in the absence of any 
TAFI inhibitor, two groups of mice were used. Mice were treated with either 
Angiotensin II (Ang II), at a dose of 750 ng/kg/min for 28 days, or a control 
pump containing normal saline (NaCl 0.9%).  
2.9.1 Alzet® Mini Pump Insertion  
In brief, mice were anaesthetised in an anaesthetic chamber using volatile 
isoflurane at an initial dose of 5 litres/min with 2 litres/min of oxygen. Once mice 
were anaesthetised, they were weighed, and then transferred onto a warmed 
operating table. Anaesthesia was maintained using isoflurane at 1.5-2 litres/min 
with 2 litres/min of oxygen. At induction, mice were administered with 
Vetergesic® (Reckitt Benckiser) as an intra-peritoneal injection (dose range 0.1-
1 mg/kg) in order to minimise post operative pain. A small amount of Lubrithal™ 
Ophthalmic Eye Gel was applied to the eyes of the mice to prevent drying of the 
cornea during anaesthetic. Mice were then laid prone, and their position 
secured using Micropore™ surgical tape. A small area of the dorsal surface of 
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the neck was shaved using an electric razor, and the site of the incision cleaned 
using 70% ethanol. A small midline incision was made, and a subcutaneous 
channel created along the left dorsal flank, lateral to the spine, using closed 
needle holders. Alzet® mini-pumps were prepared containing sufficient drug 
concentrations for the weight of each animal (See Appendix 5). Pumps were 
inserted cap-first into the subcutaneous pouch and the incision closed using a 
continuous 6-0 vicryl® suture (Ethicon US LLC). Upon completion, mice were 
ear notched to allow for individual follow up (see Appendix 6), and given an 
intra-peritoneal bolus of warmed NaCl 0.9% (25 mls/kg) before recovery. Once 
awake, mice were placed in a warm, clean cage, and returned to their normal 
cage environment once fully recovered. The procedure for the insertion of a 
mini-pump is illustrated in Figure 14. 
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Figure 14. Insertion of an Alzet mini-osmotic pump under general anaesthesia 
Mice were laid prone, and their position secured using micropore surgical tape. Anaesthesia 
was maintained using inhaled isoflourane 2 litres/min. Fur was removed from a small area 
between the shoulder blades, and a longitudinal incision made through the skin. A 
subcutaneous pouch was created using blunt dissection, by inserting a pair of closed needle 
holders through the incision and along the left flank. An Alzet mini-osmotic pump was inserted 
cap-first into the pouch, and the wound closed using a continuous suture of 6-0 vicryl. 
 
 
Page | 74  
 
Following pump insertion, mice were closely monitored. Their wounds were 
carefully observed to ensure there was no evidence of any postoperative 
infection. The established mortality rate related to this model is between 30-
40%; this most commonly occurs between days 3-8 post-operatively and is due 
to aortic rupture. During this ‘at risk’ period, mice were observed at least twice 
daily, and any animals showing signs of pain or distress were terminated using 
Home Office Schedule 1 approved methods.  
2.9.2 Non-invasive Blood Pressure and Heart Rate measurement by tail cuff 
plethysmography 
Following mini-pump insertion, mice underwent non-invasive monitoring of their 
heart rate (HR) and blood pressure (BP) using the CODA device (Kent Scientific 
Corporation). In brief, animals were restrained using an animal nose cone 
holder and kept in a chamber warmed to 37°C. The occluder cuff (O-cuff) and 
the volume pressure recording (VPR) cuff were placed on the tail of the mouse, 
approximately 0.5 cm from the base of the tail, with the O-cuff lying proximal to 
the VPR cuff. The CODA device was set to record a total of 28 readings. The 
first ten readings of any session were set as acclimatisation readings and were 
discarded. Following this, there were three sets of six cycles, with 5 seconds 
between sets and 5 seconds rest between cycles. All mice underwent a ‘training 
session’ where blood pressure measurements were not recorded in order to 
allow them to become familiar with the environment and the test. On two 
subsequent occasions, the test was repeated, and measurements recorded. 
This was done to ensure that there was no false hypertension or tachycardia 
related to the stress of the examination. BP and HR readings over a session 
were analysed for quality. All readings within a single session that met the 
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quality criteria (flow volume was measured, the animal was not moving, the 
graph trace was deemed to be ‘good’) were then averaged to give a result of BP 
and HR for each mouse. A sample trace is shown in Figure 15.  
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Figure 15. Sample reading from tail cuff plethysmography, used for the non-invasive 
measurement of heart rate and blood pressure in mice 
In order to measure blood pressure and heart rate, mice were restrained using an animal nose 
cone device. They were kept at 37°C throughout the course of the experiment. Two tail cuffs 
were applied to the tail of the mouse, with the O-cuff proximal to the VPR cuff. For each 
session, there were 10 acclimatisation cycles, then 3 sets of 6 cycles when measurements were 
taken. The occlude trace (shown in red) falls steadily, whilst the VPR trace rises slowly. Where 
the VPR trace rises and before the two traces intersect, and measurement of blood pressure is 
taken. Heart rate, flow rates and volume are also measured, and in combination allow for an 
assessment of the quality of the trace. 
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2.9.3 Termination of the Experiment and Blood Collection 
At 4 weeks post-pump implantation, mice were anaesthetised using inhaled 
isoflurane at 5 litres/min, then maintained at 2 litres/minute until the point of 
death. Mice were placed supine, the abdomen cleaned with 70% ethanol, and a 
midline incision made along the linea alba from pelvis to sternum. The 
abdominal contents were moved to the right to expose the inferior vena cava 
(IVC). IVC puncture was performed using a 26 G needle on a 1 ml syringe (BD 
Plastipak TM), and the whole blood volume was collected (up to 1 ml) onto 0.1 M 
sodium citrate at a ratio of 9 parts blood to 1 part citrate. Blood was then stored 
on ice until centrifugation and storage. Following exsanguination, the thorax 
was opened through a midline incision. The left ventricle was cannulated, and 
the circulation was perfused with 8-10 mls of phosphate buffered saline (PBS). 
If the aorta was to be taken for paraffin block fixation, this PBS infusion was 
then followed by 5 mls of 4% Paraformaldehyde, PFA (P6148, Sigma-Aldrich 
Co. LLC.). Macroscopic imaging of the aorta was undertaken using the OPMI-
PICO videomicrometer (Carl Zeiss AG). 
2.9.4 Processing of Blood Samples 
Samples of whole blood collected from IVC were kept on ice until processing. 
They were then centrifuged at 14,500 rpm for 20 minutes using a table-top 
micro-centrifuge (Eppendorf MiniSpin plus, Scientific Laboratory Supplies 
Ltd.UK). The supernatant was collected into a clean Eppendorf tube, flash 
frozen in liquid nitrogen, and stored at -40°C until analysis. 
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2.9.5 Harvesting of the Aorta and preparation for ex-vivo study 
The aorta was harvested en-bloc from the mid-thoracic level to below the left 
renal artery. For protein studies, a sample of liver (for control) and the aorta 
were flash frozen in liquid nitrogen. For histological examination, the aorta was 
placed in 4% PFA for a minimum of 24 hours before being processed. After a 
minimum of 24 hours, these samples were dehydrated using a 17 hour 
programme (detailed in Appendix 7) on a Leica TP1020 tissue processing 
carousel (Leica Microsystems) and embedded in paraffin (Sigma-Aldrich Co. 
LLC.). Blocks were sectioned using a Leica RM2125 microtome (Leica 
Microsystems) into 5 µm sections, and collected onto slides (4951PLUS4 
Superfrost™Plus, Thermo Scientific Ltd), left to dry at 37°C overnight, and 
stored before staining. 
2.10 Administration of TAFI inhibitors 
Following optimisation of the Ang II model of AAA, mice were treated with 
inhibitors of TAFI. Two different inhibitors were used separately. Their site of 
action is shown in Figure 16. The first, UK-396082, a small molecule inhibitor of 
activated TAFI developed by Pfizer (Bunnage et al., 2007), was resynthesised 
by Dr Richard Foster and Dr Charlotte Revill of the School of Chemistry at the 
University of Leeds. The dosing of this inhibitor was based upon previous 
studies in rats (Owen et al., 2010). After discussion with the University 
Veterinarian, a dosing regimen for subcutaneous infusion taking into account 
bioavailability and half-life was selected. The drug was dissolved in a solution of 
normal saline, and was administered at a dose of 30 mg/kg/min via a 
subcutaneous Alzet® 1004 mini-osmotic pump. The drug was initially tested for 
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toxicity, before being administered in conjunction with Ang II. When given in 
combination, two mini-osmotic pumps were inserted under the same general 
anaesthetic. As described above, a pump containing Ang II was inserted on the 
left flank, and a second pump containing UK-396082 was implanted on the right 
flank. 
The second inhibitor used in this model was MA-TCK26D6, a monoclonal 
antibody that targets the plasmin-mediated activation of TAFI. This inhibitor was 
provided as a generous gift from Prof Ann Gils (KU Leuven). In previous studies 
from the laboratory of Ann Gils, a dose based on a 26-fold antibody:TAFI ratio 
(26 mg/kg) was used. All of these experiments, however, were done under 
terminal anaesthesia, and so injection volume did not need to be limited. 
Indeed, the dose used in the laboratory of Prof Gils (26 mg/kg) required an IV 
injection volume which exceeds the amount permitted by the UK Home Office 
Licence for recovery experiments (which suggests that the maximum volume for 
administration should be no more than 200 μl in a single IV dose). Further work 
in their laboratory had also suggested that the half-life of antibody inhibitors was 
14 days in murine models. Mice were therefore given a single IV dose of MA-
TCK26D6 to last the duration of the experiment (28 days), with the volume 
injected set as the maximum amount permissible by the UK Home Office (200 
μl IV of 2.179 mg/ml MA-TCK26D6, 435.8 μg per mouse, which for an average 
25 g mouse is equivalent to 17 mg/kg). Injections were administered under 
direct vision into the femoral vein.  
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2.10.1 Femoral Vein Injection of MA-TCK26D6 
Mice were anaesthetised in an anaesthetic chamber using volatile isoflurane at 
an initial dose of 5 litres/min with 2 litres/min of oxygen. Once fully 
anaesthetised, mice were weighed, and then transferred onto a warmed 
operating table. Anaesthesia was maintained using isoflurane at 1.5-2 litres/min 
with 2 litres/min of oxygen. At induction, mice were administered with 
Vetergesic® (Reckitt Benckiser) as an intra-peritoneal injection (dose range 0.1-
1 mg/kg) in order to minimise post-operative pain. Mice were laid supine and 
their limbs held in position using Micropore™ surgical tape. Fur was removed 
from a small area over their left groin using Veet® hair removal cream. A small 
incision was made slightly inferior to the inguinal ligament, and the femoral vein 
exposed using blunt dissection. Using a 31 G needle (328280 BD ULTRA-
FINE™ Needle Insulin Syringe, Beckton Dickinson and Company), 200 μl of 
MA-TCK26D6 or NaCl 0.9% (control) was injected under direct vision into the 
femoral vein. Pressure was applied to the site of venepuncture immediately 
after removal of the needle using a small piece of sterile gauze for two minutes. 
Once haemostasis was ensured, the gauze was carefully removed by 
dampening with NaCl 0.9% to allow a smooth removal without dislodging any 
clot that may have formed. The wound was then washed using 0.9% NaCl. The 
fat was closed over the vein using a single stitch of 8-0 Vicryl®, before the skin 
was closed using continuous suturing of 8-0 Vicryl®. The procedure for femoral 
vein injection is illustrated in Figure 17. 
Prior to administration in combination with Ang II, MA-TCK26D6 was given in 
isolation to 8 mice. Mice were sacrificed at 7, 10 and 28 days, and blood taken 
from the IVC for ROTEM analysis. There was no evidence of any toxicity or 
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adverse effects of MA-TCK26D6. Mice behaved normally, and showed no 
spontaneous bleeding.  
Mice were then given Ang II and MA-TCK26D6 in combination. Under a single 
general anaesthetic, a subcutaneous mini-osmotic pump containing Ang II (750 
ng/kg/min) and an IV injection of MA-TCK26D6 (200 μl) were administered as 
described above. 
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Figure 16. Site of action of TAFI inhibitors MA-TCK26D6 and UK-396082 
Two inhibitors of TAFI were used. MA-TCK26D6 is a monoclonal antibody which inhibits 
plasmin-mediated activation of TAFI to TAFIa, and spares TAFIa’s anti-inflammatory properties. 
UK-396082 is a small molecule inhibitor which directly binds and inhibits the catalytic site of 
TAFIa, leading to inhibition of all TAFI activity in the circulation. 
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Figure 17. Femoral vein injection under general anaesthesia 
Anaesthesia was maintained using inhaled isofluorane at 2 litres/min. The mouse was laid 
supine, and its position secured using micropore surgical tape. The left leg was held in 
extension. Fur was removed using veet hair removal cream from a small area of skin overlying 
the left groin, and a longitudinal incision was made. Careful, blunt dissection deep to this 
incision revealed the femoral artery and vein as they emerged from below the inguinal ligament. 
The vein was injected using a 31G needle. Following injection, pressure was applied using 
sterile gauze. Once haemostasis was ensured, the wound was closed with a continuous 8-0 
vicryl suture. 
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2.11 Late Treatment with MA-TCK26D6 
After analysis of the effect of MA-TCK26D6 on mortality rates and AAA 
formation in the Ang II model of AAA, the effect of late administration of the 
inhibitor, once the AAA disease process had been established, was 
investigated. To do this, mice underwent a baseline ultrasound scan (USS) 
using the Vevo®2100 pre-clinical scanner (FUJIFILM VisualSonics Inc.), before 
an Ang II pump was implanted as described in Section 2.9. The mice then 
underwent a second scan after 1 week, after which they were given a single IV 
dose of MA-TCK26D6 as described in Section 2.10.1. They were then 
maintained in normal laboratory conditions, and were scanned again 14 days 
later to observe any effect of the MA-TCK26D6 on AAA progression. The 
experiment was terminated after 28 days, blood taken, and the aortas imaged 
and collected for histology as described above. A control group were treated 
with the same protocol, but given an injection of 0.9% NaCl into their left 
femoral vein at 7 days, rather than an MA-TCK26D6 injection. 
2.12 Vevo®2100 Ultrasound Imaging 
For the Vevo®2100 USS imaging, mice were anaesthetised in an anaesthetic 
chamber using volatile isoflurane at an initial dose of 5 litres/min with 2 
litres/min of oxygen. Once the mouse was anaesthetised, they were transferred 
onto a pre-warmed scanning table platform, and anaesthesia maintained using 
volatile isoflurane at 2 litres/min with 2 litres/min of oxygen. The animals were 
positioned supine, and their arms and legs were secured onto the electrode 
pads using Micropore™ surgical tape, to allow for electrocardiogram (ECG) and 
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respiratory monitoring throughout. Good contact was ensured using an 
electrode cream (SignaCreme ElectrodeCream, Parker Labs).  A rectal probe 
(RET-3, Kent Scientific Corporation) was used to continuously monitor the 
animals temperature. The fur was removed from the entire abdomen using an 
electronic razor followed by Veet® hair removal cream, in order to ensure good 
contact between the skin and the USS probe. The abdomen was covered with 
USS scanning gel (MediSupplies Ltd.). A MS550D MicroScan™ transducer at 
22-55 MHz was used. Images were focused at a depth of 4 mm. A series of 
images of the abdominal aorta were taken, both in cross section and 
longitudinally. Colour Doppler and pulse wave Doppler were used to ensure the 
positioning of the abdominal aorta. A 3D USS image of the suprarenal aorta 
was obtained for the 10.5 mm superior to the right renal artery, in the position 
where any AAA would be expected to be located. An electrocardiogram-gated 
(ECG-gated) image was obtained of the longitudinal aorta in order to assess 
distensibility. Following the scan, the mice were recovered in a warm clean 
cage, before being returned to their usual maintenance environment.  
Scan images were processed remotely using VevoLab 1.7.0 and VevoVasc 
software. The aortic diameter was measured in cross section at a position 5 mm 
proximal to the right renal artery. Longitudinally, the aortic diameter was 
measured in its maximal diameter using an ECG-gated image at maximal 
systole. Distensibility was calculated using an ECG-gated image and VevoVasc 
software. The aortic volume was calculated using a 3D reconstruction of the 
10.5 mm of the abdominal aorta proximal to the right renal artery, which is the 
site of any AAA formation.  
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2.13 Turbidity and Turbidity-Lysis 
The turbidity and turbidity-lysis protocols which have previously been used in 
humans (Scott et al., 2011) were adapted for use in murine plasma. Plasma 
samples were collected under terminal anaesthesia and processed as 
described above. Prior to use, plasma samples were defrosted and allowed to 
reach room temperature. 
Murine plasma samples (100 μl, diluted 1:4 in 50 mM HEPES buffer with 0.1% 
BSA, pH 7.4) were added to each well of a 96-well Greiner bio-one microtitre 
plate.  An activation mix (25 μl) containing murine thrombin (MCT-5020-50, 
Cambridge Biosciences, UK) 0.2 units/ml, 10 mM CaCl2 +/- tPA 50 ng/ml in a 50 
mM HEPES buffer, were added to each well.  Concentrations shown are the 
final concentrations per well. Plasma samples were run in duplicate without any 
tPA, and in duplicate with tPA. The absorbance was measured every 12 
seconds for 90 minutes at 405 nm using a Molecular Devices SPECTRAmax 
Plus 384 plate reader (Molecular Devices LLC. USA).  
2.14 Confocal Microscopy 
Plasma samples were collected and stored under terminal anaesthesia as 
described above. For each sample, a clot containing murine fluorescein 
isothiocyanate-labelled (FITC-labelled) fibrinogen was prepared. In order to do 
this, a mixture containing 30 μl of plasma, CaCl2 (final concentration 20 mM) 
and murine FITC-fibrinogen (Oxford Biomedical Research, USA, final 
concentration 50 μg/ml)  was made in TBS up to a total volume of 54 μl. A 
reaction mix (6 μl) containing murine thrombin (MCT-5020-50, Cambridge 
Biosciences, UK), final concentration in plasma 0.5 units/ml, was added to the 
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samples. Thirty microlitres of this mixture was immediately transferred into one 
side of a capillary confocal slide (80601 Thistle Scientific Ltd. UK), and the 
sample monitored to ensure it crossed onto the other side of the slide by 
capillary action. Once prepared, the slides were kept in a dark humidity 
chamber at room temperature for 2-4 hours in order to ensure that the clot was 
completely formed. Slides were then imaged using a Zeiss LSM-700 inverted 
confocal microscope at 63x magnification. Images were obtained from at least 4 
different parts of the clot in order to ensure an accurately representative 
sample. Images were then analysed using Image J. 
2.15 Rotational Thromboelastometry 
Whole blood samples were used for Rotational Thromboelastometry (ROTEM) 
analysis. Samples of whole blood were collected from the IVC onto sodium 
citrate, and kept on ice until analysis. The ROTEM®-delta system (ROTEM, 
Tem International GmBH), with ROTEM® mini-cups were used. In brief, 105 μl 
of blood, 7 μl of star-tem® reagent and 7 μl ex-tem® reagent were added to 
each mini cup. For studies of lysis, exogenous tPA (Technoclone GmbH, 
Austria) was added to each sample in a range of concentrations from 2 nM to 
20 nM, and lysis monitored over a 2 hour period. There are a number of 
parameters that can be measured using ROTEM. In this study, measures were 
taken of the Maximum Clot Firmness (MCF), which is measured in millimetres, 
and reports the greatest vertical amplitude of the ROTEM trace. It reflects the 
absolute strength of the fibrin and platelet clot, and can be decreased with 
reduced platelet number/function or decreased fibrinogen level. The Lysis Index 
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at 60 minutes (LI60) was also measured, and describes the stability of the clot 
remaining after 60 minutes in relation to the MCF. 
2.16 Murine D-dimer ELISA 
Plasma levels of D-dimer, a fibrin degradation product, were measured in the 
plasma of mice that developed AAA, and compared with mice receiving a 
control infusion of NaCl 0.9%. Levels of D-dimer were measured using a 
commercially available kit (Cat No. 024579, US Biological Life Sciences) 
according to the manufacturer’s instructions. In brief, a standard curve was 
produced using known concentrations of D-dimer from 0-5000 ng/ml. Fifty 
microlitres of standard or plasma sample was added to each well, followed by 
50 μl of detection reagent A. The plate was incubated for 1 hour at 37°C. The 
wells were emptied and washed 3 times. 100 μl of detection reagent B was then 
added to each well, and the plate was incubated for 30 minutes at 37°C. It was 
emptied and washed five times. TMB substrate (90 μl) was added to each well, 
and incubated for 15 minutes at 37°C, after which 50 μl of stop solution was 
added to each well, and the absorbance was read at 450 nm using a 
ThermoScientific MultiSkan™ Go 3.2 spectrophotometer. Rather than a 
standard sandwich ELISA, this kit uses the approach of a competitive inhibition 
reaction, with the D-dimer in the plasma samples (or standards) competitively 
binding to the pre-coated ELISA plate at the same time as biotin labelled D-
dimer in the detection reagent A. The higher the D-dimer in the plasma sample, 
the lower the amount of biotin labelled D-dimer that can bind to the plate. 
Avadin-bound HRP (detection reagent B) is only able to bind to the biotin 
labelled D-dimer, and so the absorbance following the addition of TMB is 
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negatively associated with the amount of D-dimer in the plasma sample. A 
standard curve was produced using the known standard samples (as provided 
by the manufacturers), and the levels of plasma D-dimer calculated using this 
curve.  
2.17 Murine TAFI ELISA 
Levels of total TAFI antigen in the murine plasma samples were measured 
using an in-house ELISA which was kindly shared with us by Prof Ann Gils (KU 
Leuven). Nunc-Immuno™ Maxisorp™ ELISA plates (Thermo Fisher Scientific 
Inc.) were coated with 200 μl of RT-36A2F5 at a concentration of 4 μg/ml 
diluted in 0.01 M phosphate buffered saline (PBS). Plates were incubated for 72 
hours at 4°C. After 72 hours, the wells were emptied and blocked with 300 μl 
per well of an albumin buffer (0.01 M PBS containing 1% BSA). The plates were 
incubated for two hours at room temperature. The wells were emptied, and 
washed four times with 300 μl of 0.01 M PBS buffer containing 0.002% 
TWEEN®-20 using a BioTek MultiFlo automatic plate washer (BioTek 
Instruments Inc.). The wells were completely emptied by blotting onto absorbent 
paper, before being prepared for storage. Prior to storage, the wells were filled 
with 200 μl of mannitol-saccharose solution (100 g mannitol and 20 g 
saccharose per litre dH2O), incubated for 2-4 minutes, and then emptied 
completely by blotting on absorbent paper. The plates were then covered in foil 
to protect them from moisture and light, and stored at -20°C until needed. Prior 
to application of the plasma samples, the plates were allowed to warm to room 
temperature, and were washed four times using 0.01 M PBS with 0.002% 
TWEEN®-20. Plasma samples were collected and stored as described above. 
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Plasma was diluted 1 part plasma in 500 parts PTAE buffer (0.01 M PBS 
containing 0.002% TWEEN®-20, 0.1% BSA and 5 mM EDTA). Serial dilutions 
of this 1/500 sample in PTAE buffer were then performed to give four 
concentrations for each plasma sample (1/500, 1/1000, 1/2000 and 1/4000). On 
each plate, two standard samples were included in order to test for inter-plate 
variability of the assay. These were samples taken from two normal mice (one 
male and one female) that had not undergone any experimental procedures. 
These standards were diluted to the same concentrations as the plasma 
samples to be tested (1/500-1/4000). Each plate also contained a standard 
curve, produced using purified murine TAFI which was a kind gift from Prof Ann 
Gils (KU Leuven). The first point of the standard curve was diluted to 30 ng/ml 
in PTAE buffer, and then serial dilutions were performed to give a total of six 
dilutions (30, 15, 7.5, 3.25, 1.625 and 0.8125 ng/ml respectively). A final well 
containing just PTAE buffer was used as a blank. Either plasma sample or 
standard solution (180 μl) was added to each well, and the plate was incubated 
overnight at 4°C. 
Following overnight incubation, the wells were emptied, and were again washed 
four times using a 0.01 M PBS 0.002% TWEEN®-20 buffer, after which, the 
wells were emptied completely by blotting against absorbent paper. The 
antibody RT-82F12-HRP was used as the capture antibody for this ELISA. It 
was diluted 1/4000 in PTA buffer (0.01 M PBS containing 0.1% BSA and 
0.002% TWEEN®-20), and 170 μl of this solution was added to each well. The 
plates were incubated for 2 hours at room temperature. Following incubation, 
the wells were emptied, and were washed four times using 0.01 M PBS 0.002% 
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TWEEN®-20 buffer. After washing, the wells were again completely emptied by 
blotting on absorbent paper.    
To produce a colorimetric reaction, 160 μl of a substrate solution containing o-
Phenylenediamine (OPD) were added to each well. To prepare the substrate 
solution, a 20 mg OPD tablet (P7288 Sigma-Aldrich Co. LLC.) was dissolved in 
30 mls of 0.05 M phosphate citrate buffer pH 5.0 (containing 7.30 g Citric Acid, 
251275 Sigma-Aldrich Co. LLC. and 11.87 g sodium phosphate dibasic, S7907 
Sigma-Aldrich Co. LLC. in 1 litre dH2O). For every 30 mls of substrate solution, 
12 μl of 30% H2O2 (H1009 Sigma-Aldrich Co. LLC.) was added. The plates 
were incubated for 60 minutes at room temperature, during which time they 
were covered in foil to protect them from light. After 60 minutes, 50 μl of 4 M 
H2SO4 was added to each well to stop the reaction. The absorbance was 
measured using a ThermoScientific MultiSkan™ Go 3.2 spectrophotometer 
(Thermo Fisher Scientific Inc. USA) at 492 nm OD. The TAFI content in the 
plasma samples was then calculated using a standard curve generated by 
plotting the absorbance against the concentration of TAFI in the standard TAFI 
samples.  
2.18 Murine CRP ELISA 
The levels of C-reactive protein (CRP) in the plasma of mice were measured at 
28 days following initiation of Ang II and TAFI inhibitor administration using a 
commercially available ELISA kit (ab157712 CRP PTX1 Mouse ELISA kit, 
Abcam® plc). The ELISA was conducted according to the manufacturer’s 
instructions. In brief, a standard curve was produced by diluting a calibrator of 
known concentration to a range of concentrations between 0-25 ng/ml. Plasma 
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samples were diluted 1/10 in the sample diluent. All samples were run in 
duplicate. Sample or standard (100 μl) was added to each well of a pre-coated 
microwell plate, and incubated at room temperature for 10 minutes. The wells 
were emptied and washed four times. One hundred microlitres of enzyme-
antibody conjugate was added to each well. The plate was incubated for 10 
minutes in the dark at room temperature. The wells were washed and 100 μl of 
TMB substrate was added to each well.  The plate was incubated for precisely 5 
minutes before 100 μl of stop solution was added. The absorbance was 
measured using a ThermoScientific MultiSkan™ Go 3.2 spectrophotometer at 
450 nm OD. A standard curve was produced using the standards of known 
concentration as provided by the manuacturers, and the levels of CRP in the 
plasma samples were calculated from this curve. 
2.19 Murine PAP ELISA 
The plasma levels of the plasmin-anti-plasmin (PAP) complex were measured 
after 28 days of treatment with Ang II, with or without a TAFI inhibitor, using a 
commercially available ELISA kit (Bioassay Technology Laboratory Cat No 
E0286 Mo, Shanghai Crystal Day Biotech Co. Ltd, assay range 5-600 ng/ml). 
The assay was performed according to the manufacturer’s instructions. In brief, 
a standard curve was produced using the supplied standard at a range between 
0-640 ng/ml. For the standards, 50 μl of standard and 50 μl of streptavidin-HRP 
was added to each well. For the plasma samples, 40 μl sample, 10 μl PAP 
antibodies and 50 μl of streptavidin-HRP was added to each well. The plate was 
then incubated at 37°C for 1 hour. The wells were emptied, washed and blotted 
onto absorbent paper. Fifty microlitres of chromagen solution A and 50 μl of 
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chromagen solution B was added to each well. The plate was incubated in the 
dark at 37°C for 10 minutes, and 50 μl of stop solution was added to each well. 
The absorbance was read at 450 nm OD using a ThermoScientific MultiSkan™ 
Go 3.2 spectrophotometer. A standard curve was produced using the standards 
of known concentrations as provided by the manufacturers, and the levels of 
PAP in the plasma samples were calculated from this curve. 
2.20 Analysis of Macroscopic Images of AAA using Image J 
Images were analysed using Image J software. Aortic images taken at 10x 
magnification were inverted using Image J to allow for clearer identification of 
the margins of the aorta (see Figure 18 for sample images). Three 
measurements were taken from the widest part of the abdominal aorta, and 
three measurements were taken from the normal thoracic aorta. The average of 
these three measurements was then used to calculate the aortic ratio 
(abdominal aortic size (mm)/thoracic aorta size (mm), ratio of greater than or 
equal to 1.5 taken as being aneurysmal). 
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Figure 18. Measurement of aortic size and calculation of the aortic ratio using ImageJ 
In-situ photographs were taken of the aortas of mice at 4x, 6x and 10x magnification using a 
OPMI-PICO videomicrometer (Carl Zeiss AG). Using ImageJ, these images were inverted in 
order to be able to more accurately determine the edges of the aorta. Using an image taken at 
10x magnification, three diameter measurements were taken in a section of normal thoracic 
aorta (T) and three measurements were taken across the widest section of the suprarenal 
abdominal aorta (A). These measurements were averaged, and the aortic ratio calculated by 
dividing the size of abdominal aorta (mm) by the thoracic aorta (mm). RK=right kidney, LK=left 
kidney, AAA=abdominal aortic aneurysm, Black arrow – denotes the position of the diaphragm. 
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2.21 Quantification of TAFI in Aortic Tissue 
Fresh aortas were harvested from mice treated with Ang II that developed 
aneurysms (n=8), and saline control treated mice (n=8) as described above. 
The tissue was immediately flash frozen on liquid nitrogen and kept at -40°C 
until analysis. The protocol was first optimised using liver samples (which were 
expected to have a relatively higher TAFI content) before being repeated using 
aortas. 
2.21.1 Homogenisation of Tissue 
Tissue samples were allowed to warm to room temperature. A small amount of 
tissue (approximately 50 μg) was placed into the bottom of a 2 ml round 
bottomed Eppendorf tube. Lysis buffer (120 mM NaCl, 50 mM Tris, 20 mM 
Sodium Fluoride, NaF, 1 mM Benzamidine, 1 mM EDTA, 6 mM ethylene glycol 
tetraacetic acid, EGTA, 15 mM  PPi, 55.6 mM glycerophosphate, 1% Nonidet P-
40 (Sigma-Aldirch Co. LLC.), 0.1 mM phenylmethanesulfonylfluoride, PMSF, 10 
μg/L leupeptin, 10 μg/l aprotinin, 1 ml/l phosphatase inhibitor cocktail 2 (P5726 
Sigma-Aldrich Co. LLC.) and 1 ml/l phosphatase inhibitor cocktail 3 (P0044 
Sigma-Aldrich Co. LLC.) was added to each Eppendorf; 100 μl for aorta 
samples and 500 μl for liver samples. The samples were incubated in the lysis 
buffer on ice for 30 minutes. A lysis bead (Retsch stainless steel cone balls 
6mm, 22.455.0003C) was added to each Eppendorf. Samples were transferred 
into the QIAGEN TissueLyser II (83500 QIAGEN, Netherlands) and lysed at 30 
Hz (1800 oscillations/min) for 2 minutes. The samples were then centrifuged 
using a table top microcentrifuge (Eppendorf MiniSpin plus, Scientific 
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Laboratory Supplies Ltd.UK) at 14,500 rpm for 10 minutes, and the supernatant 
was collected into a clean Eppendorf tube.  
2.21.2 Total Protein content in the tissue homogenate 
Total protein concentration in the supernatant was measured using a Pierce™ 
BCA Protein Assay kit (Thermo Fisher Scientific Inc.) following the 
manufacturer’s protocol. In brief, a series of standards of known protein 
concentration (range 0-2000 μg/ml) were produced using serial dilutions of a 2 
mg/ml BSA stock solution. Samples of aortic homogenate were diluted 1 part 
homogenate to 8 parts dH2O and samples of liver homogenate were diluted 
1/50 in dH2O. Sample or standard (25 μl) were added in duplicate to each well 
of a 96-well plate (Greiner bio-one microtitre plate, Greiner Bio One 
International GmbH). Protein assay solution (200 μl) was added to each well 
(Reagent A:Reagent B mixed in a 50:1 ratio) using a multi-channel pipette. The 
plate was covered using a microplate adhesive cover (Thermo Fisher Scientific 
Ltd.) to prevent any evaporation, and the plate was incubated at 37°C for 30 
minutes. The absorbency was read using a Dynex Revelation 4.21 microplate 
reader (Dynex Technologies Ltd. UK) at 540 nm OD. A standard curve was 
plotted using the absorbencies of the BSA standards, and the total 
concentration of protein in the homogenates was extrapolated from this graph.  
2.21.3 Measurement of TAFI in the tissue homogenate 
The murine TAFI ELISA was performed using the aortic tissue homogenates. 
The protocol was based upon the ELISA for plasma TAFI (see section 2.17). 
The standard curve was prepared as described previously. In order to assess 
the best dilutions for the homogenate samples, the ELISA was performed using 
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the homogenate of murine liver samples and a single control aortic sample. The 
total protein level was measured in these homogenates using the protocol 
described above. A liver sample with high total protein (25.3 mg/ml) and a 
sample with low total protein (10.3 mg/ml) were selected for optimisation of the 
ELISA. These samples, along with a sample from a single control aorta were 
serially-diluted starting with 1/50 to give a range of 8 dilutions (1/50, 1/100, 
1/200, 1/400, 1/800, 1/1600, 1/3200 and 1/6400). The absorbencies yielded by 
these samples are shown in Figure 19. Based on this, four dilutions of 1/25, 
1/50, 1/100 and 1/200 were used when measuring TAFI in the aorta 
homogenates.  For each sample, the total TAFI level in the tissue samples was 
measured, and the TAFI concentration as a percentage of the total protein in 
the tissue was calculated.  
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Figure 19. Dilution profiles of TAFI in liver and aortic samples 
Levels of TAFI in the homogenate of tissue from control mice was measured using ELISA. 
Homogenates from livers with high total protein content (red square) and low total protein 
content (purple square), as well as from a sample aorta (blue circle) were serially diluted to give 
a range between 1/50 to 1/6400. Based on the absorbencies of these dilutions, a dilution profile 
for the tissue ELISA was selected, with homogenate samples being diluted to 1/25, 1/50, 1/100 
and 1/200. 
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2.22 Histological examination of murine AAA 
Sections from murine aorta were stained for general morphology (haematoxylin 
and eosin, H+E), collagen (Picosirus red, PSR), elastin, collagen and smooth 
muscle cells (Millers Van Gieson, MVG) and fibrin (Martius Scarlet Blue, MSB).  
2.22.1 Preparation of slides for staining 
Prior to staining, samples were first deparaffinised and rehydrated. They were 
deparaffinised by soaking in xylene (534056 Sigma-Aldrich Co. LLC.) for five 
minutes, then a second, clean xylene bath for a further 5 minutes. Samples 
were transferred into 100% ethanol for 5 minutes, before being transferred into 
clean 100% ethanol for a further 5 minutes. Samples were rehydrated by 
moving them through a series of ethanol solutions; 70% ethanol for 3 minutes, 
50% for 3 minutes, 25% for 3 minutes, before being washed in water for 2 
minutes. 
2.22.2 Haematoxylin and Eosin 
Samples were deparaffinised and rehydrated as described above. 
Haematoxylin stain for nuclei was applied first (7 g/L Harris Haematoxylin 
Stain80, Sigma-Aldrich Co. LLC.), with slides incubated in the stain at room 
temperature for 10 minutes. Slides were then washed under running water for 
10 minutes. The colour was optimised by reducing the background colour or 
increasing the ‘blue’ as appropriate. The background was reduced by incubating 
the slides in a 1% HCl and 70% ETOH solution for 30 seconds before washing 
under running water for a further 3 minutes. Colour was increased by incubating 
in a 0.2% ammonium sulphate solution for 60 seconds, before washing under 
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running water for a further 3 minutes. Once the stain appeared acceptable, the 
slides were dipped into 3 solutions of 70% ethanol prior to staining with eosin. A 
stock of eosin stain was produced by adding 1.25 g of Eosin Y (E4009 Sigma-
Aldrich Co. LLC.) to 100 mL of 90% ethanol and 25 mL of molecular grade 
dH2O, before the solution was diluted 1:4 by adding a further 300 mL of 100% 
ETOH, 75 mL of molecular grade dH2O and 2.5 mL of 40% glacial acetic acid. 
The slides were incubated in this stain for 30 seconds, then rinsed three times 
in molecular grade dH2O.  
2.22.3 Picosirus Red  
Slides were stained for haematoxylin as described above. They were then 
counterstained with picosirus red in order to visualise the collagen. One gram of 
Direct Red 80 (365548 Sigma-Aldrich Co. LLC.) was added to 1 litre of a 
saturated aqueous solution of picric acid (197378 Sigma-Aldrich Co. LLC.). 
Slides were incubated in this solution for 60 minutes before being washed in 
running water for 5 minutes, and then left to dry for 20 minutes at 70°C. 
2.22.4 Millers Van Gieson 
Following deparaffinisation and rehydration as described above, samples were 
oxidised by soaking them in a 0.5% solution of potassium permanganate 
(223468 Sigma-Aldrich Co.LLC.) for 10 minutes. Slides were washed in running 
water for two minutes, before being soaked in a 2% solution of oxalic acid 
(247537 Sigma-Aldrich Co.LLC.) for 1 minute in order to reduce any 
subsequent background during staining. Next, slides were washed in running 
water for 2 minutes, before being dipped in 3 serial solutions of 96% ETOH. The 
samples were incubated in the Miller’s stain for 1 hour. Slides were washed in 4 
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serial 100% ETOH solutions for 2 minutes at a time, in order to ‘de-stain’ the 
Miller’s stain from the slide, before being washed under running water for 5 
minutes. Slides were transferred into the Van Geison stain and incubated for 30 
minutes at room temperature. Slides were washed in molecular grade dH2O 
until the water was clear, and left to dry at 70°C for 20 minutes.  
2.22.5 Martius Scarlet Blue 
Samples were stained for fibrin using Martius Scarlet Blue (MSB) (Lendrum et 
al., 1962) using a kit from Atom Scientific (RRSK2, Atom Scientific Ltd, UK) 
according to the manufacturer’s instructions. In brief, samples were stained in 
Weigerts Iron Haematoxylin for 10 minutes. They were then washed in running 
water, before being de-stained by incubating for 3 minutes in a 1% HCl and 
70% ETOH solution. They were washed again in running water, and stained 
with a 0.5% Martius Yellow solution for 3 minutes. After another wash in running 
water, they were transferred into 1% Crystal Ponceau in 1% acetic acid for 5 
minutes, washed again and transferred into 1% Phophotungstic acid for 5 
minutes. After a further wash in running water, they were placed into a Methyl 
Blue solution (1% methyl blue in 1% acetic acid) for 2-5 minutes. Slides were 
finally washed in running water, and left to dry at room temperature.  
2.22.6 Dehydration and Mounting of Slides  
After staining, samples were dehydrated by serial soaking first in 96% ethanol 
for 2 x 2 minutes, then xylene for 2 x 2 minutes. Slides were allowed to air dry 
for 15 minutes before microscope cover slips (C9056, Sigma-Aldrich Co. LLC.) 
were applied using DPX mounting medium (06522, Sigma-Aldrich Co. LLC.). 
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Slides were imaged using an Olympus BX40 Dual View Microscope and Image 
Pro-Plus 8.0 at 4-20x magnifications. 
2.23 Data Analysis and Sample Size selection 
Raw data obtained in the laboratory was initially collected into Microsoft Excel. 
GraphPad Prism v6 was used to represent the data graphically. Statistical tests 
were performed using IBM SPSS Statistics v20 (SPSS Inc. Chicago, Illinois, 
USA) and GraphPad Prism v6. Statistically significant results were taken as 
p<0.05.  
The samples sizes for the various plasma assays were determined by using 
pilot data. For the intact TAFI ELISA, with a standard deviation in each group of 
4 μg/ml with 90% power at p<0.01, 23 per group were required to detect a 
significant difference in the mean values. As the variation was higher in the pilot 
data for the TAFIa/TAFIai (standard deviation up to 19 ng/ml) and TAFI-AP 
ELISAs (standard deviation up to 250 ng/ml), when the same conditions were 
applied, 105 and 163 respectively were required per group. For the TAFI activity 
assay, due to wide inter-group variation, with standard deviation of up to 16 
minutes, under the same conditions, 129 were needed per group. Therefore, 
the aim was to perform each assay on >200 per group. For the assays relating 
to turbidity-lysis in patient samples, sample size was based upon the difference 
previously detected in lysis in this group of patients (Scott et al., 2011). The aim 
was to test if the delay in lysis could be corrected by altering TAFI levels, and to 
do this with 90% power at p<0.01, only 9 samples were needed per group. As a 
result, 32 patients were used per group, to allow for the detection of an effect 
that was subtle than a complete correction in the change in lysis. 
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For the data on polymorphisms in proteins involved in fibrinolysis, genotype 
distribution was compared with the Hardy-Weinberg Equilibrium. The sample 
size used for these gene studies provided >80% power to detect a genotype 
relative risk of 1.3 for an average allele frequency of 0.2, with a disease 
prevalence of 8% and α = 0.05 (Menashe et al., 2008). The difference in the 
distribution of genotypes between groups was analysed using Pearsons Chi-
Squared testing. 
For the murine work investigating TAFI inhibition in-vivo, the sample size was 
based upon pilot data relating to the Angiotensin II model in our institution, with 
Angiotensin II given at a dose of 750 ng/kg/min. Using our results, in order to 
detect a change in AAA ratio of 1.3 (reverting from the mean for AAA in our pilot 
data 2.3 ± 0.9 to the normal 1.0 ± 0.2), with 90% power at p<0.05, 6 animals 
would be needed to appreciate an effect. Given the known mortality of this 
model, 12 mice were used per group.  
For the data on TAFI in plasma in human AAA, normality was tested using 
Shapiro-Wilk. A normal distribution could not be achieved by transforming data 
using Log10 or natural Log, and so data was analysed as non-parametric data. 
Data on turbidity and turbidity lysis in human plasma was also tested for 
normality using Shapiro-Wilk, and was transformed using Log10, and 
subsequently analysed as parametric data. Non-parametric data was analysed 
using Mann-Whitney U testing, and parametric data was analysed using 
Student T-testing. Non-parametric data is presented as median (Inter-quartile 
range), and parametric data as mean ± standard deviation. For patient 
demographics, continuous data is presented as median (Inter-quartile range) 
and categorical data as number of subjects (% of total), with differences 
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between the groups analysed initially using student T-test for continuous data 
and Pearsons Chi-Squared for categorical data, prior to binary logistic 
regression analysis. For murine studies, groups were compared using student 
T-test, and data presented as mean ± standard deviation.  
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Chapter 3 Results – The Role of TAFI in Human AAA 
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The role of TAFI in human AAA was investigated using samples of plasma and 
DNA from patients with AAA and control subjects who were recruited as part of 
the Leeds Aneurysm Development Study (ethical approval granted by Leeds 
East Research Ethics Committee 03/142). Plasma samples were collected and 
processed as described in Section 2.2, page 48. Plasma levels of intact TAFI 
zymogen, TAFI activation peptide (TAFI-AP) and activated and inactivated TAFI 
(TAFIa/TAFIai) were measured using ELISA. Plasma TAFI activity was 
determined using a modified clot lysis assay. Patients with AAA and control 
subjects were genotyped for four common polymorphisms of proteins involved 
in fibrinolysis (TAFI Thr325Ile, α2AP Arg6Trp and Arg407Lys, and tPA 
7351C→T). Finally, the role of TAFI in the delayed lysis seen in patients with 
AAA was explored using turbidity-lysis assays with exogenous TAFI and an 
inhibitor of TAFI, PCI. 
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3.1  Plasma levels of activated and inactivated TAFI, and the TAFI 
activation peptide, are higher in patients with AAA than control 
subjects 
Plasma levels of intact TAFI zymogen, TAFIa/TAFIai measured in combination, 
and TAFI-AP were all measured using ELISA techniques as described on Page 
49. The assays were performed on a total of 259 patients with AAA and 227 
control subjects. The basic demographics of these two groups are shown in 
Table 1. The two groups were compared for compounding risk factors, such as 
cardiovascular disease and smoking. As might be expected, there were some 
differences in the incidence of MI (27.0% in AAA patients vs. 7% in controls, 
p<0.001), hypertension (62.5% vs. 39.7%, p<0.001) and smoking status 
(current smokers 21.2% vs. 11.9%, p=0.005), but after binary logistic 
regression, only aortic diameter remained different between the two groups 
(AAA 4.9(3.8-6.0) cm vs. control 1.8(1.6-2.1) cm, p<0.001).  
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Table 1. Demographics of AAA patients and control subjects in whom levels of plasma 
TAFI, TAFIa/TAFIai and TAFI-AP were measured 
 Patients (AAA) 
n=259 
Controls (no AAA) 
n=227 
p-value 
Aorta size (cm)  4.9 (3.8-6.0) 1.8 (1.6-2.1) <0.0001 
BMI (weight kg/height m2)  27.6 (24.4-
30.7) 
27.8 (24.7-30.4) 0.98 
Age (years)  74.0 (64.0-
79.0) 
69.0 (63.0-75.0) <0.0001 
Male n(%)  211 (81.5%) 166 (73.1%) 0.03 
Drug history n(%)  Aspirin 182 (70.3%) 80 (35.2%) <0.0001 
Statin 210 (81.1%) 105 (46.3%) <0.0001 
Past Medical 
History 
 n(%)  
DM 38 (14.7%) 27 (11.9%) 0.42 
MI 70 (27.0%) 16 (7.0%) <0.0001 
Angina 61 (23.6%) 18 (7.9%) <0.0001 
CVA/TIA 35 (13.5%) 27 (11.9%) 0.59 
↑BP 162 (62.5%) 86 (37.9%) <0.0001 
Smoking Status 
n(%)  
Current 55 (21.2%) 26 (11.5%) 0.007 
Ever 229 (88.4%) 150 (66.1%) <0.0001 
DM - Diabetes Mellitus, MI - Myocardial Infarction, CVA/TIA - Cerebrovascular Accident or 
Transient Ischaemic Attack, ↑BP – Hypertension, AAA – abdominal aortic aneurysm, BMI – 
body mass index. Results are shown as median (interquartile range) and number (percentage 
of patients). Differences between groups were analysed using Pearsons Chi-Squared 
(categorical data) and Student T-test (continuous data). 
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The levels of intact TAFI zymogen were measured using an in-house ELISA 
from the laboratory of Prof Ann Gils in KU Leuven. MA-T12D11 was used as the 
coating antibody, with MA-T30E5A2-HRP used as the detection antibody. 
Results are shown as median (inter-quartile range). All samples were diluted to 
four different concentrations, and all plates were run at least twice to ensure an 
adequate number of duplicates for each sample. This is described in detail on 
Page 53. The quality control data for this ELISA is shown in Figure 20 (panels 
A-B). There was no difference in the levels of intact TAFI zymogen between 
patients with AAA and control subjects (13.1 (11.0-15.7) μg/ml vs. 12.7 (10.6-
15.2) μg/ml respectively, p=0.37, panel A, Figure 21).  
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A C 
B D 
  
Figure 20. Intra-assay variability for the Intact TAFI and TAFI-AP ELISAs 
Each point represents the mean value for each sample per plate, generated using 4 different 
dilutions of the standards on a single plate. The black line represents the mean value for that 
standard across all plates. The dark blue lines represent 1-standard deviation from the mean, 
with the light blue line(s) showing 2-standard deviations from the mean. All plates containing a 
control sample that fell > 2 standard deviations away from the mean were repeated. 
A – Variation in the level of intact TAFI in ABJ60, a single patient standard over time 
B – Variation in level of intact TAFI in NPP, a standard based on 25 healthy individuals, over 
time 
C – Variation in the level of the TAFI-AP in ABJ60 over time 
D – Variation in the level of the TAFI-AP in NPP over time 
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Figure 21. Plasma levels of TAFIa/TAFIai and TAFI-AP are increased in patients with AAA, 
and are associated with aneurysm size 
Levels of TAFI, TAFIa/TAFIai and TAFI-AP were measured in the plasma of patients with AAA 
(n=259) and control subjects (n=227) using ELISAs. There was no difference in the plasma 
levels of total TAFI zymogen in patients with AAA compared with controls (p=0.37, Panel A). 
The levels of TAFIa/TAFIai and TAFI-AP were significantly increased in patients with AAA 
compared with control subjects; TAFIa/TAFIai, p<0.0001, Panel B, and TAFI-AP, p<0.0001, 
Panel C. Levels of TAFIa/TAFIai and TAFI-AP were positively correlated (r=0.1656, p=0.001), 
Panel D. The increase in plasma levels was associated with AAA size; patients with large AAA 
(>5cm, n=154) had the highest levels, even compared to patients with small AAA (3-5cm, n=93), 
Panels E and F. Data are presented as median (IQR).  
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The levels of TAFI-AP were also measured using an in-house ELISA from KU 
Leuven. MA-T12D11 was used as the coating antibody and MA-T18A8-HRP 
was used as the detection antibody. Again, all samples were diluted to four 
different concentrations, and all plates were run at least twice to ensure an 
adequate number of duplicates for each sample as described on Page 59. The 
quality control data for this ELISA is shown in Figure 20 (panels C and D). 
Results are shown as median (inter-quartile range). The levels of TAFI-AP were 
significantly higher in plasma of patients with AAA compared with plasma from 
control subjects (318.7 (195.4-483.3) ng/ml vs. 248.6 (193.4-325.0) ng/ml, 
P<0.0001, panel C, Figure 21). 
The levels of TAFIa/TAFIai were measured in combination using a commercially 
available ELISA (Asserachrom® TAFIa/TAFIai, ref 00616, Diagnostica Stago 
UK Ltd). Quality control testing was done for each plate using a high and low 
control as per the manufacturer’s instructions. Results are shown as median 
(inter-quartile range). Again, the levels of TAFIa/TAFIai were significantly higher 
in patients with AAA compared with control subjects (20.5 (14.5-33.4) ng/ml vs. 
14.2 (10.9-19.2) ng/ml, P<0.0001, panel B, Figure 21).  
Plasma levels of TAFIa/TAFIai and TAFI-AP were positively correlated 
(r=0.1656, p=0.001), indicating that the results of these ELISAs are both 
indicators of the amount of TAFI that has been activated in the plasma samples 
(panel D, Figure 21).  
 AAA subjects were divided into two groups based on the size of their AAA; 
small AAA (3-5 cm, n=93) or large AAA (>5 cm, n=154). Both the levels of TAFI-
AP and TAFIa/TAFIai increased with the size of the AAA. TAFI-AP levels were 
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320.6 (193.5-478.8) ng/ml in patients with small AAA, increasing to 321.4 
(207.5-509.4) ng/ml in patients with large AAA (p=0.0002). TAFIa/TAFIai levels 
were 19.1 (13.9-31.9) ng/ml in the plasma of patients with small AAA, 
increasing to 22.4 (14.8-39.0) ng/ml in patients with large AAA (p<0.0001). 
There was no difference in the levels of the intact TAFI zymogen between 
patients with small and large AAA (13.2 (10.9-16.1) µg/ml vs. 13.1 (11.2-15.5) 
µg/ml, panels E and F, Figure 21).  
 
3.2 TAFI Activity is decreased in the plasma of patients with AAA 
compared with control subjects 
In order to measure just active TAFI in the plasma samples, a modified clot lysis 
assay was used. Clot lysis assays were performed with and without the 
presence of PCI, a potent inhibitor of TAFI. The difference in the time to half 
lysis when PCI is present is a proxy of the activity of TAFI in the sample, and is 
termed the TAFI-related retardation to lysis time. This is illustrated in Figure 12. 
Results are presented as median (inter-quartile range). The TAFI-related 
retardation to lysis time was significantly lower in patients with AAA compared 
with control subjects (44.25 (34.25-54.25) mins vs. 52.38 (39.06-63.31) mins, 
p<0.0001, Figure 22, panel A). In order to adjust for differences in the intact 
zymogen levels of TAFI in the samples prior to its activation with thrombin and 
thrombomodulin, the TAFI-specific anti-fibrinolytic activity was calculated for 
each sample, which was taken as a ratio of the TAFI-related retardation to lysis 
divided by the intact zymogen levels (as established by the intact TAFI ELISA). 
The TAFI-specific anti-fibrinolytic activity in plasma from patients with AAA was 
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significantly lower than the activity in samples from control subjects (3.15 (2.42-
4.15) vs. 3.94 (2.76-5.24), p<0.0001, Figure 22, panel B). 
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Figure 22. TAFI-related retardation to lysis and TAFI-specific anti-fibrinolytic activity is 
decreased in patients with AAA compared with control subjects 
Using a modified clot lysis assay, the TAFI-related retardation to lysis was measured in the 
plasma of patients with AAA (n=214) and control subjects (n=210). Results are presented as 
median (IQR). The TAFI-related retardation to lysis time was decreased in patients with AAA 
compared with control subjects (p<0.0001, Panel A). By comparing these results with the levels 
of intact TAFI (as measured by ELISA), the TAFI-specific anti-fibrinolytic activity was calculated. 
The TAFI-specific anti-fibrinolytic activity was decreased in patients with AAA compared with 
control subjects (p<0.0001, Panel B).  
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3.3 The correlation between polymorphisms of proteins involved in 
fibrinolysis and AAA 
DNA was extracted from the whole blood of patients with AAA (n=602) and 
control subjects (n=490), and Taqman genotyping assays were used to analyse 
four polymorphisms in proteins related to fibrinolysis; TAFI Thr325Ile, α2AP 
Arg6Trp, α2AP Arg407Lys and tPA 7351C→T. These methods are described in 
full in Chapter 2.7. Larger numbers of subjects were included for this part of the 
thesis in order to ensure that genotyping results had significant power. The 
basic demographics of these patients are shown in Table 2. As was the case 
when a smaller population was used for the studies of plasma TAFI levels, there 
were some differences in relation to evidence of cardiovascular disease 
between patients with AAA and control subjects, but again, after binary logistic 
regression analysis, only aortic size remained significantly different between the 
two groups. Results are shown as a percentage of subjects in each group being 
in possession of the rare allele, followed by the odds ratio (95% confidence 
intervals). 
All genotype distributions were in keeping with the Hardy-Weinberg equilibrium. 
In addition, the allele frequencies for all four of the polymorphisms are in the 
range expected based on previously published results of these polymorphisms 
in disease states and in healthy populations (Brouwers et al., 2001, 
Christiansen et al., 2007, Uitte de Willige et al., 2011). The allele frequencies 
and comparison of the results with the Hardy-Weinberg equilibrium are shown 
in Table 3. A sample of the output generated using PCR and end-point 
genotyping is shown in Figure 23. 
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Table 2. The Demographics of patients with AAA and control subjects in whom 
genotyping was undertaken to establish the presence of polymorphisms of TAFI, α2AP 
and tPA 
 Patients (AAA)  
n=602  
Controls (no 
AAA)  
n=490  
p-value 
Aorta size (cm)  4.69 (4.57-4.81)  1.94 (1.90-1.98)  <0.0001 
Family History n(%)  50 (8.3%)  42 (8.6%)  0.91 
BMI (weight kg/height m
2
)  27.09 (26.70-
27.48)  
27.64 (27.26-
28.03)  
0.06 
Waist-hip ratio  0.95 (0.94-0.96)  0.93 (0.92-0.94)  <0.0001 
Age (years)  74.7 (73.7-75.0)  70.0 (69.3-70.7)  <0.0001 
Male n(%)  497 (82.8%)  377 (76.9%)  0.02 
Drug history, 
n(%)  
Aspirin  396 (65.9%)  214 (43.7%)  <0.0001 
Statin  438 (72.9%)  239 (48.8%)  <0.0001 
Past Medical 
History, n(%)  
DM  85 (14.1%)  62 (12.7%)  0.923 
MI  159 (26.5%)  48 (9.8%)  <0.0001 
Angina  142 (23.6%)  76 (15.5%)  0.02 
CVA/TIA  106 (17.6%)  63 (12.9%)  0.04 
↑BP  343 (57.1%)  198 (40.4%)  <0.0001 
Smoking 
Status, n(%)  
Current  136 (22.7%)  78 (15.9%)  0.006 
Ever  543 (90.1%)  339 (69.2%)  <0.0001 
DM - Diabetes Mellitus, MI - Myocardial Infarction, CVA/TIA - Cerebrovascular Accident or 
Transient Ischaemic Attack, ↑BP – Hypertension, AAA – abdominal aortic aneurysm, BMI – 
body mass index. Results are shown as median (inter quartile range) and number (percentage 
of patients). Differences between groups were analysed using Pearsons Chi-Squared 
(categorical data) and Student T-test (continuous data). 
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Table 3. Mutant Allele frequency and Results of Hardy-Weinberg Equilibrium for the 
population genotyping of TAFI Thr325Ile, α2AP Arg6Trp, α2AP Arg407Lys and tPA 
7351C→T 
 Mutant allele 
frequency  
Total Population  
X
2
  P  
Arg6Trp  0.20  0.3459  0.5564  
Arg407Lys  0.17  2.49  0.1143  
tPA 7351C→T  0.36  0.3860  0.5343  
Thr325Ile  0.30  0.0080  0.9285  
Page | 119  
 
 
 
Figure 23. Example output of end-point genotyping using TaqMan Genotyping assays 
and real-time PCR 
Genotyping was carried out using TaqMan genotyping assays. In these assays, allelic 
discrimination is based on the 5’ to 3’ exonuclease activity of the Taq DNA polymerase. For 
each SNP, two different TaqMan probes are used, one specific to the wild type (WT) and one 
specific to the variant allele. A 5’ reporter dye and a 3’ quencher dye are covalently linked to 
each of the two probes. When the probes are intact, the reporter dye (fluorescence dye) is not 
observed because it is in close proximity to the quencher dye. However, during PCR 
amplification, the reporter and quencher dyes are released due to the 5’ nuclease activity of the 
Taq DNA polymerase. This results in increased fluorescence of the relevant probe’s reporter 
dye (WT or variant). At the end of the PCR reaction, the relative amount of the two reporter 
dyes can be used to determine the genotype. This can be plotted on a graph as shown above.  
The example genotyping result shown is that of TAFI Thr325Ile; blue triangles represent Thr/Thr 
homozygotes, red triangles represent Thr/Ile heterozygotes, and green triangles represent Ile/Ile 
homozygotes.  
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3.3.1 TAFI Thr325Ile 
The Thr325Ile polymorphism is positioned in the thermoregulatory centre of the 
TAFI gene. This coding polymorphism results in a TAFIa molecule that has a 
longer half-life at 37°C and a higher anti-fibrinolytic potential. The possession of 
this polymorphism has previously been linked with the incidence of some 
cardiovascular diseases (Shi et al., 2014). In the case of AAA, there was no 
association between possession of an isoleucine allele and AAA, with 52.3% of 
AAA patients and 49.2% of controls being in possession of at least one 
isoleucine allele, OR 1.13 (0.89-1.44), p=0.31 (Figure 24, Panel A). 
3.3.2 Alpha-2-Antiplasmin Arg6Trp and Arg407Lys 
There was a strong positive correlation between possession of a tryptophan 
allele at position 6 and possession of a lysine allele at position 407, suggesting 
that in α2AP, these alleles are in linkage disequilibrium (see Table 4, Pearson 
Chi-Squared p<0.0001). In the case of AAA, we found that there was a 
significant reduction in the number of patients in possession of a lysine allele at 
position 407 compared with control subjects (29.1% vs. 34.9%, OR 0.77 (0.53-
0.98), p=0.04, see Figure 24, panel C). Despite the strong association between 
these two polymorphisms, there was no significant difference in the genotype 
distribution of the Arg6Trp polymorphism and AAA (Figure 24, panel B). 
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Table 4. The association between the Arg6Trp and Arg407Lys polymorphisms of α2AP 
p<0.0001 
Arg407Lys  
Total Arg/Arg Arg/Lys Lys/Lys 
Arg6Trp  Arg/Arg  662 46 1 709 
Arg/Trp  78 256 4 338 
Trp/Trp  6 20 19 45 
Total  746 322 24 1092 
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3.3.3  tPA 7351C→T   
 The tPA 7351C→T polymorphism lies in the enhancer region of the tPA gene, 
and results in a decrease in the rate of tPA release from the vascular 
endothelium. It has previously been associated with MI (Ladenvall et al., 2002). 
There was no association between this polymorphism and AAA, with the 
percentage of patients in possession of a T allele being similar between the two 
groups (57.5% of patients with AAA and 59.2% of control subjects, OR 0.93 
(0.73-1.19) p=0.57, Figure 24, panel D). 
 
All of these genotyping results are summarised in Table 5. 
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Figure 24. The genotype distributions of α2AP Arg407Lysand Arg6Trp, TAFI Thr325Ile 
and tPA 7351C→T. The Arg407Lys polymorphism of α2AP is negatively associated with 
AAA. α2AP Arg6Trp, TAFI Thr325Ile and tPA 7351C→T are not associated with the 
presence of AAA. 
The genotype distribution of α2AP Arg407Lys (Panel C) and Arg6Trp (Panel B), TAFI Thr325Ile 
(Panel A) and tPA 7351C→T (Panel D) were studied in patients with AAA (n=602) and control 
subjects (n=490) using DNA extracted from whole blood, Taqman genotyping assays and PCR. 
Results are presented as the percentage of each group (patient or control) being in possession 
of each genotype. Patients with AAA are represented by the light blue bars, control subjects are 
shown as the dark blue bars. Only the Arg407Lys polymorphism was associated with AAA, with 
patients being less likely to be in possession of the rare Lys allele compared with control 
subjects (29.1% vs. 34.9%, p=0.04, panel C).  
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Table 5. The Arg407Lys polymorphism of α2AP is negatively associated with AAA 
  Aneurysm 
n=602 (%)  
Control 
n=490 (%)  
OR (95% CI)  Chi-squared  
α2AP No Trp (Arg/Arg)  403 (66.9)  306 (62.4)  1   
Arg6Trp Trp  199 (33.1)  184 (37.6)  0.82 (0.64-1.05)  P=0.12  
 Arg/Trp  169 (28.1)  169 (34.5)    
 Trp/Trp  30 (5.0)  15 (3.1)    
α2AP No Lys (Arg/Arg)  427 (70.9)  319 (65.1)  1   
Arg407Lys Lys  175 (29.1)  171 (34.9)  0.77 (0.59-0.98)  P=0.04*  
 Arg/Lys  161 (26.7)  161 (32.9)    
 Lys/Lys  14 (2.3)  10 (2.0)    
tPA  No T (C/C)  256 (42.5)  200 (40.8)  1   
7351C→T T  346 (57.5)  290 (59.2)  0.93 (0.73-1.19)  P=0.57  
 C/T  260 (43.2)  232 (47.3)    
 T/T  86 (14.3)  58 (11.8)    
TAFI No Ile(Thr/Thr)  287 (47.7)  249 (50.8)  1   
Thr325Ile Ile  314 (52.3)  241 (49.2)  1.13 (0.89-1.44)  P= 0.31  
 Thr/Ile  257 (42.7)  202 (41.2)    
 Ile/Ile  58 (9.6)  39 (8.0)    
DM - Diabetes Mellitus, MI - Myocardial Infarction, CVA/TIA - Cerebrovascular Accident or 
Transient Ischaemic Attack, ↑BP – Hypertension, AAA – abdominal aortic aneurysm, BMI – 
body mass index. Results are shown as median (interquartile range) and number (percentage 
of patients).  
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3.4 TAFI Thr325Ile is associated with TAFI activity levels in-vitro  
The correlation between the Thr325Ile genotype and TAFI activity levels in-vitro 
was investigated in a total of 391 study participants (both AAA and controls). In 
this population, the relative genotype frequencies were 49.4% Thr/Thr (n=193), 
42.2% Thr/Ile (n=165) and 8.4% Ile/Ile (n=33). It has previously been shown 
that, when activated, TAFI 325Ile has a longer half-life and a higher anti-
fibrinolytic activity in-vitro compared with the more common TAFI 325Thr. In the 
population under study, possession of an isoleucine allele was positively 
associated with increasing TAFI activity, determined using the modified clot 
lysis assay. Activity increased in a stepwise fashion with possession of an 
isoleucine allele, with Ile/Ile homozygotes having the longest TAFI-related 
retardation times (Thr/Thr 46.0 (33.5-55.5) mins, Thr/Ile 48.0 (37.6-60.3) mins, 
p=0.04, and Ile/Ile 56.5 (38.3-68.9) mins, p=0.004, panel A), and the highest 
TAFI-specific anti-fibrinolytic activity (Thr/Thr 3.1 (2.5-4.2), Thr/Ile 3.9 (2.7-5.1), 
p=0.002, and Ile/Ile 4.6 (3.6-6.3), p<0.0001, panel B).  
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Figure 25. TAFI- related retardation to lysis time and TAFI-specific anti-fibrinolytic activity 
is increased with possession of the TAFI 325Ile polymorphism 
Using a modified clot lysis assay, the TAFI-related retardation to lysis was measured in the 
plasma of 391 study participants of known TAFI Thr325Ile genotype (Thr/Thr n=193, Thr/Ile 
n=165 and Ile/Ile n=33). Results are presented as median (IQR). The TAFI-related retardation 
to lysis time was increased in those with an isoleucine allele, and increased in a stepwise 
fashion for Thr/Ile heterozygotes and Ile/Ile homozygotes (Thr/Thr 46.0 (33.5-55.5) mins, Thr/Ile 
48.0 (37.6-60.3) mins, p=0.04, and Ile/Ile 56.5 (38.3-68.9) mins, p=0.004, panel A). By 
comparing these results with the levels of intact TAFI (as measured by ELISA), the TAFI-
specific anti-fibrinolytic activity was calculated. The TAFI-specific anti-fibrinolytic activity was 
increased in a stepwise fashion with possession of an isoleucine allele (Thr/Thr 3.1 (2.5-4.2), 
Thr/Ile 3.9 (2.7-5.1), p=0.002, and Ile/Ile 4.6 (3.6-6.3), p<0.0001, Panel B).  
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3.5 The delay in clot lysis in patients with AAA may be attributed to TAFI 
It has previously been shown that clot lysis time is delayed in fibrin clots 
produced ex-vivo using plasma samples of patients with AAA, compared with 
control subjects (Scott et al., 2011). 
Plasma samples from patients with large AAA (n=32) were compared with 
plasma samples from control subjects (n=32). The basic demographics of these 
two groups are shown in Table 6. Turbidity-lysis experiments, using thrombin as 
the initiator of clot formation, confirmed a delay in the lysis time of patients with 
AAA compared with controls (AAA 34.28 ± 19.68 mins vs. controls 27.79 ± 
6.173 mins, Figure 26, panel A). Through analysis of these lysis curves, it is 
clear that the delay in lysis in patients with AAA occurs late, after lysis has 
already been initiated. Diabetes is known to result in a prolongation of clot lysis 
(Bailey et al., 2015). Thus, due to the significant difference in the number of 
people with a diagnosis of diabetes between the patient and control groups, the 
data was analysed again, but with any diabetic participants excluded. Even 
once these patients had been excluded, there was still a difference, albeit 
slightly smaller, in the time to half lysis between patients and controls (32.35 ± 
3.35 mins vs. 28.08 ± 1.09 mins, p=0.19), indicating that the delay in lysis time 
seen was not attributable only to the increase in diabetes in the patient 
population. The addition of excess TAFI (15 µg/ml final concentration in excess 
of plasma TAFI levels) to control plasma samples resulted in a delay in the lysis 
time that replicated the pattern seen in patients with AAA (lysis time increased 
from 27.79 ± 6.173 mins without additional TAFI to 29.08 ± 24.77 mins with 
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additional TAFI, p<0.0001, Figure 26, panel E). The addition of PCI (final 
concentration 30 µg/ml) to plasma samples of patients with AAA resulted in a 
decrease in lysis time back to the levels seen in controls (lysis times decreased 
from 34.28 ± 19.68 mins without PCI to 28.12 ± 7.195 mins with PCI, p=0.04, 
Figure 26, panel C). When thrombomodulin (final concentration 0.6 units/ml) 
was added to the activation mix (in order to ensure that all of the TAFI within the 
samples were activated), there was still a delay in the lysis time in patients with 
AAA compared with controls (AAA 123.5 ± 39.35 mins vs. controls 100.5 ± 
17.14 mins, p=0.002, Figure 26, panel B). However, adding additional TAFI to 
the control samples did not result in any delay to lysis in these conditions (104.7 
± 15.05 mins without additional TAFI vs. 100.5 ± 17.14 mins with additional 
TAFI, Figure 26, panel F). As would be expected, addition of PCI to the samples 
of patients with AAA resulted in a decrease in the time to half-lysis (123.5 ± 
39.35 mins without PCI to 41.48 ± 25.76 mins, p<0.0001, Figure 26, panel D). 
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Table 6. The demographics of patients with AAA and control subjects used for the study 
of the effect of TAFI on turbidity-lysis in patients with AAA 
 Patients (AAA) 
n=32 
Controls (no AAA) 
n=32 
p-value 
Aorta size (cm)  6.0 (5.1-7.0) 2.0 (1.9-2.5) <0.0001 
BMI (weight kg/height m2)  25.7 (24.4-27.8) 26.4 (24.0-29.9) 0.26 
Age (years)  72.5 (69.3-77.0) 72.5 (71.0-78.0) 0.40 
Male n(%)  32 (100%) 31 (96.9%) 1.0 
Drug history n(%)  Aspirin 23 (71.9%) 16 (50%) 0.12 
Statin 23 (71.9%) 13 (40.6%) 0.02 
Past Medical 
History 
 n(%)  
DM 8 (25.0%) 1 (3.1%) 0.02 
MI 7 (21.9%) 3 (9.4%) 0.30 
Angina 6 (18.8%) 5 (15.6%) 1.0 
CVA/TIA 11 (34.4%) 2 (6.3%) 0.01 
↑BP 22 (68.8%) 10 (31.3%) 0.006 
Smoking history n(%) 30 (93.9%)` 22 (68.8%) 0.02 
DM - Diabetes Mellitus, MI - Myocardial Infarction, CVA/TIA - Cerebrovascular Accident or 
Transient Ischaemic Attack, ↑BP – Hypertension, AAA – abdominal aortic aneurysm, BMI – 
body mass index. Results are shown as median (interquartile range) and number (percentage 
of patients).  
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Figure 26. Turbidity-Lysis curves in the plasma of patients with AAA show a late delay in 
lysis which can be attributable to TAFI 
Turbidity-lysis curves were generated using plasma samples from patients with large AAA 
(n=32) and control subjects (n=32). Using an activation mix containing thrombin, calcium and 
tPA, the lysis times of patients with AAA (blue line) were increased compared with control 
subjects (red line); this was due to a late delay in lysis (Panel A). A delay in lysis was also seen 
when thrombomodulin was included in the activation mix (Panel B). When potato 
carboxypeptidase inhibitor (PCI) was added to the plasma of patients with AAA (green line) and 
clotting was activated using thrombin and calcium, the secondary delay in lysis was abolished 
(Panel C). In the presence of thrombomodulin, addition of PCI had a marked effect, as all TAFI 
activity in the sample was inhibited (Panel D). When exogenous TAFI was added to the plasma 
of control subjects (orange line), a secondary delay in lysis, akin to that seen in patients with 
AAA was seen (Panel E). There was no effect of adding additional TAFI in the presence of 
thrombomodulin (Panel F). 
 
Page | 131  
 
Due to the non-uniform pattern of lysis in these samples, the area under the 
curve (AUC) was calculated in order to better represent the difference in the 
lysis profiles. These results demonstrated the same patterns, with a reduction in 
AUC in control subjects compared with AAA patients, which could be corrected 
with the addition of PCI to the AAA samples (AAA 656.5 ± 695.2, control 399.9 
± 134.3, AAA and PCI 542.8 ± 519.1).  
Together, these results show that TAFI does appear to play a role in the delay 
in lysis that has previously been demonstrated in the plasma of patients with 
AAA, and that this delay in lysis time can be corrected through the inhibition of 
TAFI. This is summarised in Figure 27.  
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Figure 27. There is a delay in the fibrinolysis time in patients with AAA, and this can be 
corrected through the inhibition of TAFI 
Turbidity-lysis profiles were generated using plasma samples from patients with AAA (n=32) 
and control subjects (n=32). An activation mix containing thrombin, calcium and tPA was used 
to initiate the reaction. There was a delay in the time to half lysis of patients with AAA (blue 
triangles) compared with control subjects (red circles), 34.28 ± 19.68 mins vs. 27.79 ± 6.173 
mins. The addition of exogenous TAFI at 15 µg/ml to the plasma of control subjects (orange 
circles) resulted in a delay in lysis time (27.79 ± 6.173 mins to 29.08 ± 24.77 mins, p<0.0001). 
The inhibition of TAFI in the plasma of patients with AAA using potato carboxypeptidase 
inhibitor (green triangles) resulted in a decrease in the time to half lysis (34.28 ± 19.68 mins to 
41.48 ± 25.76 mins, p=0.04). 
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3.6 The histological examination of the intra-luminal thrombus reveals 
an organised fibrin network 
Samples of intra-luminal thrombus (ILT) taken from patients with AAA 
undergoing an open operation were collected, processed and paraffin 
embedded. Transverse sections of 5 µm were taken through the samples of ILT 
in order to be able to histologically examine its structure from luminal surface 
through to the clot adjacent to the aortic wall. Samples were stained using 
Martius Scarlet Blue, which stains fibrin of different ages in different colours, 
with mature fibrin appearing red, newly laid fibrin and erythrocytes appearing 
yellow and old fibrin staining blue (Lendrum et al., 1962). In all samples, the 
layers of the ILT could be clearly delineated, and, seemed to be divisible into 
the three layers that have been previously described; the luminal layer, the 
medial layer, and the abluminal layer. The luminal layer in all cases showed an 
abundance of both erythrocytes (yellow) and fibrin (red). In the medial layer, 
there is still some mature fibrin (red), but this is starting to degrade (blue), and 
there are fewer erythrocytes (yellow). In the abluminal layer, there is little/no 
mature fibrin (red), and in fact, all that can be seen is degraded fibrin (blue) with 
very few erythrocytes.  Example sections from two different patients undergoing 
open AAA repair are shown in Figure 28. Both are taken at 4x magnification, 
with Panel A showing the sections through a relatively thick ILT, compared to 
Panel B which shows the sections through a much thinner ILT. In both, the 
same three layers can be appreciated, implying that even in patients with a 
relatively low ILT volume, the process of ILT deposition is likely to have been as 
chronic as in those patients with a greater ILT burden. 
 A 
B  
Sections of 5μm were taken through samples of human ILT, and were 
stained for fibrin using Martius Scarlet Blue. Nuclei were stained using 
Weigerts Iron Haematoxylin, Martius yellow was used to stain erythrocytes 
yellow, Crystal Ponceau was used to stain fibrin red and methyl blue was 
used to stain collagen, and old, degraded fibrin, blue. Shown here at 4x 
magnification, histologically, the layers of the ILT can be well differentiated, 
with the luminal layer being rich in fibrin and erythrocytes, whilst at the 
surface adjacent to the aortic wall (the abluminal surface) there is no fresh 
fibrin, and only scattered erythrocytes (marked with a black arrow). Panel A 
shows a sample from a patient with a high volume of ILT, with Panel B 
showing a sample from a patient with low volume ILT. 
 
Red – fibrin, Yellow – new fibrin and erythrocytes, Blue – old fibrin 
 
Figure 28. Histological sections through Intra-Luminal Thrombus (ILT), showing the layers of fibrin within the ILT
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3.7 Discussion - The Role of TAFI in human AAA 
The aim of this chapter was to investigate the role of TAFI in human AAA. In 
particular, the aim was to investigate TAFI levels, TAFI activity and TAFI 
polymorphisms in patients with AAA in relation to AAA size, growth and clinical 
outcome. 
Patients were recruited for this study through the Leeds Aneurysm 
Development Study, a large prospective cohort study of patients with AAA and 
control subjects based in the north of England. All patients with AAA presenting 
to the Leeds Teaching Hospitals Trust were invited to take part. Control 
subjects were recruited from other surgical outpatient departments, as well as 
through volunteers from the general public. The large size of this cohort gives a 
unique opportunity to study multiple factors relating to patients with AAA. 
However, due to the nature of recruitment of such a cohort, the control 
population is not as well matched for age and gender as may be desirable. The 
control population tends to be younger, and there are more women in this 
population. However, when looking at a large population from this cohort, as in 
the gene polymorphism studies, it can be seen that after binary logistic 
regression analysis, the only factor that remains statistically significantly 
different between the two populations is the size of the abdominal aorta. Where 
smaller populations were used from within the cohort, as with the lysis 
experiments, patients were selected from the population at random, but extreme 
outliers of age were removed in order to better match the two groups under 
study. Originally, the aim had been to study TAFI in relation to AAA growth and 
clinical outcome. AAA growth is complex, with a number of different models 
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suggested for AAA growth, none of which fit every patient with the disease 
(Bailey et al., 2013a). Despite having access to scan data for a number of AAA 
patients over a period of up to 10 years, due to the heterogeneous nature of 
AAA growth, many thousands of participants with multiple scans over the study 
period would be needed in order to make meaningful conclusions relating to 
TAFI levels and AAA growth. In addition, the time of recruitment to the study 
(and the collection of the blood samples used for analysis) was varied across 
the study population, with some patients being recruited early, with small AAA, 
and others being recruited once their AAA had already grown to a size large 
enough to warrant elective intervention. This is a reflection of the silent nature of 
AAA disease; often patients are not aware that they have an AAA until it is 
identified incidentally. Whilst this allows us to compare the levels in patients with 
differing sizes of AAA, it does not allow us to collect growth data for all of the 
patients in the study; for some, a blood sample was only collected shortly before 
their large AAA underwent repair. This also makes it difficult to draw 
conclusions in relation to clinical outcome. The time point at which patients are 
recruited in relation to their disease progression is not fixed (as would be the 
case for a patient with an acute myocardial infarction, for example), and so 
drawing conclusions relating to plasma TAFI levels and survival would be 
misinformed. Due to the nature of this prospective cohort, the only data we have 
in relation to mortality is usually the date of death. Cause of death data, should 
it be available, may be more useful, as conclusions could be drawn in relation to 
TAFI levels and an increased risk of, for example, cardiovascular death. 
Another slight issue with the study relates to the control group. The ideal control 
group for such a study would be an age-matched population without any 
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presence of cardiovascular disease, but finding a significant number of entirely 
healthy people of the correct age group to compare to patients with AAA is 
extremely difficult. Indeed, allowing for the fact that a number of the ‘healthy’ 
controls did actually have a history of cardiovascular disease, it may be that the 
differences detected in TAFI activity between patients and controls would have 
been even more pronounced had the control population not had any history of 
disease.  
All plasma samples were collected from patients without the use of a tourniquet 
in order to allow collection of a free-flowing venous sample. Samples were 
taken onto cold citrate, and kept on ice, before being centrifuged at 4°C. This 
protocol was followed closely, and such conditions for collection are important in 
order to ensure that any TAFI within the sample remains stable (Foley et al., 
2013). Samples were stored at -40°C until analysis. The maximum length of 
time that plasma samples were stored for was 10 years, and evidence suggests 
that this time frame allows for the preservation of plasma fibrinolytic proteins 
(Hernestal-Boman et al., 2010). 
TAFI levels in the plasma of patients with AAA were studied using a number of 
different sandwich ELISA systems. Historically, there has been some difficulty in 
measuring TAFI using ELISAs, as a number of antibodies were specific only for 
one of the two alleles of the Thr325Ile polymorphisms (Willemse and Hendriks, 
2006). In addition, the difference in half-life between these two forms of TAFI 
may have lead to falsely high or low results in patients who are homozygotes of 
either form of TAFI. The ELISAs used for this study were not specific for either 
isoform, and so, should have detected both forms with equal specificity. 
Although the half-life of the two forms is different, by measuring TAFIa/TAFIai in 
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combination, any TAFI already inactivated in the sample should have still been 
detected in equal measure, thus correcting for the difference in half-life between 
the two forms. Using the intact TAFI and TAFI-AP ELISAs from KU Leuven, the 
protocols of which I learnt by spending time in the laboratory of Professor Ann 
Gils, proved the most effective way to measure plasma TAFI levels. For this 
thesis, I had previously tried using commercially available ELISAs, but the 
results were extremely variable and inconsistent both within and across different 
plates (data not included). Despite this, there was still some drift in the detection 
of the Leuven ELISAs over time (see Figure 20). In order to counteract for any 
variability between plates, an even number of patient and control samples were 
measured on every plate, and any plates where the plasma levels of the 
standards fell outside two standard deviations from the mean were repeated. As 
per standard Leuven protocol, all plates were repeated at least twice, so that 
each plasma level recorded is the average of at least eight different wells (four 
dilutions on at least two different plates). This was done in order to identify 
outliers or errors in measurement, and allow for them to be repeated as 
necessary. Whilst there was no difference between the levels of the TAFI 
zymogen between patients with AAA and controls (13.1 (11.0-15.7) µg/ml vs. 
12.7 (10.6-15.2) µg/ml), the levels of TAFIa/TAFIai and the TAFI activation 
peptide were significantly higher in patients with AAA compared with control 
subjects (TAFIa/TAFIai 20.5 (14.5-33.4) ng/ml vs. 14.2 (10.9-19.2) ng/ml and 
TAFI AP 318.7 (195.4-483.3) ng/ml vs. 248.6 (193.4-325.0) ng/ml). These data 
indicate an increased TAFI turnover in patients with AAA compared with control 
subjects. AAA is a chronic disease, and so, due to the continuous plasmin 
generation within the ILT and the aortic wall (Carrell et al., 2006), it is likely that 
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increased TAFI turnover will have been present for a number of years before 
the plasma sample used for this study was collected. Whilst initially an increase 
in TAFI turnover may have lead to a decrease in the plasma levels of the TAFI 
zymogen (as more zymogen was activated), over time, it is likely that, through 
homeostatic mechanisms, the production of TAFI is increased, and this could 
keep levels of the TAFI zymogen within normal limits. The activation of TAFI 
being increased would have resulted in higher levels of TAFIa/TAFIai and the 
TAFI-AP. Although the TAFIa/TAFIai ELISA aims to measure both active and 
inactive TAFI in the plasma samples, it is likely that due to the very short half-
life of active TAFI, the majority of what is measured by this ELISA is actually 
inactivated TAFI.  
In line with the plasma levels of the total TAFI zymogen, the anticipation was 
that the TAFI activity, as measured using a clot lysis assay, in which all of the 
TAFI in the sample is activated with exogenous thrombin and thrombomodulin, 
would be similar in patients with AAA compared with control subjects. However, 
the levels of TAFI activity (as measured by the TAFI-related retardation to lysis) 
were lower in patients with AAA compared with control subjects (44.3 (34.3-
54.3) mins vs. 52.4 (39.1-63.3) mins). This is, however, in keeping with the 
findings of a much smaller study of 32 patients and 45 controls, which, using a 
commercially available kit (American Diagnostica, USA), which is based on a 
chromogenic assay, demonstrated a decrease in TAFI activity in patients 
compared with controls (Dubis et al., 2014). There were several limitations to 
this previous study, including the handling of the blood samples, and the failure 
to correlate activity with genotype for the Thr325Ile polymorphism, but despite 
this, it seems to corroborate the findings of the work in this thesis, as despite 
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much larger numbers and an alternative method, the conclusion is the same. 
The explanation for the decreased TAFI activity when measured in-vitro, but no 
change in the levels of TAFI zymogen between patients with AAA and controls, 
is not clear. One hypothesis may be that the compensatory overproduction of 
TAFI in-vivo in patients with AAA (which keeps total zymogen levels within 
normal limits) may result in the production of TAFI which is less functional, and 
therefore cannot be activated in-vitro. Another explanation may be that in the 
AAA patients, other plasma proteins may be up or down regulated which 
interfere in the TAFI activity assay, and this does not occur for the controls. 
Finally, this may also be a reflection of the importance of careful handling of 
plasma samples. Despite our samples being taken on the correct anticoagulant 
(sodium citrate), and kept cold (collected on ice and centrifuged at 4°C), it may 
be that there was some unavoidable activation of TAFI in the plasma samples 
ex-vivo during processing, that resulted in higher levels of TAFIai and TAFI-AP, 
and a reduction in the in-vitro activity. However, as all of our samples from both 
patients and controls were collected and stored in the same manner, any errors 
relating to sample collection should be consistent across the whole study. 
The validity of this activity assay itself, however, does seem to be corroborated 
by an increase in activity in subjects with the isoleucine allele at position 325, a 
polymorphism that has previously been shown to result in a TAFI with a longer 
half-life and an increased anti-fibrinolytic activity (Schneider et al., 2002). Whilst, 
as would be expected, possession of an isoleucine allele at position 325 of TAFI 
was associated with an increase in TAFI activity, there was no association 
between this polymorphism and AAA. 
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In order to identify other proteins that may be involved in the changes in fibrin 
clot structure and fibrinolysis that have previously been demonstrated in 
patients with AAA, functional polymorphisms of alpha-2-antiplasmin and tPA 
were also investigated in this study population. This was not done to identify 
candidate genes for AAA development; for the identification of candidate genes, 
Genome Wide Association Studies (GWAS) and validation studies should be 
carried out in much larger numbers of patients. Indeed, GWAS studies of 
patients with AAA have already identified a number of candidate genes (Bown, 
2014, Bown et al., 2011, Jones et al., 2013), however, no single polymorphism 
is able to entirely account for the incidence of AAA, with hypertension, smoking, 
and male gender remaining the most significant risk factors for AAA. Two 
functional polymorphisms of α2AP were investigated in this group of AAA 
patients and controls. The allele frequencies identified (Arg6Trp 0.80/0.20 and 
Arg407Lys 0.83/0.17) are in agreement with previous, albeit much smaller 
published studies related to these polymorphisms (Christiansen et al., 2007, 
Lind and Thorsen, 1999, Uitte de Willige et al., 2011). A strong correlation is 
evident between these two polymorphisms, which confirms the findings of a 
much smaller study of 30 healthy controls (Lind and Thorsen, 1999). There was 
a significant association between the Arg407lys polymorphism and AAA, with 
patients with AAA statistically less likely to have the rarer lysine allele compared 
with control subjects. The exact function of this polymorphism is not yet 
established. Arg407Lys is positioned in the extended C-terminus of α2AP, 
which is the region of the molecule that is involved in competitive binding to 
plasmin(ogen). The extended C-region of α2AP is proteolytically cleaved in 
healthy subjects, with only 65% of α2AP circulating in human plasma having an 
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intact C-terminus (Sasaki et al., 1986, Sugiyama et al., 1988, Uitte de Willige et 
al., 2011). C-terminally cleaved α2AP remains an active inhibitor of plasmin, but 
reacts more slowly, as it is unable to competitively bind to the lysine residues of 
plasminogen (Clemmensen et al., 1981). It may be that the Arg407Lys 
polymorphism has an effect on the cleavage of the C-terminus and thus the 
activity of the α2AP. Previous studies have not found an association between 
Arg407Lys and the level of C-terminal cleavage (Uitte de Willige et al., 2011), 
but further studies may be needed to elucidate the exact functionality of this 
polymorphism. Arg6Trp is positioned in the N-terminus of the α2AP molecule. 
The N-terminus is important because it contains Gln14, which is the site of 
cross-linking into fibrin by activated FXIII. Like the C-terminus, the N-terminus is 
also physiologically cleaved in plasma. Twelve amino acids are removed from 
the full length form (with Methionine at its amino terminus, Met-α2AP) to 
produce a shortened, more physiologically active form, with Asparagine at its 
amino terminus (Asn-α2AP). In-vitro, Asn-α2AP is cross-linked into fibrin 13 
times faster than the full length Met-α2AP, and, as a result, clot-lysis time 
increases as the proportion of Asn-α2AP increases (Lee et al., 2004). The 
Arg6Trp polymorphism has been shown to affect the rate of N-terminal 
cleavage, with the proportion of the more active Asn-α2AP decreasing in the 
presence of the rare Trp allele (Christiansen et al., 2007). The expectation 
therefore was that there would be a negative association between this 
polymorphism and AAA, with patients being more likely to be in possession of 
the Arg allele, resulting in a greater proportion of the more active Asn-α2AP, 
which would contribute to the pathological fibrin clot structure and resistance to 
lysis that has previously been demonstrated in this disease (Scott et al., 2011). 
Page | 143  
 
There was, however, no association found between this polymorphism and 
AAA.  
Finally, a polymorphism of tPA, 7351C→T, was investigated. The tPA 
7351C→T polymorphism lies in the enhancer region of the tPA gene, and has 
been shown to be associated with the rate of tPA release from the vascular 
endothelium (Ladenvall et al., 2000), with rates of release decreased in the 
presence of the T-allele. Possession of a T-allele has previously been 
associated with MI (Ladenvall et al., 2002), although there was no association 
between this polymorphism and AAA. 
Further studies to more specifically investigate plasma levels of α2AP in relation 
to AAA are already underway; clearly, the changes seen in the fibrin clot 
structure and fibrinolysis in patients with AAA are the result of a complex multi-
faceted disease process, and are likely to be the result of the interaction 
between a number of different proteins. 
Finally, this study has demonstrated a secondary delay in the lysis in patients 
with AAA, which can be attributed to TAFI. When additional TAFI was added to 
the plasma samples of control subjects, a delay in lysis matching the pattern 
seen in patients with AAA resulted. In corroboration with this, the addition of 
PCI, a potent inhibitor of TAFI, resulted in a decrease in the lysis time in 
patients with AAA back to the levels observed in controls. This secondary delay 
in lysis time appears to correspond with the plasmin-mediated activation of TAFI 
(Leurs et al., 2003), although further investigation is required to confirm this. 
This work was done in a plasma system, not a purified system, and so, although 
no exogenous plasmin(ogen) was added, there will have been some 
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plasmin(ogen) present in the plasma samples which would have been available 
to activate TAFI once fibrinolysis had been initiated. The addition of thrombin 
and thrombomodulin to the plasma demonstrated a maximal effect on the 
prolongation of lysis time, and thus seems to have activated all of the TAFI in 
the plasma samples. However, when just thrombin was added, a delay in lysis 
in patients with AAA (and in control samples with additional TAFI), only became 
evident once lysis had already begun. This seems to suggest that in patients 
with AAA, plasmin-mediated TAFI activation may play some role. It is known 
that the levels of D-dimer (the plasmin mediated fibrin breakdown product) are 
higher in patients with AAA compared with control subjects (Parry et al., 2009). 
Also, high levels of D-dimer and plasmin-antiplasmin complexes have been 
shown within the ILT of patients with AAA (Houard et al., 2007). Further 
investigation into, for example, levels of TAFI and activated TAFI within the ILT 
of patients with AAA may help to shed some more light onto the complex 
relationship between the proteins of fibrinolysis and their specific roles in the 
pathophysiology of this disease.  
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Chapter 4 Results – TAFI Inhibition in a Murine Model of AAA 
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The role of TAFI in AAA was further investigated using the murine Angiotensin II 
model of AAA. In this model, hyperlipidaemic (ApoE-/-) mice are continuously 
infused with Angiotensin II, which results in dissection of their aortas at points of 
maximal atherosclerosis (typically in the supra-renal region of the aorta), 
followed by thrombus formation, infiltration of inflammatory cells into the aortic 
wall, elastin breakdown within the wall, and AAA formation. This method was 
first described by Daugherty et al. (Daugherty et al., 2000). The aim of my study 
was to investigate the importance of TAFI activity in the different stages of AAA 
development, using TAFI inhibitors in combination with Angiotensin II infusion.  
4.1 AAA formation in the Angiotensin II model of AAA 
Mice were implanted with Alzet mini-osmotic pumps delivering 750 ng/kg/min 
Angiotensin II (Ang II) or NaCl 0.9% (control) for 28 days.  In total, for all of the 
experiments used for this study, 35 mice were treated with Ang II alone, and 23 
were treated with NaCl 0.9% mini-osmotic pumps (control). Both sets of mice 
had no noticeable changes in phenotype throughout the course of the 28 day 
experiment, appeared healthy and active, and gained weight as would be 
expected. Overall, the mortality related to Ang II infusion was 40%, which is 
within the limits acceptable for this model. This includes those mice who were 
terminated using Schedule 1 approved methods if they appeared unwell in the 
‘at-risk’ period following initiation of Ang II infusion. Of mice surviving to 28 days 
after Ang II infusion, 52.4% developed AAA. After 28 days, macroscopic 
measurements of the aortas of mice treated with Ang II and controls were taken 
as described in Chapter 2.20. Results are presented as mean ± standard 
deviation. 
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Infusion with Ang II resulted in a mild dilatation of the entire aorta. The size of 
the thoracic aorta in mice treated with NaCl 0.9% was 0.62 ± 0.08 mm. This 
increased to 0.81 ± 0.09 mm in mice receiving Ang II who did not have a 
macroscopic AAA after 28 days, and 1.07 ± 0.25 mm in mice receiving Ang II 
who developed AAA (p <0.0001, see Figure 29, panel A). There was a more 
dramatic increase in the size of the supra-renal abdominal aorta, as is expected 
in this model of AAA. In mice treated with NaCl 0.9%, the abdominal aorta was 
0.65 ± 0.10 mm. This increased slightly in mice receiving Ang II who did not 
develop macroscopic AAA (in line with the over dilatation of their aortas) to 0.99 
± 0.18 mm (p<0.0001). In mice developing macroscopic AAA, the size of the 
abdominal aortas increased to 2.60 ± 0.83 mm (p<0.0001). This can be seen in 
Figure 29, panel B. In human disease, in order to allow for individual variations 
in the size of the ‘normal’ segment of aorta, AAA are usually assessed not only 
by size, but also as a ratio of the surrounding ‘normal’ aorta. A ratio of 
abdominal aortic size divided by thoracic aortic size of more than 1.5 is 
considered aneurysmal. In this model, there was a slight increase in ratio in 
mice treated with Ang II that did not develop macroscopic AAA when compared 
with saline controls (1.22 ± 0.19 vs. 1.04 ± 0.12, p=0.005), despite the ratio 
being below the threshold for being considered an aneurysm. In mice with 
macroscopic AAA, there was a large increase in the ratio up to 2.59 ± 1.03, 
p<0.0001, Figure 29, panel C.  
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Figure 29. Aortic dilatation in the Angiotensin II model of AAA 
ApoE-/- mice were treated with Ang II 750 ng/kg/min or NaCl 0.9%  (controls) via subcutaneous 
mini-osmotic pump for 28 days. In mice surviving to 28 days (Ang II n=21 and NaCl 0.9% n=23) 
images were taken of the aorta, and measurements taken to determine the size of both the 
thoracic aorta and the supra-renal abdominal aorta. Based on the measurements taken, mice 
were classified as AAA (n=11) or no AAA (n=10), depending on whether or not a macroscopic 
AAA was present (aortic ratio >1.5). There was an increase in the size of the thoracic aorta in all 
mice treated with Ang II; NaCl 0.9% 0.62 ± 0.08 mm, Ang II no AAA 0.81 ± 0.09 mm (p<0.0001), 
Ang II AAA 1.07 ± 0.25 mm (p<0.0001), Panel A. The size of the abdominal aorta also 
increased in all mice treated with Ang II, with a more dramatic increase in those with a 
macroscopic AAA; NaCl 0.9% 0.65 ± 0.10 mm, Ang II no AAA 0.99 ± 0.18 mm (p<0.0001), Ang 
II AAA 2.60 ± 0.83 mm (p<0.0001), Panel B. The aortic ratio in mice developing AAA was 2.59 ± 
1.04, whilst in control mice it was 1.04 ± 0.12 (p<0.0001), Panel C. 
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4.2 Fibrin Clot Structure is not altered in the Angiotensin II model of AAA 
Plasma samples from mice treated with Ang II that developed AAA (n=7) were 
compared to samples from mice infused with NaCl 0.9% (controls, n=8). 
Turbidity and turbidity lysis was performed as described in section 2.13. The 
maximum optical density (max OD), an indicator of fibre thickness and clot 
density, was not different between the AAA and control groups (0.10 ± 0.07 vs. 
0.09 ± 0.02 p=0.72, Figure 30, panel B). The time taken for the samples to 
reach the max OD was also not significantly different between the groups 
(11.11 ± 2.57 mins vs. 13.46 ± 2.32 mins, p=0.08, Figure 30, panel A), 
indicating that the clotting process proceeded in a normal fashion in both 
groups. The time to half lysis, that is, the time it takes for the optical density of 
the clot to fall to half of its maximum after in-vitro addition of tPA, which is an 
indicator of the ease of which a clot can be lysed, was also not significantly 
different between AAA and controls (50.59 ± 23.31 mins vs. 41.21 ± 14.93 mins, 
p=0.36, Figure 30, panel C). Using confocal microscopy, the microstructure of 
the fibrin clots was studied. The fibre density within the fibrin clot (measured as 
the number of fibres per 100 µm2) was also not significantly different between 
the two groups (286.3 ± 260.4 vs. 361.3 ± 217.2, p=0.634, Figure 30, panel D 
and E). In unison, these data show that AAA development in the Angiotensin II 
model of AAA, unlike in the human disease state (Scott et al., 2011), does not 
have an effect on the fibrin clot structure. Further to these structural results, 
levels of D-dimer (a fibrin degradation product), as measured by a specific 
murine ELISA, were not significantly different between AAA and controls (885.8 
± 354.0 ng/ml vs. 842.1 ± 176.0 ng/ml, p=0.76, Figure 31), indicating that there 
was not a gross overall change in the rates of fibrinolysis in this model.
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Figure 30. Fibrin clot structure is not altered as a result of Abdominal Aortic Aneurysm 
formation in the Angiotensin II model of AAA 
Turbidity and turbidity lysis was performed using plasma from mice with AAA (n=7) and mice 
treated with saline control (n=8). There was no difference in the time taken to reach the 
maximum OD (11.11 ± 2.57 mins vs. 13.46 ± 2.32 mins, panel A), the maximum OD (0.10 ± 
0.07 vs. 0.09 ± 0.02, panel B) or the time to half lysis (50.59 ± 23.31 mins vs. 41.21 ± 14.93 
mins, panel C). Fibrin clots were formed which incorporated FITC-labelled fibrinogen (control 
n=6, AAA n=4), in order to allow for the microscopic study of the fibrin clot structure. This 
confirmed that there was no difference in the fibrin fibre density in mice treated with Ang II 
developing AAA and controls (885.8 ± 354.0 ng/ml vs. 842.1 ± 176.0 ng/ml, panel D). Sample 
images of the fibrin clot structure are shown in Panel E. Whiskers represent mean and standard 
deviation of the mean.  
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Figure 31. Levels of plasma D-dimer in mice developing AAA compared with control 
saline treated mice 
Levels of D-dimer were measured in the plasma of mice treated with Ang II developing AAA and 
control (saline treated) mice, using a commercially available ELISA kit (Cat No. 024579, US 
Biological Life Sciences). There was no significant difference in the levels of D-dimer in plasma 
of mice with AAA compared with controls (885.8 ± 354.0 ng/ml vs. 842.1 ± 176.0 ng/ml). 
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4.3 The levels of TAFI within the aortic wall are not altered with AAA 
formation 
TAFI levels within the wall of the abdominal aorta were measured in mice with 
AAA (n=8) and compared with controls (n=8). The protein was extracted from 
the wall using a homogenisation and lysis protocol as described in Section 2.21. 
The total levels of protein in the homogenate were measured using a BCA 
assay (Pierce™ BCA Protein Assay kit, Thermo Fisher Scientific Inc.). The total 
TAFI levels were measured using ELISA. The amount of total protein was 
higher in the homogenate of the aortas of mice with AAA compared with 
controls (9.3 ± 4.7 mg/ml vs. 5.3 ± 2.1 mg/ml, p=0.04), although this is likely a 
reflection of the dilated nature of the vessel resulting in a larger amount of 
tissue being collected. The total TAFI levels, as measured by ELISA, were also 
slightly higher in the aortas of mice with AAA compared with controls, although 
this did not reach statistical significance (344.8 ± 251.0 ng/ml vs. 167.4 ± 28.5 
ng/ml, p=0.07), and again this may simply be a reflection of the homogenate 
containing protein from a larger amount of tissue. The TAFI levels in the tissue 
as a percentage of the total amount of protein was calculated, and described as 
a percentage. The amount of TAFI in the aortas of mice with AAA was 
comparable to that of control mice (0.00347 ± 0.0008% vs. 0.00341 ± 0.0008%, 
p=0.89). These results are summarised in Figure 32. 
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Figure 32. TAFI levels in the aortic tissue of mice with AAA is not increased compared 
with controls 
Fresh aortas were harvested from mice receiving Ang II for 28 days and developing AAA (n=8) 
and control mice treated with saline (n=8). The tissue was homogenised and the protein 
extracted using a lysis buffer. Total protein levels were measured using a BCA assay. TAFI 
levels were measured using ELISA. A standard curve as produced using purified murine TAFI 
(panel A). The levels of TAFI and total protein were higher in the aortas from mice with AAA 
(TAFI: 344.8 ± 251.0 ng/ml vs. 167.4 ± 28.5ng/ml, p=0.07, Total: 9.3 ± 4.7 mg/ml vs. 5.3 ± 2.1 
mg/ml, p=0.04) panel B and C, but the levels of TAFI as a percentage of the total protein was 
not different between the groups (0.00347 ± 0.0008% vs. 0.00341 ± 0.0008%, p=0.89), panel D. 
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4.4 Histological examination of the aortas of mice treated with 
Angiotensin II reveals loss of elastin and evidence of extensive intra-
mural thrombus 
After infusion of either Ang II (750 ng/kg/min) or NaCl 0.9% via a subcutaneous 
mini-pump for 28 days, the suprarenal aortas of mice from both groups were 
harvested, fixed in 4% paraformaldehyde and embedded in paraffin. Sections (5 
µm) were taken through the cross-section of the aorta, and were stained for 
elastin, collagen and fibrin. Images were taken using an Olympus BX Dual View 
Microscope and Image ProPlus 8.0 at 10x magnification (normal aorta) and 4x 
magnification (AAA). In sections taken from mice with AAA, there was loss of 
elastin within the internal elastic lamella compared with control samples, as well 
as evidence of intramural thrombus. Using a stain for fibrin and erythrocytes, 
there was evidence of both erythrocytes (seen in yellow) and mature fibrin 
(stained red) within the medial layer of the aortic wall. Sample images 
compared with the macroscopic appearances are shown in Figure 33. 
Page | 155  
 
 
  
A B 
M
ill
e
rs
 e
la
s
ti
n
 
 
 
 
 
P
ic
o
s
ir
u
s
 R
e
d
 
(c
o
lla
g
e
n
) 
 
M
a
rt
iu
s
 S
c
a
rl
e
t 
B
lu
e
 
(F
ib
ri
n
) 
Figure 33. Histological examination of the aortas from mice treated with Angiotensin II 
reveals structural changes typical of AAA 
Mice were infused with Angiotensin II or Normal Saline (control) for 28 days using 
subcutaneous mini-osmotic pumps. The supra-renal aortas were harvested, fixed using 4% 
paraformaldehyde and paraffin embedded. 5 μm sections were taken and stained for elastin, 
collagen and fibrin (n=10 in each group). They were then imaged using an Olympus BX40 Dual 
View Microscope. In mice treated with Ang II (Column B), changes characteristic of AAA are 
demonstrated. There is loss of elastin and collagen from within the structural matrix of the aortic 
wall (elastin is shown using a black arrow), and evidence of intra-mural thrombus, with 
erythrocyte deposition (black star) and fibrin formation (white arrow) present in the expanded 
medial layer. Column A shows images from a mouse treated with NaCl 0.9% (control). 
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4.5 Inhibition of TAFI in the Angiotensin II model of AAA results in a 
decrease in whole blood lysis time 
ROTEM was performed on whole blood taken from mice treated for 28 days 
with either MA-TCK26D6 (n=2) or UK-396082 (n=1), and compared with 
samples from control mice treated with NaCl 0.9% (n=3). Even after 28 days, 
there was still a reduction in the lysis time in the blood of mice treated with 
either one of the inhibitors compared with the control (5478.6 secs vs. >7200 
secs, supplemented with tPA, final concentration 20nM, see Figure 34). Mice 
treated with MA-TCK26D6 were also sacrificed after 7 and 10 days (n=3 in each 
group), and their blood used for ROTEM analysis. The maximum clot firmness, 
that is the maximal amplitude of the thromboelastogram, which represents the 
absolute strength of the fibrin and platelet clot, was not altered in mice receiving 
either of the two inhibitors compared with controls. Similarly, in mice receiving 
Ang II, addition of either of the two TAFI inhibitors did not alter the maximum 
clot firmness (control 54.7 ± 10.5 mm, MA-TCK26D6 7 days 59.7 ± 2.3 mm, 10 
days 58.3 ± 10.0 mm, 28 days 52.5 ± 0.7 mm, UK-396082 28 days 57.0 mm, 
Ang II 53.5 ± 7.7 mm, Ang II and MA-TCK26D6 59.7 ± 3.1mm, 59.3 ± 3.6 mm, 
see Figure 34). The LI60, an index of the proportion of the clot remaining after 
60 minutes, and thus an indicator of the lysis of a clot, showed a trend towards 
being decreased in mice receiving MA-TCK26D6 compared with control at 7 
days (30.0 ± 26.5% vs. 31.7 ± 38.6%) and 10 days (25.0 ± 21.4% vs. 31.7 ± 
38.6%), but this effect had resolved by 28 days (Figure 34). There were no 
spontaneous episodes of bleeding in mice receiving either of the two inhibitors.  
Page | 157  
 
 
A 
B C 
Figure 34. Whole blood lysis rates are reduced in mice treated with inhibitors of TAFI 
Mice were treated with UK-396082 (n=1) or MA-TCK26D6 (n=2) in order to establish the safety 
of long-term administration of the inhibitors in-vivo. At 28 days, blood was taken from the inferior 
vena cava (IVC) onto 0.1M sodium citrate (blood:citrate ratio 9:1). Whole blood was used for 
rotational thromboelastogram (ROTEM) analysis, and confirmed that even after 28 days, there 
was still a reduction in the lysis time in mice treated with either MA-TCK26D6 (blue and pink 
lines) or UK-396082 (green line) compared with control (red line), Panel A. 
The LI60 was lower in mice receiving MA-TCK26D6 compared with control at 7 days (n=3, 30.0 
± 26.5% vs. 31.7 ± 38.6%) and 10 days (n=3, 25.0 ± 21.4% vs. 31.7 ± 38.6%), but this effect 
had resolved by 28 days, n=3 (Panel B). 
The Maximum Clot Firmness (MCF) is an indicator of the absolute strength of the clot, and this 
was not altered with the use of any of the TAFI inhibitors or Ang II infusion; control 54.7 ± 10.5 
mm, MA-TCK26D6 7 days 59.7 ± 2.3 mm, 10 days 58.3 ± 10.0 mm, 28 days 52.5 ± 0.7 mm, 
UK-396082 28 days 57.0 mm, Ang II 53.5 ± 7.7 mm (Panel C).  
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4.6 Inhibition of TAFI in-vivo does not affect heart rate or blood pressure 
in the Angiotensin II model of AAA 
In the second week post-implantation of Alzet® mini-osmotic pumps, non-
invasive measurements of heart rate (HR) and blood pressure (BP) were taken 
in all groups of mice using the CODA non-invasive HR and BP device (Kent 
Scientific). Serial measurements were taken over two days (following an initial 
acclimatisation session where no readings were recorded) of diastolic blood 
pressure (DBP), systolic blood pressure (SBP) and mean arterial pressure 
(MAP). Blood pressure results were consistent across all the groups of mice, 
and are shown as mean ± standard deviation: NaCl 0.9% control DBP 76.9 ± 
14.6 mmHg, SBP 106.6 ± 18.9 mmHg, MAP 86.6 ± 15.9 mmHg; Ang II DBP 
81.3 ± 25.7 mmHg, SBP 110.9 ± 36.07 mmHg, MAP 89.7 ± 30.4 mmHg; Ang II 
and MA-TCK26D6 DBP 94.4 ± 22.6 mmHg, SBP 121.4 ± 21.2 mmHg, MAP 
103.2 ± 23.3 mmHg; Ang II and UK-396082 DBP 91.1 ± 23.9 mmHg, SBP 121.3 
± 28.2 mmHg, MAP 100.6 ± 25.2 mmHg. These results are illustrated in Figure 
35. Non-invasive measurement of HR also showed no significant differences 
between the four treatment groups, with the results for all of the four groups 
falling within normal limits. Results are given as the mean number of beats per 
minute (bpm) ± standard deviation: Saline 670.8 ± 92.5 bpm, Ang II 697.4 ± 
66.19 bpm, Ang II and MA-TCK26D6 690.6 ± 65.19 bpm, Ang II and UK-396082 
695.8 ± 78.41 bpm (see Figure 35). Mice in all four groups also showed normal 
weight gain across the study period (Figure 36). 
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Figure 35. Angiotensin II infusion and TAFI-inhibition has no effect on heart rate and 
blood pressure in an in-vivo model of AAA 
Blood pressure (BP) and heart rate (HR) measurements were taken in all groups of mice (Saline 
n=8, Ang II n=9, Ang II and MA-TCK26D6 n=9, Ang II and UK-396082 n=11) in the second 
week of the experimental period using the CODA non-invasive BP device. HRs were within 
normal limits in all four groups: Saline 670.8 ± 92.5 bpm, Ang II 697.4 ± 66.19 bpm, Ang II and 
MA-TCK26D6 690.6 ± 65.19 bpm, Ang II and UK-396082 695.8 ± 78.41 bpm. BP 
measurements were taken on two separate occasions, with at least 10 readings being 
measured on each occasion. These results were averaged for each mouse. BP readings were 
also within normal limits for all four groups: Saline 107/77, Ang II 111/81, Ang II and MA-
TCK26D6 121/94 and Ang II and UK-396082 121/91. 
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Figure 36. Angiotensin II infusion and TAFI inhibition in-vivo does not result in change in 
weight in ApoE-/- mice 
Mice were weighed at least every 7 days throughout the course of the experiment. Infusion with 
Ang II did not have an effect on weight gain, with mice maintaining a normal weight throughout 
(Panel A). Treatment with MA-TCK26D6 or UK-396082 in addition to Ang II also did not result in 
a significant change in weight across the 28 days of the experiment (Panel B). 
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4.7 Inhibition of TAFI in-vivo results in a decrease in mortality in the 
Angiotensin II model of AAA 
Mice were treated with Ang II in combination with either MA-TCK26D6 (n=12) or 
UK-396082 (n=12). Compared with mice receiving only Ang II (n=35), the 
mortality related to early rupture of the aorta was reduced in the presence of a 
TAFI inhibitor. Mortality fell from 40.0% to 16.6% for mice receiving MA-
TCK26D6 (Log-rank Mantel-Cox test p=0.16) and from 40.0% to 8.3% for mice 
receiving UK-396082 (Log-rank Mantel-Cox test p=0.05). Saline control mice 
had a 0% mortality rate. These results are illustrated in Figure 37. In all groups, 
as is typical for the model, the majority of deaths related to the Ang II infusion 
occurred early post-operatively (prior to Day 8). Post-mortem examinations 
were carried out to confirm the cause of death, and in all cases were found to 
be due to aortic rupture (thoracic or abdominal). 
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Figure 37. Inhibition of TAFI results in a decrease in mortality in the Angiotensin II model 
of AAA 
The mortality of mice treated with Ang II 750 ng/kg/min via a subcutaneous mini pump (n=35) 
was 40.0%. Mortality in the NaCl 0.9%control group (n=23) was 0%. When an inhibitor of the 
plasmin-mediated activation of TAFI (MA-TCK26D6) was given in combination with Ang II 
(n=12), mortality rates fell to 16.6%. When UK-396082, a small molecule inhibitor of active TAFI 
was delivered in combination with Ang II (n=12), mortality rates fell to 8.3% (Panel A). Mortality 
in this model of AAA typically occurred early (Days 0-8 post initiation of Ang II infusion), see 
Panel B, and, in all groups, was the result of aortic rupture (as established by post mortem 
examinations). 
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4.8 Inhibition of TAFI in-vivo affects the development of Abdominal 
Aortic Aneurysms 
Mice were treated with Ang II in combination with either MA-TCK26D6 (n=12) or 
UK-396082 (n=12). Unlike mortality, which fell regardless of which of the two 
TAFI inhibitors was used, the rates of AAA formation were affected in opposite 
ways by the two inhibitors. When UK-396082 was used, there was an increase 
in the rate of AAA formation, with 81.8% of surviving mice having a macroscopic 
AAA at 28 days compared with 52.4% of mice receiving Ang II alone (see 
Figure 38, panel A). When MA-TCK26D6 was used, however, there was a 
decrease in the incidence of AAA in surviving mice, with 30.0% having a 
macroscopic AAA at 28 days (see Figure 38, panel A). Mice that did not survive 
the experiment died due to aortic dissection and rupture as a result of the Ang II 
infusion. Thus, if all ‘responders’ to Ang II (that is rupture or the presence of 
AAA at 28 days) were analysed together, the level of response was almost 
equivalent between the Ang II and the Ang II with UK-396082 groups (71% vs. 
83%), compared to the mice receiving Ang II and MA-TCK26D6, where the total 
response rate of all mice was only 42%. When an AAA did occur, there was no 
difference in the size of the AAA between the different groups; aortic ratios were 
Ang II 2.6 ± 1.0, Ang II and UK-396082 2.7 ± 0.8, Ang II and MA-TCK26D6 2.5 
± 0.4 (Figure 38, Panel B). Sample images of typical findings at 28 days for 
each group are shown in Figure 38, panel C-F. Images were inverted in Image J 
to allow for better visualisation of the margins of the aorta.  
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Figure 38. AAA formation is altered in the presence of a TAFI-inhibitor, with rates 
increased in the presence of UK-396082 and decreased in the presence of MA-TCK26D6 
Mice were treated with saline control, NaCl 0.9%, (n=23), Ang II (n=35), Ang II and MA-
TCK26D6 (n=12) or Ang II and UK-396082 (n=12) for 28 days. At 28 days, the incidence of AAA 
in surviving mice (NaCl 0.9% n=23, Ang II n=21, Ang II and MA-TCK26D6 n=10, Ang II and UK-
396082 n=11) was established by direct imaging of the abdominal aorta.The incidence of AAA 
was increased in the mice treated with UK-396082 compared with Ang II alone (81.9% vs. 
52.4%), but decreased in mice treated with MA-TCK26D6 (30.0% vs. 52.4%), Panel A. When 
AAA did occur, there was no significant difference in the size of AAA in the different groups 
(Ang II 2.6 ± 1.0 vs. Ang II and MA-TCK26D6 2.5 ± 0.4 vs. Ang II and UK-396082 2.7 ± 0.8), 
Panel B. Sample images of typical aortas at 28 days are shown in panels C-F. Panel C – 
Saline, Panel D – Ang II, Panel E – Ang II and MA-TCK26D6, Panel F – Ang II and UK-396082. 
T – thoracic aorta, A – abdominal aorta, RK – right kidney, LK – left kidney, AAA – abdominal 
aortic aneurysm. 
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4.9 Histological examination of murine aortas following TAFI inhibition  
After 28 days, aortas were removed en-bloc from mice treated with NaCl 0.9% 
(n=10), Ang II (n=10), Ang II and MA-TCK26D6 (n=10) and Ang II and UK-
396082 (n=10) to allow for histological examination. Aortas were incubated in 
4% paraformaldehyde for at least 24 hours before being processed and paraffin 
embedded. Transverse sections (5 µm thick) were taken using a Leica RM2125 
microtome (Leica Microsystems), and collected onto slides. Sections of the 
aorta were stained using H+E, PSR, MVG and MSB to allow for visualisation of 
collagen, elastin and fibrin within the samples. They were imaged using an 
Olympus BX40 Dual View Microscope and Image Pro-Plus 8.0 at 4-20x 
magnifications. 
Compared to sections from mice treated with Ang II alone, there was evidence 
of increased intra-luminal clot formation, increased loss of elastin and 
disordered deposition of collagen in sections taken from mice treated with Ang II 
and UK-396082, but no evidence of intra-mural thrombus was seen on any 
sections. Figure 39 shows representative images from two mice treated with 
Ang II and UK-396082. By staining with Miller’s stain, the composition of elastin 
in the internal elastic lamina can be seen; in some aortas, there was evidence 
of just gross dilatation with a thinning of elastin (Panel A), whilst in others there 
was evidence of a discrete rupture in the elastin (Panel B).  By staining using 
Martius Scarlet Blue, the composition of any thrombus could be analysed. In 
some sections, there was evidence of a well established ILT (see Panel A), with 
old fibrin (stained in blue) being present within the thrombus. Unlike in human 
AAA, the laying down of the ILT does not seem to be in a sedimentary fashion 
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beginning at the aortic wall. In all cases where clot was seen, it lay centrally 
within the lumen.  
The majority of mice treated with Ang II 750 ng/kg/min and MA-TCK26D6 did 
not develop AAA after 28 days. The histological appearance of these aortas 
was akin to that of control treated animals (see Figure 33). When AAA did 
occur, there was evidence of aortic dissection and disruption of the internal 
elastic lamina. Example results are shown in Figure 40. 
 
 
 A H+E Millers elastin Picosirus Red Martius Scarlet Blue 
B     
Figure 39. Histological Examination of the abdominal aorta of mice treated with Angiotensin II and UK-396082 
In mice treated with Ang II 750 ng/kg/min in combination with UK-396082 30mg/kg/min, over 80% of mice had developed AAA at 28 days. There was gross 
heterogeneity in the macroscopic and microscopic appearance of these AAA. Unlike in the aortas from mice treated with Ang II alone, there was evidence of 
intra-luminal thrombus in a number of sections. Some mice displayed evidence of complete elastin breaks/dissections through the internal elastic lamina (as 
is seen in Panel B), whilst others showed elastin thinning and gross aortic dilatation without an area of specific elastin breakage (Panel A). 
 A Millers elastin Picosirus Red Martius Scarlet Blue 
B 
 
   
Figure 40. Histological Examination of the abdominal aorta of mice treated with Angiotensin II and MA-TCK26D6 
In mice treated with Ang II 750 ng/kg/min in combination with MA-TCK26D6, there was a reduction in the incidence of AAA from 52.4% to 30% after 28 days. 
Those mice that did not develop aneurysms had, on histological examination, aortas that resembled those of saline controls (see Figure 33).  This can be 
seen in Panel A. In those mice that did develop AAA, there was no evidence of intra-luminal thrombus, but there was evidence of dissection of the aortic wall 
and deregulated elastin and collagen within the internal elastic lamina and media (Panel B). 
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4.10 Plasma levels of PAP, but not CRP or TAFI, are affected by TAFI 
inhibition in-vivo 
Samples of free-flowing blood were taken from the inferior vena cava of mice 
after 28 days of treatment with NaCl 0.9%, Ang II, Ang II and MA-TCK26D6 and 
Ang II and UK-396082. Blood samples were centrifuged to give platelet poor 
plasma as described in section 2.9.4.  Using ELISAs, the plasma levels of 
plasmin-antiplasmin complex (PAP), C-reactive protein (CRP) and TAFI were 
measured in mice from each group (n=10 per group).  
Standard curves were created for each of the three ELISAs using known 
concentrations of PAP, CRP and TAFI. These are shown in Figure 41.  
Plasma levels of PAP showed a slight decrease in mice treated with UK-396082 
compared with Ang II alone; Ang II 82.5 ± 19.5 ng/ml, Ang II and MA-TCK26D6 
82.4 ± 14.4 ng/ml, Ang II and UK-396082 64.2 ± 26.3 ng/ml (p=0.09), and a 
significant decrease compared with mice treated with saline alone (NaCl 0.9% 
89.5 ± 21.1 ng/ml vs. Ang II and UK-396082 64.2 ± 26.3 ng/ml, p=0.02), Figure 
41, panel A.  
Plasma levels of TAFI zymogen were not significantly different between the 
groups, with all mice, regardless of TAFI-inhibitor treatment, having levels in the 
normal plasma range (NaCl 0.9% 3.5 ± 1.4 μg/ml, Ang II 3.4 ± 2.3 μg/ml, Ang II 
and MA-TCK26D6 3.5 ± 1.0 μg/ml, Ang II and UK-396082 3.6 ± 2.4 μg/ml, see 
Figure 41, panel B). 
Plasma levels of CRP were significantly lower in mice receiving only Ang II, 
compared with saline or Ang II in combination with MA-TCK26D6 or UK-396082 
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(NaCl 0.9% 4.1  ± 3.2 ng/ml, Ang II 1.7 ± 0.6 ng/ml, Ang II and MA-TCK26D6 
3.5 ± 1.7 ng/ml, Ang II and UK-396082 4.0 ± 2.4 ng/ml, p=0.03), Figure 41, 
panel C. All of these results still fall within the normal range for plasma CRP 
levels (in inflammatory conditions, murine plasma levels can reach 2 µg/ml 
(Black et al., 2004)). 
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Figure 41. Plasma levels of PAP, TAFI and CRP in response to TAFI inhibition in-vivo 
Plasma levels of PAP, TAFI and CRP were measured in mice receiving saline (n=10), Ang II 
(n=10), Ang II and MA-TCK26D6 (n=10) and Ang II and UK-396082 (n=10) using ELISAs.  
Typical standard curves for each ELISA are shown on the right hand side of the figure.  Plasma 
levels of PAP were lowest in mice treated with UK-396082 in addition to Ang II (64.2 ± 26.3 
ng/ml vs. saline 89.5 ± 21.1 ng/ml and Ang II 82.5 ± 19.5 ng/ml, p=0.02). Plasma levels of TAFI 
were not significantly different between the groups (Saline 3.5 ± 1.4 μg/ml, Ang II 3.4 ± 2.3 
μg/ml, Ang II and MA-TCK26D6 3.5 ± 1.0 μg/ml, Ang II and UK-396082 3.6 ± 2.4 μg/ml). 
Plasma levels of CRP were slightly reduced in mice treated with Ang II alone, although CRP 
levels were not elevated outside of the normal range in any of the four groups.    
* 
* 
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4.11 The changes characteristic of the Angiotensin II model can be 
demonstrated in-vivo using the Vevo 2100 Ultrasound scanner 
The growth of AAA during the 28 day experimental period was monitored using 
the Vevo pre-clinical USS system (FUJIFILM VisualSonics Inc.) and a MS550D 
MicroScan™ transducer at 22-55 mHz. Figure 42 shows the typical 
development of AAA over time in this model as seen on ultrasound scan. At 
baseline, the aorta can be observed both in cross-section and longitudinal 
section, and is uniform in size and shape. After 1 week, there is evidence of 
gross dilatation of the abdominal aorta, with evidence of dissection through the 
intimal layer of the vessel wall. By week 3, the aneurysm becomes well 
established, with a large amount of thrombus between the intimal and medial 
layers, and evidence of flow remaining within the lumen of the aorta. 
Using colour Doppler imaging, it was possible to visualise flow within the aorta, 
and to differentiate between the main lumen and dissections in the early stages 
of the Angiotensin II model of AAA. This can be seen in Figure 43. 
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Figure 42. Development of AAA in the Angiotensin II model of AAA as visualised using 
ultrasound imaging 
The abdominal aorta of mice treated with Ang II was visualised using a Vevo2100 pre-clinical 
ultrasound scanner (n=7). At day 0, the aorta is uniform in shape, with a normal diameter and 
arterial blood flow in seen within the lumen (red area). After 7 days of treatment with Ang II, the 
aorta is dilated, there is evidence of inflammation and turbulent flow can be seen within an area 
away from the main lumen (shown in blue). After 21 days, there is an area of dense thrombus 
within the medial/intimal layer, with reduced flow compared with at day 7, and an established 
AAA. 
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Figure 43. There is evidence of aortic dissection in the early stages of the Angiotensin II 
model of AAA 
Aortic dissection is typical of the early stages of the Angiotensin II model of AAA, and this was 
clearly detected in some mice (n=2) using in-vivo abdominal aorta ultrasound scanning at 1 
week post initiation of Angiotensin II infusion. Panel A shows a cross sectional image of the 
abdominal aorta with a large dissection flap. Panel B shows a colour Doppler of the dissection, 
with arterial flow demonstrated in the main lumen (red), but only a small amount of slow flow in 
the dissection (blue). A=aortic lumen, S=spine, yellow arrow=dissection flap. 
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4.12 TAFI inhibition after AAA formation has no effect on AAA 
progression in-vivo  
Inhibition of plasmin-mediated TAFI activation with MA-TCK26D6 prevented 
AAA formation in the Angiotensin II model of AAA. Therefore, the effect of 
giving MA-TCK26D6 to mice once AAA had been established was investigated. 
In order to do this, mice were subjected to an abdominal ultrasound scan (USS) 
prior to any treatment in order to measure the baseline size of the aorta. Mice 
were then implanted with a pump delivering Ang II at a dose of 750 ng/kg/min 
as described in section 2.9.1. One week after implant, all surviving mice 
underwent a second scan, before being treated with either MA-TCK26D6 
(n=11) or a saline control injection (n=7) of the same volume. Mice were 
scanned again at 21 days in order to establish the effect of the treatment. They 
were then sacrificed at day 28 and their aortas measured in-situ.  
Mice were weighed every 7 days in order to monitor for any negative health 
effects of either inhibitor. Mice in all groups gained weight normally (see Figure 
44), appeared healthy, and showed no episodes of spontaneous bleeding. 
Although there was some mortality prior to day 7, there was no subsequent 
mortality after administration of either the MA-TCK26D6 or control injections.   
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Figure 44. Late treatment with TAFI-inhibitors after AAA formation did not affect weight 
gain in the Angiotensin II model of AAA 
Mice treated with Ang II alone (n=23), Ang II then MA-TCK26D6 at 7 days (n=11) and Ang II 
then NaCl 0.9% at 7 days (n=7) gained weight normally across the study period. 
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4.12.1 Aortic cross-sectional diameter 
Using images taken from scans at baseline, 7 days and 21 days, AAA 
progression in the presence and absence of MA-TCK26D6 was measured. The 
aortic diameter was measured at a fixed point (5 mm above the right renal 
artery) in all mice. The inner to inner luminal diameter was used, as this was 
better defined in the USS images, and also is the current gold standard in 
human AAA imaging. The aortic diameter at all time points was equivalent in 
mice treated with MA-TCK26D6 at day 7 and mice treated with a saline (NaCl 
0.9%) control injection. Results are shown as mean ± standard deviation. Day 
0: MA-TCK26D6 1.19 ± 0.14 mm vs. NaCl 1.12 ± 0.08 mm, Day 7: MA-
TCK26D6 1.56 ± 0.47 mm vs. NaCl 1.60 ± 0.42 mm, Day 21: MA-TCK26D6 
1.93 ± 0.62 mm vs. NaCl 2.02 ± 0.69 mm, Figure 45, panel A and B). There was 
no difference in the change in aortic diameter over time between the two groups 
(MA-TCK26D6 increased by 0.7 ± 0.2 mm, NaCl increased by 0.9 ± 0.3mm, 
p=0.65, Figure 45, panel C).  
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Figure 45. Delayed TAFI inhibition has no effect on the progression of AAA, as measured 
by cross-sectional diameter of AAA, in the Angiotensin II model of AAA 
AAA were induced in hyperlipidaemic mice by infusion of Ang II 750 ng/kg/min. After 7 days, 
mice were treated with a single injection of either MA-TCK26D6 (n=11) or NaCl 0.9% control 
(n=7). AAA progression in both groups was monitored using Vevo2100 pre-clinical ultrasound 
scanning. After two weeks, there was no difference in the cross-sectional diameter of AAA in 
mice receiving the treatment versus those given a control injection (MA-TCK26D6 1.93 ± 0.62 
mm vs. NaCl 2.02 ± 0.69 mm, panel A and B). There was no difference in the change in aortic 
diameter over the whole course of the experiment in mice receiving MA-TCK26D6 compared to 
controls (MA-TCK26D6 increased by 0.7 ± 0.2 mm, NaCl increased by 0.9 ± 0.3 mm, p=0.65, 
panel C).  
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4.12.2 Aorta 3D reconstructions 
In order to gain a better representation of the aneurysmal aortic segment (rather 
than a single diameter measurement), the 10.5 mm of aorta lying proximal to 
the right renal artery was scanned in cross-section every 0.1 mm, and a 3D 
reconstruction of this segment of the aorta was produced. This was created by 
mapping the aorta on multiple images, and then removing all of the background 
in order to just isolate the aorta on the images. A sample of this can be seen in 
Figure 46. The volume of this segment was then calculated using VevoVasc 
software. Samples of reconstructions from each treatment group can be seen in 
Figure 47. Although there was a slight difference in the aortic volumes between 
the two groups at baseline (MA-TCK26D6 10.36 ± 2.89 mm3 vs. NaCl 8.09 ± 
0.71 mm3, p=0.02), by day 7 when the treatment was given, there was no 
difference in the volume of the aorta between the groups (MA-TCK26D6 19.99 
± 11.02 mm3 vs. NaCl 16.44 ± 7.44 mm3), and, following treatment, the aortic 
volumes in each group had increased by the same amount (MA-TCK26D6 
increased by 4.45 mm3 following treatment, vs. NaCl which increased by 3.00 
mm3). See Figure 47. 
  
Figure 46. 3-Dimensional reconstruction of the Abdominal Aorta in the Angiotensin II model of AAA 
Using the Vevo 2100 pre-clinical ultrasound scanner, serial cross sectional images were taken of the region 10.5 mm proximal to the right renal artery. The 
aortic diameter was mapped in multiple sections, and a 3D reconstruction of the segment of the aorta at risk of aneurysm formation created. The volume of 
this section was then calculated using VevoVasc software.  
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Figure 47. Delayed TAFI inhibition has no effect on the progression of AAA, as measured 
by the volume of AAA, in the Angiotensin II model 
AAA were induced in hyperlipidaemic mice by infusion of Ang II 750 ng/kg/min. After 7 days, 
mice were treated with a single injection of either MA-TCK26D6 (n=11) or NaCl control (n=7). 
AAA progression in both groups was monitored using Vevo2100 pre-clinical ultrasound 
scanning, and 3D reconstructions of the aortic segment at risk of AAA formation were created. 
There was no difference in the change in aortic volume over time between mice receiving MA-
TCK26D6 and controls (MA-TCK26D6 increased by 4.45 mm
3
 following treatment, vs. NaCl 
which increased by 3.00 mm
3
), panel A and B. Example 3D constructions showing AAA 
progression over time are shown in panel C (MA-TCK26D6 treated) and panel D (NaCl control). 
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4.12.3 Aortic distensibility  
Using an ECG-gated ultrasound image of the abdominal aorta (taken in 
longitudinal section), the distensibility of the aortic wall (defined as the amount it 
moves with each beat of the cardiac cycle) was measured using VevoVasc 
software. As would be expected, the overall distensibility across all groups 
decreased over time as AAA developed, and wall became less elastic (Baseline 
91.92 ± 29.08 1/Mpa falling to 53.11 ± 29.03 1/Mpa, p=0.0001, Figure 48, panel 
A). There was no difference in the change of distensibility over time in those 
mice receiving treatment with MA-TCK26D6 compared with NaCl 0.9% controls 
(MA-TCK26D6 decreased by 37.01 ± 30.19 1/Mpa vs. NaCl 0.9% decreased by 
58.88 ± 37.31 1/Mpa, Figure 48, panel C). 
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Figure 48. Aortic distensibility decreases with AAA formation, but is not affected by TAFI-
inhibition, in the Angiotensin II model of AAA 
Using an ECG-gated ultrasound image of the abdominal aorta (taken in longitudinal section), 
the distensibility of the aortic wall was measured using VevoVasc software. The overall 
distensibility across all groups decreased over time as AAA developed (n=18) Baseline 91.92 ± 
29.08 1/Mpa falling to 53.11 ± 29.03 1/Mpa, p=0.0001, panel A). There was no difference in the 
change of distensibility over time in those mice receiving treatment with MA-TCK26D6 (n=11) 
compared with controls (n=7) (MA-TCK26D6 decreased by 37.01 ± 30.19 1/Mpa vs. NaCl 
decreased by 58.88 ± 37.31 1/Mpa, panels B and C). 
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4.13 Discussion – TAFI-inhibition in the Angiotensin II model of AAA 
The aim of this chapter was to study the role of TAFI and TAFI inhibition in an 
in-vivo murine AAA model, and investigate proteins involved in fibrinolysis in 
plasma and aortic sections from this model.  
A previous study examined the effect of TAFI on AAA development in-vivo by 
using the porcine pancreatic elastase infusion model (PPE model) in TAFI-/- 
mice (Schultz et al., 2010). They showed that TAFI offered some protection 
against AAA formation, as TAFI-/- mice developed larger AAA which were more 
prone to rupture than the wild type. Furthermore, this group provided evidence 
for the role of plasmin in AAA development and rupture, as when TAFI-/- mice 
were given tranexamic acid (a potent inhibitor of plasmin formation from 
plasminogen), AAA formation was reduced and rupture was completely 
abolished.  The Angiotensin II model was chosen for this study. There are 
advantages and disadvantages to all three of the current murine models, as no 
one single model accurately represents the human disease process. The PPE 
model results in a rapid, chemically induced degradation of elastin within the 
aortic wall. Whilst elastin degradation is an integral part of the human disease 
process, it does not appear to be the trigger to AAA formation. The calcium 
chloride model again relies on topical chemical treatment to the aortic wall. 
Unlike the PPE model, where the insult to the aortic wall occurs from the luminal 
surface, in the calcium chloride model, the insult is applied to the adventitial 
surface, and the lumen is relatively protected (apparently the opposite of the 
human disease process). This model again causes degradation of elastin, likely 
through an intense inflammatory process related to the application of calcium 
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chloride. Unlike the PPE model and the Angiotensin II model, however, the 
calcium chloride model only results in a very modest dilatation of the aorta, 
which makes appreciating changes in AAA size as the result of pharmacological 
intervention difficult at a macroscopic level. The Angiotensin II model was 
chosen because, in relation to the fibrinolysis effects seen in AAA, it seemed to 
better model the human disease. In the majority of cases of classical AAA 
associated with atherosclerotic disease, there is not an acute dissection which 
results in AAA formation. However, there is evidence of thrombus formation 
resulting in inflammation and expansion in the human disease, and, as this 
thesis aimed to study a protein related to fibrinolysis, this part of the AAA 
mechanism seemed one of the most important to be able to replicate. In 
addition to this, the Angiotensin II model of AAA results in gross dilatation of the 
aorta which is appreciable on in-vivo ultrasound imaging, and this allowed for 
the in-vivo monitoring of AAA development at serial time points without the need 
for animal sacrifice. The ultrasound imaging of the AAA in-vivo allowed the 
confirmation of the likeness of this model to the human disease. Using 
measures of aortic distensibility, I was able to show that, in line with human 
AAA, the wall of the aorta becomes stiffer as the AAA develops. Whilst there is 
a mortality associated with this model that is higher than in the calcium chloride 
model, the ability to see gross aortic dilatation using USS and thus the ability to 
monitor this in-vivo without the need to sacrifice animals at sequential time 
points meant that overall, animal numbers were comparable to, or even lower 
than, those that would have been required using an alternative model. Finally, 
this model is the only one which demonstrates the sex diamorphism seen in the 
development of AAA in humans, and thus one could argue carried the most 
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physiological similarities. However, if animal numbers were no obstacle, in order 
to properly draw conclusions regarding TAFI inhibition in-vivo, all three models 
should be studied in relation to TAFI. This would require the production of a 
TAFI/ApoE-/- for the Angiotensin II model, and a TAFI-/- for the calcium chloride 
and PPE models. The PPE model and the calcium chloride models would then 
be repeated in wild type mice treated with MA-TCK26D6. Clearly, such studies 
are beyond the scope of this thesis. 
Previous work from our laboratory has shown that there is a difference in the 
clot structure and fibrinolysis in patients with AAA compared with control 
subjects (Scott et al., 2011). As a result, the fibrin clot structure of clots 
produced using plasma taken from mice developing AAA in the Angiotensin II 
model was studied in relation to plasma from controls. The fibrin clot structure in 
mice with AAA, however, was not different from controls, suggesting that the 
changes in fibrin clot structure seen in humans is the result of a more complex, 
chronic disease process. The mice used for this study were only treated with 
Angiotensin II for 28 days. As most AAAs in humans develop over a period of 
years, it may be that the more rapid expansion seen in this model did not allow 
for the development of the pathological clot structure that can be found in the 
human disease state.   
The downstream effects of Angiotensin II include vasoconstriction, increased 
sympathetic nervous system activity and the increased secretion of aldosterone 
(Peach, 1977), all of which contribute to hypertension in mice treated with 
Angiotensin II. In this study, however, there was no effect of Angiotensin II 
infusion on blood pressure. Blood pressures were taken over several days 
beginning at day 8 following the commencement of Angiotensin II infusion. 
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Recent studies have shown a clear increase in the blood pressure (BP) of 
ApoE-/-mice treated with Angiotensin II, which proceeds over the first 7-10 days 
of the infusion, and is then maintained (i.e. the hypertension is not a transient 
effect) (Haggerty et al., 2015). There are several reasons why this effect may 
not have been detected in this study. Firstly, BPs were measured using a 
volume/pressure tail cuff system. Although this has its advantages, as it is 
simple and non-invasive, it can have limited accuracy (Feng et al., 2008, Kurtz 
et al., 2005, Whitesall et al., 2004). Another option would have been telemetry, 
which has a greater degree of accuracy, but requires an invasive procedure for 
implantation (which carries its own associated mortality), requires very precise 
placement, and is expensive. Although telemetry is more accurate for 
measuring mean arterial pressures and pulse pressures, systolic blood 
pressure measurements are generally consistent between the two techniques 
(Haggerty et al., 2015). Secondly, the work in this chapter used a dose of 
Angiotensin II of 750 ng/kg/min. In the literature, doses of Angiotensin II used in 
this model of AAA vary from 500-1000 ng/kg/min, with the majority of studies 
choosing 1000 ng/kg/min. The reason a slightly lower dose was chosen in this 
instance was to attempt to minimise mortality associated with aortic rupture. 
When a dose of 500 ng/kg/min is used, there is no effect on BP (this is seen to 
be a ‘subpressor’ dose), and AAA formation rates are around 50% (Cassis et 
al., 2009). In fact, it has been demonstrated that the AAA formation associated 
with Angiotensin II infusion occurs via a mechanism which is independent of 
BP, as AAA still occur even when anti-hypertensive medication is administered 
alongside Angiotensin II (Cassis et al., 2009). Ultimately, it may be that the dose 
of Angiotensin II used in this study (750 ng/kg/min) remains in the subpressor 
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range, and so no obvious increase in BP with Angiotensin II infusion could be 
detected. 
For the purposes of this thesis, TAFI was inhibited in-vivo using two different 
inhibitors. The first, MA-TCK26D6 is a monoclonal antibody that specifically 
inhibits plasmin-mediated TAFI activation. As such, it is likely that this inhibitor 
will only be active in areas of high plasmin(ogen) concentrations, such as within 
any thrombus that is formed. The mice treated with this inhibitor would also 
have retained the anti-inflammatory properties of TAFI. The second inhibitor, 
UK-396082, has previously been extensively characterised in-vivo and is an 
inhibitor of all active TAFI. Whilst the dosing of both of these inhibitors was 
based upon previous studies, in comparing the effect of these two inhibitors in-
vivo it is hard to know if they were given at equivalent pharmacologically 
effective concentrations. Two inhibitors of the same kind, given by the same 
route, but with different inhibitory targets (such as two monoclonal antibodies 
targeting different activities of the TAFI molecule), would probably have allowed 
for more accurate comparisons to be made between the two groups.  ROTEM 
was used to test for the effects of the TAFI inhibitors in-vivo. Whilst this has 
been used in recent years to measure TAFI activity in whole blood samples 
from mice (Mishra et al., 2014), both this and studies of plasma lysis are not 
particularly sensitive to subtle changes in TAFI activity (Foley et al., 2013). Even 
using a commercially available substrate method to measure TAFI activity may 
not have proved more accurate due to the  interference of the other plasma 
carboxypeptidase, carboxypeptidase N (Foley et al., 2013). 
Despite these issues, there was clearly an effect of the TAFI inhibitors on this 
model of AAA. In both cases, the mortality associated with the Angiotensin II 
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model of AAA was decreased. This suggests that clot formation and resistance 
of this clot to fibrinolysis early in the Angiotensin II model somehow increases 
the likelihood of aortic rupture. It may be that the prevention of clot formation at 
the site of dissection results in a decrease in the inflammatory response usually 
seen at this early stage, and thus prevents further damage to the aortic wall. 
The difference in the development of AAA with each inhibitor implies that later in 
the disease process, the route by which TAFI is activated is important. Using 
MA-TCK26D6, plasmin-mediated activation of TAFI is inhibited. Mice treated 
with this inhibitor had a reduction in the incidence of AAA development 
compared to mice receiving Angiotensin II alone. However, mice receiving UK-
396082, an inhibitor of all active TAFI, had an increase in the incidence of AAA 
development. This pattern is more akin to the results of the PPE model in the 
TAFI-/- mouse. Taken together, these results seem to suggest that whilst the 
prevention of clot formation early in the development of AAA seems to prevent 
rupture associated mortality, the later stages of AAA development in this model 
rely on an inflammatory response at the site of injury. When the anti-
inflammatory properties of TAFI are intact, and clot formation is prevented using 
MA-TCK26D6, there was a reduction in mortality and a reduction in AAA 
formation. However, when a global TAFIa inhibitor was used, clot formation was 
prevented, but there would have been no TAFI-related inhibition in the 
inflammatory response at the site of dissection, and thus AAA formation 
proceeded even without the initial clot formation. This hypothesis is also 
supported by the results of the mice given a dose of MA-TCK26D6 after AAA 
formation. In this group, clot formation at the site of injury and subsequent 
inflammation would have progressed in a normal fashion. Once this process 
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had occurred, the addition of a TAFI inhibitor preventing further plasmin-
mediated TAFI activation had no effect, because the inflammatory response 
resulting the AAA formation and expansion was already established. This theory 
is further supported by the data relating to the levels of TAFI in the aortic wall. 
The levels of TAFI within the aortic wall of mice developing AAA was extremely 
low, and no higher than that in controls. This suggests that whilst TAFI may be 
important in the initial stages of this model, when clot formation occurs, beyond 
this stage, it appears that inflammation, or other factors at play in the AAA wall, 
may be more important than plasmin-mediated processes. 
Plasma levels of CRP were measured in the mice in an attempt to quantify the 
potentially increased inflammatory process that may have been at work in mice 
treated with Ang II in combination with UK-396082 but not in the mice treated 
with Ang II in combination with MA-TCK26D6. However, unlike in humans, 
murine CRP is not an acute phase reactant (Ku and Mortensen, 1993), and so 
could not necessarily be expected to increase in line with such a localised 
inflammatory process. Indeed, the measurement of more specific inflammatory 
substrates of TAFI, such as C3a or C5a, may have provided a more specific 
measure of the effect of TAFI inhibition on inflammation in this model.  
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Chapter 5 Overall Discussion and General Conclusions 
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5.1 General Discussion 
The aim of this thesis was to explore TAFI and its relationship with AAA. AAA is 
just one disease in a spectrum of cardiovascular diseases that, despite ongoing 
research and tireless health campaigning, remain a major global health 
problem. AAA is often not an isolated disease, and patients with AAA are 
frequently affected by a number of other atherothrombotic cardiovascular 
diseases, such as coronary artery disease and stroke, and in fact, are at 
significant risk of cardiovascular death (Brady et al., 2001). A pathological 
change in fibrin clot structure, towards a denser clot with smaller pores that is 
more resistant to lysis, is evident in patients across the whole spectre of 
cardiovascular diseases, and is even evident in the healthy relatives of patients 
with disease (Mills et al., 2002, Bhasin et al., 2008). The aetiology of this 
remains poorly understood; in many cases, whether such changes are cause or 
effect is yet to be fully determined (Bridge et al., 2014b). In line with all 
cardiovascular disease, the fibrin clot structure is altered in patients with AAA, 
and they show denser ex-vivo clots, with smaller pores, and an increased 
resistance to lysis (Scott et al., 2011).  
It is not fully understood what triggers the formation of AAA in humans. With the 
advent of the UK national screening programme, more patients will be 
diagnosed with AAA in its early stages. For this group of patients, an important 
target seems to be the development of a pharmacological therapy that would 
prevent, or at least slow, AAA expansion. By doing so, even if the incidence of 
AAA remains unchanged, the incidence of those reaching the threshold for 
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surgery would be dramatically reduced, and, in line with this, the incidence of 
AAA rupture would also be reduced. 
TAFI is intricately involved in the prevention of fibrinolysis. Acting as an indirect 
inhibitor of plasmin, it cleaves C-terminal lysine residues from partially degraded 
fibrin molecules, thus removing the site of co-localisation of plasminogen and 
tPA, and preventing the production of plasmin. TAFI is therefore of interest 
when investigating the cause of the resistance to lysis that can be observed in 
patients with AAA. Previous research in this area is very limited, consisting of 
only two studies. Both were based on very small populations, and, in both, 
methodological oversights may result in some discussion as to the validity of the 
results. The first measured TAFI zymogen levels in patients with ruptured 
(n=10) and non-ruptured (n=17) AAA, and quoted extremely high TAFI levels in 
both groups (in some cases >50 μg/ml), which fall outside the reference range 
of the commercially available ELISA which they employed. Furthermore, they 
failed to include a control group, and so whether these values are a reflection of 
extremely high TAFI levels in patients with large AAA, or an error related to the 
assay, is unclear (Hobbs et al., 2007).  The second study to date compared 
TAFI activity in plasma from patients with AAA (n=32) and control subjects 
(n=45), and, using a commercially available chromogenic assay, found a 
reduction in TAFI activity in AAA patients compared to controls (Dubis et al., 
2014). Neither of these studies related TAFI levels or activity to the functional 
Thr325Ile polymorphism. The work in this thesis has provided more robust 
evidence for the potential role of TAFI in human AAA. By using a large study 
population with more than two hundred patients and controls, the study was 
adequately powered to detect even small differences between the two groups. 
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By measuring as many TAFI isoforms as possible by ELISA (intact TAFI 
zymogen, TAFIa/TAFIai and TAFI activation peptide), I was able to better 
appreciate the role of TAFI in human AAA. For instance, if TAFI zymogen levels 
alone had been measured, one might conclude that there was no role for TAFI, 
as plasma levels were comparable between AAA and controls. However, by 
including the ELISAs of both TAFIa/TAFIai and TAFI activation peptide, a 
significant role for TAFI became more apparent. There is currently no perfect 
method for the determination of TAFI activity in human plasma (Foley et al., 
2013). In this thesis, a decrease in TAFI activity was demonstrated using a clot 
lysis assay, confirming the results of the only previous study, which employed a 
chromogenic substrate technique (Dubis et al., 2014). These results in 
combination may at first appear contradictory, with evidence of increased 
activity in-vivo through increased plasma levels of TAFIa/TAFIai and TAFI-AP, 
but a decrease in activity in the in-vitro assay despite normal TAFI zymogen 
levels. One hypothesis is that overproduction of TAFI in-vivo in patients with 
AAA (which keeps total zymogen levels within normal limits) may result in the 
production of some TAFI which is less functional, and therefore cannot be 
activated in-vitro. Another explanation is that in the AAA patients, other plasma 
proteins may be up or down regulated and lead to an interference in the TAFI 
activity assay, which does not occur for the controls.  
AAA disease is clearly a complex and multi-faceted disease. It is therefore 
entirely plausible, and in fact, probable, that the alterations seen in fibrinolysis in 
the ex-vivo clots of patients with AAA are the result of the interaction of a 
number of different plasma proteins. In order to generate novel hypotheses and 
direct potential next avenues for study, polymorphisms of proteins involved in 
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the fibrinolysis pathway were investigated in patients with AAA and controls. 
Clearly, a study such as this is not designed to be able to identify candidate 
genes for AAA, but instead, this study was used to highlight which other 
proteins may be of potential interest for further study. The Arg407Lys 
polymorphism of α2AP was found to be negatively associated with AAA. 
Plasmin-antiplasmin complexes have previously been suggested as a potential 
biomarker for expansion and rupture in patients with AAA (Moris and 
Georgopoulos, 2013). Studies into the role of α2AP in AAA have now been 
commenced in the LEADS population.  
In addition to the study of humans with AAA, this thesis also investigated the 
effect of TAFI inhibition on AAA development using an in-vivo murine model. A 
single previous study in this area had used a PPE model of AAA, and 
demonstrated an increase in the incidence of AAA and rate of rupture in TAFI-/- 
mice (Schultz et al., 2010). In order to be able to investigate, model, and 
manipulate human disease states, the scientific community is highly reliant on 
animal studies. For AAA, models have been created in a number of species. A 
canine model of AAA has been employed to investigate endovascular therapies. 
This model involves the balloon dilatation of a polytetrafluoroethylene (PTFE) 
graft ex-vivo, which is then implanted in place of the infra-renal aorta (Chaer et 
al., 2006). Early porcine models were created by mechanical disruption of the 
external aortic wall via a crushing injury (Zatina et al., 1984). These large animal 
models of AAA have proved particularly useful in evaluating the short term 
success of surgical interventions. The problem with creating an animal model of 
AAA is that the initial stages that result in the human disease are not fully 
understood, and so it is difficult to develop a model to represent them. Clearly, 
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these large animal models, based on mechanical injury to the aortic wall, whilst 
useful for evaluating the technical success of surgical treatments, do not 
provide the opportunity to study the mechanisms related to AAA development. 
To this extent, three murine models have been developed and are currently 
used to study AAA in-vivo. These are the calcium chloride model, the PPE 
model and the Angiotensin II model, and all three are described in detail in 
Chapter 1. The advantages of these models over larger animal models are that 
they provide the opportunity to study the early stages of AAA development. 
However, as the initial stages of human AAA development are not known, the 
debate remains as to which model best replicates the human pathology 
(Bruemmer et al., 2011). 
There are advantages to using murine models in the study of human disease. 
The murine genome is remarkably similar to the human genome (Waterston et 
al., 2002), and can be easily manipulated to mimic human disease states. Mice 
are the smallest mammals available for laboratory study, have a short 
generation time, and an accelerated life span (with one mouse year being 
equivalent to over 30 human years), making them a cost effective and efficient 
model for study.    
The initial results from the in-vivo part of this thesis proved interesting. TAFI 
was inhibited through two different mechanisms with conflicting results. Whilst 
both resulted in a decrease in mortality, it was only the inhibition of plasmin-
mediated activation of TAFI that resulted in a decrease in AAA incidence. Using 
UK-396082, a global inhibitor of all active TAFI, proved consistent with the 
TAFI-/- mouse with regards to AAA formation, since the incidence of AAA was 
dramatically increased in mice receiving UK-396082. Both of these inhibitors 
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were given at the initiation of AAA in the model, and although this may offer 
insight into the importance of clot formation in the early stages of the disease, it 
cannot be directly applied to a therapeutic agent for AAA disease in humans, as 
any treatment would only be commenced once an AAA was established. In fact, 
as a result of the data relating to the delayed treatment with MA-TCK26D6, the 
relevance of a TAFI-inhibitor in the treatment of human AAA disease has to be 
brought into question. The results of this study showed that delayed treatment 
with MA-TCK26D6 once a AAA was established had no effect on AAA 
expansion. Even with the suggestion that there may be a number of the 
inhibitors of plasmin involved in the pathological clot structure observed in AAA, 
as TAFI-inhibition had no effect on expansion, it may be that in late AAA 
disease, one, or several, of the other mechanisms related to AAA development, 
beyond those involved thrombosis and fibrinolysis, may to be a better target for 
pharmacological intervention. This does not, however, rule out the importance 
of further investigation into thrombosis and fibrinolysis in this group of patients. 
Independent of all other risk factors, the incidence of myocardial infarction and 
cardiovascular related death in patients with AAA is increased compared with 
the general population (Brady et al., 2001). Whilst TAFI may not be a 
therapeutic target when it comes to preventing the expansion of AAA, the 
results described in Chapter 3, showing that there is evidence of increased 
TAFI turnover in patients with AAA, and that the delay in fibrinolysis in this 
patient group can be corrected using a TAFI inhibitor, suggest that TAFI may 
still be an important target in protecting this patient group against 
cardiovascular-related mortality. 
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5.2 General Conclusions 
In summary, there are several main conclusions to be drawn from this thesis. 
Firstly, I have shown that there is evidence of an increase in TAFI turnover in 
patients with AAA. Secondly, the delay in lysis seen in ex-vivo clots of patients 
with AAA (Scott et al., 2011) can be corrected through inhibition of TAFI, 
implying that TAFI may have a role in the systemic changes in fibrinolysis 
observed in this patient group. Thirdly, the pathological fibrin clot structure seen 
in patients with AAA appears to be related to the chronicity of AAA disease, 
rather than simply being a result of the presence of AAA, as demonstrated by 
the normal ex-vivo fibrin clot structure of mice with AAA. Finally, I have shown 
that, in the Angiotensin II model of AAA, TAFI-inhibition protects mice from the 
mortality associated with the model. Further to this, specific plasmin-mediated 
TAFI inhibition in-vivo also prevents AAA formation during the initial stages of 
the Angiotensin II model of AAA, but has no effect on the expansion of an 
already established AAA. 
5.3 Future Work 
Until a pharmacological target for the prevention of AAA development and 
expansion is identified, there will continue to be active interest in research into 
AAA formation and development. This thesis has explored the potential role of 
TAFI in some detail, and has rejected TAFI as a suitable target for the 
prevention of AAA expansion in human disease. Based on the results of the 
α2AP polymorphism Arg407Lys, investigation into α2AP levels and cleavage 
rates in the plasma of patients with AAA is already underway. The pathological 
clot structure observed in this group of patients, however, is yet to be fully 
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investigated, and perhaps changes to the fibrin clot itself, rather than proteins 
involved in its regulation, might hold the key to ‘normalising’ the pathological clot 
structure. Whilst the ex-vivo clots of patients with AAA, and indeed patients with 
cardiovascular disease in general, show a denser, stiffer structure that is 
resistant to lysis, which of these two pathological features (i.e. stiffness or 
resistance to lysis) is most important in disease has not been elucidated. As 
such, further work to specifically investigate stiffness and/or resistance to lysis 
of fibrin clots in AAA is already underway. Several programmes of work are 
planned. The first will use a number of new transgenic murine models, focusing 
on three main areas; defective fibrin formation, reduced fibrin mechanical 
stability, through alterations of fibrinogen gamma chain cross-linking, and 
decreased resistance of fibrin to fibrinolysis. The second programme of work 
will consider related aspects of fibrin biology via a different approach. Rather 
than using a number of specific murine strains, this programme will employ the 
hydrodynamic gene transfer of mutant fibrinogen α-chain cDNA in the fibrinogen 
knock out mouse. The cDNA will be mutated to prevent firstly α-chain/α-chain 
cross-linking, and then α2AP cross-linking, and compare clot formation and lysis 
in-vivo with each of these alterations individually, and then in combination, 
before assessing the effect on AAA formation.  These studies will aim to identify 
which structural and functional characteristics of the fibrin clot play key roles in 
aneurysmal disease. It will also help to identify whether or not targets altering 
fibrin formation and stability could be possible therapeutic targets for 
aneurysmal disease.  
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Appendix 1 - Protocol 
Background 
An abdominal aortic aneurysm (AAA) is a focal dilatation of the abdominal aorta greater than three 
centimetres in maximal diameter. The condition spontaneously evolves towards rupture, which confers a 
mortality risk in the region of 80% despite emergency surgery. The current principles of management 
involve watchful waiting with targeted intervention once the annual risk of rupture outweighs the mortality 
risks of intervention. This treatment threshold is currently set at 5.5 cm in otherwise fit patients. Open 
aneurysm repair (OAR) or endovascular aneurysm repair (EVAR) are both suitable treatment modalities. 
The clinical risk factors for AAA include male sex, smoking, high blood pressure and age; diabetes is 
thought to be protective. Although atherosclerosis clusters with AAA, it’s precise role in aneurysm 
development remains unclear. The pathobiology of AAA incorporates transmural inflammation, loss of 
vascular smooth muscle from the arterial media, over production of matrix metalloproteinases which 
destroy collagen and elastin. Acting in concert these factors lead to aneurysm formation, but the precise 
event that precipitates this process remains unknown. Furthermore, the factors which influence the 
ongoing growth of AAA once established are debated. It is also apparent that patients with AAA are at 
increased cardiac risk, but how this cardiac risk is related to the presence of AAA is also unclear. 
Aims 
The overall aim of the LEADS project is to investigate AAA development, growth and outcomes, and thus 
identify novel treatments.  In order to do this, a Leeds based AAA database will collect demographic and 
diagnostic information on AAA and control patients and store patients’ blood, DNA, RNA, protein, plasma 
and AAA tissue. 
History 
The Leeds Aneurysm Development Study (LEADS) (Leeds East 03/142) was first established in 2003 as a 
small case-control study (AAA vs. Controls) focused on the differences in inflammatory and coagulation 
markers in male patients with AAA and controls. The important novel findings stemming from this work led 
to the continuation of the study and widening of the inclusion criteria. In 2005 women were invited to 
participate in the study and in 2006 the study minimum age limit was reduced from 65 years to 55 years. 
As the project grew it became apparent that links should be made between the blood results observed at 
recruitment, and aneurysm tissue and post-operative blood samples. Thus, following an amendment to the 
protocol in 2006, these samples were collected for further study.   
As the study grew in size and the findings were disseminated locally, the opportunity arose to collaborate 
with other researchers within and outside of the faculty at The University of Leeds. These new members of 
the research team offered fresh hypotheses relating to the development and growth of AAA. As a result, 
and again following amendments to the protocol in 2008 – 2010 data collected now includes aneurysm 
imaging and growth, genetics, survival and arterial stiffness (pulse wave velocity), with an aim of recruiting 
a total of 1500 aneurysm and 1500 control patients. As specified in the consent form, all participants are 
followed prospectively from the time of recruitment. This offers extensive information as to the dynamics of 
aneurysm expansion (by analysing serial USS and CT scans), AAA prognosis and patient survival. In 
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addition, an application has been submitted to link to the Office of National Statistics data set in order to 
collect reliable mortality data for our cohort. 
As a result of increasing public health awareness, particularly with regard to smoking and changes in 
medications (statins and ACE-inhibitors), the number of patients with AAA has declined over the last ten 
years. As a result of decreasing patient numbers, but more significantly as a consequence of huge 
advances in endovascular aneurysm repair, the number of people in the UK undergoing open AAA repair 
has vastly decreased. Hence, a collection of aneurysm tissue linked to a data set which includes 
peripheral blood samples, patient characteristics and imaging is undeniably of importance internationally 
as a resource for further research in this area.  Thus even upon completion of recruitment for this study, 
we will have established a valuable resource for continued research into the cause of AAA disease, which 
can be utilized for future medical students, BSc, MD and PhD projects through the Light Laboratories and 
the University of Leeds. 
Study Design and Methodology 
This is a prospective observational study recruiting cases (patients with AAA) and control (patients with 
normal diameter aorta) from a variety of sources. We aim to recruit a minimum of 1500 AAA patients and 
1500 age and sex matched controls in order to allow the use of multilevel mixed effects modelling as part 
of the growth analysis.  
This target will also provide sufficient patients for the genetic polymorphism analysis, which also requires 
significant patient numbers. Depending on the frequency of the genetic mutation of interest, in order to 
achieve at least 80% power with 95% confidence, at least 1000 patients are typically required per analysis. 
In addition, we aim to compare the AAA patient group with a control group to assess the overall impact of 
the risk factors such as cardiovascular disease history or e.g. smoking on the development of AAA. We 
seek to recruit 1500 controls in order to allow effective use of propensity score methods when applied to 
AAA patient subgroups. 
Recruitment of Subjects 
AAA 
Patients undergoing routine ultrasound surveillance for small AAA (3-5.4 cm AAA) and those admitted for 
elective/semi-urgent AAA intervention (>5.4cms) will be recruited from a variety of sources.   
Inclusion criteria for AAA.  
 Caucasian 
  Age ≥ 55 years 
 Aortic Diameter on Ultrasound (30mm) 
  Able to provide informed consent.  
Exclusion criteria for AAA 
 Non Caucasian – very low incidence 
Page | 221  
 
 Age <55 years – very low incidence 
Control 
Controls will be recruited from a variety of sources comparable with the initial source of referral of the AAA.  
These will include Vascular Surgery Out-patients Department (OPD), General Surgery OPD, Urology OPD, 
Cardiology OPD, Neurology and Diabetes OPD and General Practitioners in addition to volunteers who 
come forward as a result of advertisements in Trust and local media. All controls will have imaging of their 
abdominal aorta (ultrasound or CT scan) to confirm an anterio-posterior diameter of less than 30 mm.   
From the results of previous ultrasound screening programmes, a normal aorta (<30mm) at age 65 
ensures that the patient is most likely to be free of an aneurysmal dilatation for life. The exact scanning 
protocol for control subjects may be changed in order to match with guidelines laid out by the National 
Abdominal Aortic Aneurysm Screening Programme. 
Inclusion criteria for controls 
 Caucasian 
  Age ≥ 55 years 
 Normal Aortic Diameter on Ultrasound (<30mm) 
  Able to provide informed consent.  
Exclusion criteria for controls 
 Non Caucasian – very low incidence 
 Age <55 years 
Consent 
Participants will be welcomed to take part at any time. Typically, participants are invited to participate at an 
outpatient clinic and provided with the patient information leaflet (enclosed). They are then given at least 
24 hours (but typically one week) to consider participation before being contacted by the senior research 
nurse to arrange recruitment. Written, informed consent will be obtained at recruitment (usually during a 
recruitment visit or occasionally on attendance for vascular surgery inpatient treatment) using a 
standardised written consent form (as enclosed).  Consent will be taken by the Lead Research Nurse, by 
the Chief Investigator and by the Chief investigators research fellows, as he deems appropriate. All those 
taking consent will have undergone NIHR approved Informed Consent training, as well as Good Clinical 
Practice training. 
Should an individual who has given consent to take part lose capacity during the study, they would be 
would be withdrawn from the follow up process. Identifiable data or tissue already collected with consent 
would be retained and used in the study. No further data or tissue would be collected or any other 
research procedures carried out on or in relation to the participant. 
Demographics, Medical History, Anthropometrics, Haemodynamics, Doppler & Arterial Stiffness 
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At the recruitment visit, patients will complete a standard proforma (enclosed) documenting demographics, 
medical history, drug history, social history and family history. The questionnaire is completed via 
structured face to face interview with a member of the research team. Following this, a full patient 
assessment is undertaken. This comprises: 
 Measurement of systolic and diastolic blood pressure with oscillometric cuff 
 Measurement of height and weight, and calculation of Body Mass Index (BMI) 
 Measurement of abdominal circumference, hip circumference and waist circumference 
 Ultrasound scan of the abdominal aorta (see below) 
 ECG 
 Palpation of peripheral pulses, Doppler of peripheral pulses and calculation of ankle-brachial 
pressure index (ABI) 
 Arterial Stiffness measurement using Vicorder (see below) 
Blood Sampling & Analysis 
Venous blood is taken from the antero-cubital vein from the non dominant arm. A tourniquet is applied to 
aid identification of the vein, and inflated to 40mmHg. Once the needle position is confirmed within the 
vein, the tourniquet is released, and the first 10mls of blood are discarded, as per the laboratory protocol 
for all clotting studies. 50mls of free flowing venous blood is collected. 
As part of their routine clinical care, blood samples are sent to the Leeds Teaching Hospitals NHS Trust 
Pathology Lab for routine tests. These results are then fed back to the supervising clinician or general 
practitioner. The remainder is transferred within 30mins to the Laboratory for processing and storage prior 
to experiments. This consists of 11ml of blood on room temperature citrate, two 6ml samples on EDTA, 
10ml of blood on cold citrate and 3ml of blood on cold heparin.  
1.2ml of the room temperature blood is put through the ROTEM device in order to elicit an immediate 
measurement of coagulation through the intrinsic and extrinsic pathways. The remainder is then 
centrifuged; the two cold samples are spun at 4000rpm for 30mins at 4 °C and the room temperature 
sample at 4000rpm for 20mins at room temperature. The resultant plasma is aliquoted and flash frozen in 
liquid nitrogen, before being stored at -80°C.  
This plasma is used for all coagulation studies and screens for biomarkers of AAA and cardiovascular 
disease. 
The two EDTA tubes each containing 6mls of whole blood are stored at -20°C to be used for DNA and 
RNA extraction. A grade D research technician (Fraser Macrae, BSc) is responsible for the processing and 
initial analysis of blood samples.  
For patients and controls who fulfill any of the following secondary exclusion criteria, blood is only taken for 
DNA, RNA and protein extraction and analysis, so as not to bias results of any coagulation studies. These 
criteria are: 
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 Recent Surgery (less than 3 months) 
 Active chronic inflammatory conditions  
 Recent Thrombotic (arterial and venous) event (less than 3 months) 
 Anticoagulation treatments; Warfarin, Factor Xa inhibitors, Therapeutic Tinzaparin 
 Active malignancy 
Vicorder 
The Vicorder device will be used to measure arterial compliance and elasticity. This is done by 
simultaneously recording a pulse wave from the carotid brachial and femoral and ankle sites by using an 
oscillometric method. First a neck pad is applied over the carotid artery to prevent compression of the 
trachea and compression of both carotid arteries at the same time. Next the cuff is placed around the 
patient’s right thigh. Both carotid and femoral cuffs are inflated automatically to 65mmHg and the 
corresponding oscillometric signal from each cuff is digitally analysed to extract, in real time, the pulse 
delay. After acquiring several steady pulses the recording is frozen on the display and the transit time in 
milliseconds presented. The distance between the upper edge of the right femoral cuff and the sternal 
notch minus the distance between the lower edge of the carotid cuff and the sternal notch is recorded and 
entered into the computer and displayed as PWVcf (pulse wave velocity common femoral). The procedure 
is then repeated with the cuff at (i) brachial and femoral and (ii) brachial and ankle.  If the pulse wave is 
poor on one side the cuffs will be switched to the opposite side. Further details can be seen at 
www.dopstudio.co.uk. The recording takes just over one hour and no patients have reported any adverse 
effects.  
Imaging 
All subjects (AAA and controls) will undergo ultrasound examination of the abdominal aorta (maximum 
anteroposterior (AP) diameter, position and area of ILT) at the university. The results of these scans are 
initially stored on the hard drive of the ultrasound machine in an anonymised format, before being 
transferred to a secure university server for long term storage.  This ultrasound examination at recruitment 
will be separate to any AAA surveillance the patient undergoes at the Leeds Teaching Hospitals NHS 
Trust. We will ensure all patients with AAA are enrolled in a suitable surveillance programme if they wish 
as part of the National Abdominal Aortic Aneurysm Screening programme (NAAASP). Following 
recruitment in the study and initial USS examination at the University, subsequent aortic imaging (USS, 
Colour Doppler USS, CTA, MRA, Angiography) reports will be obtained from the Leeds Teaching Hospitals 
NHS Trust secured results server and added to the anonymised database held within the University.  
As patients reach their intervention threshold all patients will undergo further imaging, usually CT, or if 
contraindicated, MRA, as part of the routine NHS care within the Leeds Teaching Hospitals NHS Trust. 
The images are stored on a secured, limited access PACS system. We will transfer anonymised CT 
images to CD to allow transfer of images to the University where they will be analysed in the department of 
Biomechanical Engineering using relevant software. This work involves the segmentation, mapping and 
ultimately geometric analysis of the AAA and the ILT in three dimensions. The aims of this work are: (1) 
compare the ultrasound and CT/MRI, (2) to study the force and stresses upon the wall, (3) to study the 
flow through the aorta and (4) to model the impact of a metal stent on the aorta. Non-identifiable patient 
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images will be stored on the encrypted University server only. The CDs containing these images will be 
stored in a limited access locked room in the University accessible to the lead research nurse and the PI. 
All patients recruited as control subjects will also undergo USS at the University. They will be counselled 
as to the potential implications of finding an incidental AAA in the same manor as patients attending 
NAAASP visits at the Leeds Teaching Hospitals NHS Trust. Any control patients found to have an AAA will 
pass into the AAA group and will be enrolled in the Leeds Teaching Hospitals NHS Trust AAA surveillance 
protocol. 
Growth modelling 
It is well established that once an AAA has developed it tends to grow with time, however, the pattern of 
growth is much more unclear. AAA measurements obtained from the Leeds Teaching Hospitals NHS Trust 
server from patients enrolled in the study will be used for this analysis by a team of biostatisticians led by 
Dr Paul Baxter. The statistics team will only have remote access to blinded data (see below) for their 
analyses. Growth modelling work will use multilevel mixed effects models to characterise the growth of 
AAAs within patients. Linear mixed models with random slopes and intercepts can be considered a 
reasonable basic model. However, more complex non-linear mixed models of quadratic and logistic growth 
are also of interest. As an alternative, allowing for autocorrelation in residuals from a linear mixed model 
will be used as a simple strategy for modelling non-linearity in growth. Autocorrelation can be addressed 
by Box-Jenkins autoregressive moving average (ARMA) structures or contrasted with a spatial 
autocorrelation model that allows for unequal spacing of observations through time. Growth mixture 
modelling will provide an alternative, experimental strategy, for characterising growth. Modelling with 
propensity score matched controls is likely to use techniques including linear and generalised linear 
models with multilevel and latent variable techniques, where appropriate, to respect complex data 
structures. 
Operative Samples 
In those patients who require open surgery, the following samples will be taken (1) abdominal aortic wall, 
(2) Intra-luminal thrombus, and (3) blood from the AAA sac. All of these samples are normally discarded at 
the time of surgery.   
In those patients who require endovascular stenting a blood sample will be obtained from (i) the sheath 
placed in the femoral artery and (ii) a catheter placed in the AAA sac. The sheath and passage of the 
catheter through the AAA are part of the normal procedure; blood is normally aspirated from these sheaths 
/catheters and then flushed with heparinised saline. 
Follow-up 
1. Control patients 
There is no routine follow up for the purposes of this study. 
2. Small AAA 30-54mm 
In addition to the NHS follow up US scans (see above), those patients with a small AAA 30-54mm will be 
invited to return at yearly intervals (until the AAA exceeds 55mm) to update their demographic data and 
medications and to give a repeat blood sample. 
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3. Large AAA >55mm at recruitment in those suitable for elective repair 
Those patients who undergo a successful AAA operation (Open or Endovascular) will be recalled back to 
the LIGHT, University of Leeds (if they are fit and well) or we can visit them at home after 3 and 12 months 
for a repeat blood sample and a repeat ultrasound examination of the AAA repair site. Previous large scale 
studies have demonstrated that patients return back to a normal quality of life after 3 months and as such 
the majority would be fit enough to travel. Post operative imaging undertaken as part of routine clinical 
care as outlined by LTHT protocols will be accessed electronically by the research team. 
4. Large AAA >55mm in patients who have declined/been turned down for intervention 
The medical results server held by the LTHT will be accessed annually for blood results (including Hb, 
WCC, Plts, Clotting, U&E, CRP and Creatinine and Lipid Profile) and/or any subsequent relevant imaging 
in order to track AAA growth. In addition, should they wish to return, these patients are also invited back on 
a yearly basis in order to update their demographic data and medications and to give a repeat blood 
sample. 
At recruitment, consent is taken for all patients and controls to be followed up through Hospital Episode 
Statistics (HES), Office of National Statistics mortality data (ONS) and The Myocardial Infarction National 
Audit Project (MINAP) to allow collection of relevant information regarding patient outcomes, specifically 
relating to cardiovascular morbidity, and mortality. 
Laboratory Methods 
Plasma levels of TAT, F1+F2, D-dimer, TAFI, PAI-I AG, tPA Ag, plasminogen, alpha2-antiplamin, MMP’s, 
insulin and proinsulin are be measured using ELISA kits as well as commercially available antibodies, and 
fibrinogen is assayed using the Clauss Method. Thrombin generation is measured using the Calibrated 
Automated Thrombogram (CAT). Other coagulation factors (FVII, FIX, vWF, FXI, FXII) may also be 
measured by ELISA. 
Cardiovascular Disease (CVD) biomarkers would be analysed using relevant biochemical and 
immunological  methods.  
Measurement of plasma glucose and lipid sub-fractions are carried out in the routine laboratories of the 
Chemical Pathology department of the LGI.  
Insulin resistance is assessed using the HOMA model with fasting insulin/glucose product, which we have 
found to be a subtle indicator of insulin resistance in relatives of type 2 diabetic subjects compared to 
controls. In addition there is evidence that proinsulin is inadequately processed in the presence of insulin 
resistance and that the insulin:proinsulin ratio is a good indicator of underlying insulin resistance. This will 
be investigated as a marker of insulin resistance in these subjects. 
Factor XIII activity is assayed by a method which employs cadaverine incorporation as a surrogate for 
fibrin cross-linking and which has been developed in the Unit of Molecular Vascular Medicine in Leeds. 
Factor XIII A and B subunit antigens will be assayed by in house ELISA. These assays have a sensitivity 
of 0.4ng/ml of Factor XIII A and B subunits with an intra-assay coefficient of variation of 4% and 6% 
respectively. 
Assessment of fibrin structure/function; Fibrin permeation characteristics 
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Measurement of the permeability of fully polymerised and cross linked fibrin provides structural data 
regarding fibre thickness and the mass-length ratio. This is done by assessing the permeation or Darcy 
constant Ks.
 
The Ks represent the surface of the gel allowing flow through a network and thus provides 
information on the pore structure will be calculated using the following formula:  Ks =  
Q. L .η
 /A t ∆P  where 
Q Is the volume of liquid (ml) with the viscosity η (10
-2
  poise) flowing through a clot with length L (1.3 cm) 
and a cross-sectional area A (0.049 cm
2
) in time t (sec) under pressure ∆ P (dyne/cm
2
).  Duplicate clots 
are formed for each plasma sample, using human thrombin and calcium. Samples are incubated in a moist 
atmosphere for 2 hours to allow for full clot formation and cross-linking. The fibrin clots will be washed with 
0.05 mol/L Tris-Cl , pH 7.5, 0.1 mol/L NaCl, and permeated with the same buffer at a pressure drop of 4 
cm. Flow rate of the buffer through the clots is analysed by measuring total buffer filtrate at 30minute 
intervals.  
Fibrin polymerisation 
Fibrin polymerisation will be studied by following generation of turbidity at 350 nm over the time course of 
clot formation.  Turbidity analysis provides kinetic information regarding the lag period and rate of fibrin 
polymerisation, in addition to fibre thickness, which can be calculated from the maximum absorbency at 
complete clot formation.
   
Clot formation of each sample will be triggered in duplicate with thrombin and 
calcium in microtiter plate.  Immediately upon addition of thrombin/calcium, absorbency will be read every 
7 seconds at 350 nm for 15 minutes using a Dynex MRX-TC2 plate reader in kinetic mode. Parameters 
such as lag phase before start of fibrin polymerisation slope of the polymerisation curve (A/min) and 
maximum absorbency at full polymerisation will be recorded. The addition of a fibrinolytic agent (tPA) 
allows for analysis of lysis of the fibrin clot, again reading the absorbency every 7seconds over a period of 
up to 8 hours until full lysis has occurred.  
Visco-Elastic properties 
Fibrin cross-linking by FXIIIa is a strong determinant of the elasticity of the fibrin clot. We have recently 
purchased ROTEM equipment. The ROTEM provides a fully automated method to measure visco-elastic 
properties of the fibrin clot in whole blood samples or in blood plasma.  In collaboration with physics 
(Leeds University) we have also developed magnetic tweezers equipment which we may use to 
investigate visco-elastic properties in more detail. 
Confocal Microscopy 
Fibrin clot structure will be imaged using confocal microscopy. In brief, thrombin and FITC fibrinogen will 
be added to plasma samples, and placed into a 6 channel confocal microscopy plate. After an incubation 
period to ensure full clot formation and fibrin cross linking, the clots can be imaged using the confocal 
microscope. This provides both 2dimensional and 3 dimensional images. In addition to providing detailed 
pictorial representations of the clot, this will also allow accurate measurement of fibre thickness and pore 
size (by taking relevant measurements at known magnifications).  
Scanning electron microscopy.  
Fibrin clot structure will be further investigated by scanning electron microscopy. We will make use of 
electron microscopes (Camscan Series 4 and Camscan CS-44-EX) available in the microscopy suit of the 
Department of Material Sciences at the University of Leeds. Clots will be made as previously described.  
The clot will be extensively washed with 0.067 mol/l Na-cacodylate buffer Ph 7.2, fixed with 2 % 
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gluteraldehyde in cacodylate buffer overnight. Samples will be further processed dehydration using a 
stepwise acetone gradient, critical point drying and sputter coating with palladium-gold.  Each sample will 
be observed in at least 6 different areas for digital image analysis.  Overall clot structure will be analysed, 
in addition to measurement of fibre image analysis.  Overall clot structure will be analysed, in addition to 
measurement of fibre thickness and number of branch points per area using Image software version 1.24 
(Wayne Rasband, National Institutes of Health, USA). 
Molecular Biology 
DNA extraction 
DNA is extracted from the whole blood samples taken at recruitment. Prior to extraction, samples are 
defrosted in a room temperature water bath.  
The process uses a commercially available DNA extraction kit (QIAGEN maxi spin kit). In brief, protease 
and a lysis buffer are added to the whole blood samples, and then incubated at 75°C for 10minutes. 100% 
ethanol is added, and following a thorough mixing stage, the samples are decanted into the QIAGEN spin 
column. They are centrifuged at 3000rpm for 2minutes, and the filtrate discarded. The column is then 
washed in a two stage process, before being transferred into a clean centrifuge tube. The elution buffer is 
added, the column incubated to ensure DNA binding, and two final centrifugation stages are undertaken. 
The concentration of the resulting DNA sample solution is elicited using the Nanodrop reader, at an 
absorbance of 260nm. Samples are diluted to a final concentration of 10ng/µL using DNAase and RNAase 
free TBS, and stored at 4°C. Long term storage of concentrated DNA for future work is at -20°C. 
RNA Extraction 
RNA will be extracted using a standardized TRIreagent protocol. Total RNA is extracted from VSMC using 
Tri-reagent (Sigma), bromocriptine and glycogen. RNA precipitates were re-suspended in water followed 
by DNase 1 turbo digestion at 37oC for one hour. RNA can be quantified using Ribogreen® (Molecular 
Probes, Invitrogen). 0.6ug of RNA is reverse transcribed to cDNA using the Applied Biosystems High 
Capacity RNA to cDNA kit (RT+). 0.6ug is also used for a genomic DNA control in a reaction without 
reverse transcriptase (RT-). Real time PCR is performed using SYBR Green I on a LightCycler (Roche). 
The specificity of PCR is confirmed by performing RT negative control experiments and melt curve 
analysis of PCR products. PCR cycle crossing points (Cp) are determined using a fit points methodology 
(Light Cycler Software 3.5). Relative abundance of target RNA is quantified as compared to the 
housekeeper gene beta actin. 
Protein Extraction 
Vascular smooth muscle cells are collected on ice cold phosphate buffered saline and pelleted at 4oC 
before lysis using Laemmli sample buffer supplemented with complete protease inhibitor (Roche). The 
lysate is centrifuged to remove particulate matter and equal ammounts of protein are separated by 8% 
sodium dodecyl sulphate polyacrylamide gel electrophoresis and transferred onto nitrocellulose 
membrane. Membranes are incubated with blocking buffer for two hours at room temperature followed by 
incubation with primary antibodies of interest overnight at 4oC. Membranes are washed and incubated 
with the secondary antibody of interest. Signals are detected using super signal west pico 
chemiluminescent. 
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Genotyping 
Currently, DNA samples are genotyped for known polymorphisms of Fibrinogen, Factor XIII and TAFI. 
Commercially available probes are used (Taqman Genotyping Assays). Genetic polymorphisms in other 
coagulation and fibrinolysis related proteins will also be investigated.  
In brief, the probe is added to TaqMan Genotyping MasterMix in a 20:1 ratio (henceforth referred to as 
MasterProbe). 2.7µL of MasterProbe and 2.2µL of the diluted DNA (10ng/µL) are added to each well of a 
384 well plate. Two no template controls (containing only MasterProbe) are included on each plate. A 
LightCycler480 is used for programming the real time PCR. Each run consists of 50 amplifications, with 
end-point genotyping following cooling. 
Operative Samples 
Participants undergoing open aneurysm repair at Leeds Teaching Hospitals NHS Trust as part of their 
usual care will be given the opportunity to donate tissue samples as part of the study. All tissue taken as 
part of this process would usually be discarded during the operation. 
Aortic Wall 
A segment of anterior aortic wall will be biopsied at the time of surgery and divided into different transport 
media as follows: (1) Dulbecco’s Modified Eagle Medium supplemented with 10% foetal calf serum and 
1% penicillin/streptomycin transported on ice to Dr Porter’s primary tissue culture lab and (2) sterile 0.9% 
saline, transported at room temperature to the lab for histological analysis. 
Dr Porter and her team will undertake Smooth muscle cell isolation & culture. An explant technique will be 
used to acquire primary vascular smooth muscle cells (vSMC). The media will be isolated and dissected 
into small fragments (1mm
3
) and transferred in 2ml of culture medium to tissue culture flasks and 
maintained at 37
o
C in a humidified incubator in 5% CO2 in air. After 1-2 weeks, vSMC will be observed to 
migrate out from the explants and passaged in order for experimentation. The primary cells will be 
confirmed as SMC by staining for intracellular smooth muscle -actin and myosin heavy chain-2 fibres. 
Isolated vSMC can be used for DNA, mRNA and protein characterisation, in addition to functional and 
phenotypic analysis studies. Functional studies include proliferation, invasion, migration and apoptosis 
assays. Secretory function can be demonstrated with the use of zymography. Phenotypic studies will allow 
the identification of extracellular markers that will help characterise the vSMC.  
Our early work suggests that vSMC isolated from AAA exhibit poor proliferation, reduced migration and we 
have observed a flatter more rhomboid phenotype compared to vSMC isolated from internal mammary 
artery in use in the lab. To further understand the driving forces behind this altered phenotype, the vSMC 
will be used for calcium signalling experiments in conjunction with Prof. Beech using a range of 
pharmacological agents, RNA interference strategies and antibodies. This work will involve isolation of 
mRNA/protein from the cultured vSMC in addition to functional assays as previously described.  
Intraluminal Thrombus  
The material will be fixed in formalin before sectioning on a microtome to allow immunohistochemical 
analysis of blood coagulation and fibrinolysis related proteins.  Blood and tissue samples taken from the 
same patient will be appropriately coded to allow them to be matched during analysis.  
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Data Management 
The LEADS database itself is managed by Thomas Fleming, Data Management Technology Group, 
University of Leeds. All information stored on this database is annonymised. The master database of 
information is stored on a password protected computer in an access-limited area of the university. Access 
to the original database is limited to the database manager, the lead research nurse, and the vascular 
research administrative assistant who works alongside her (David Watson). Access-only use is granted to 
members of the research team at the discretion of the principal investigator.  
 
Identifiable patient information is held only as paper copies, and is kept in a secure, locked drawer in a 
limited access area of the University of Leeds. The lead research nurse (Mrs Anne Johnson) acts as the 
custodian for this information, and is the only one to have access to the identifiable data. Personal 
identifiable information will be destroyed five years after the end of the study. 
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Appendix 2 - Patient Information Sheet 
 
 
Version 1 March 2013 
You are being invited to take part in a RESEARCH study.  Before you decide, it is important for you to 
understand why the research is being done and what it will involve.   
Please read the following information carefully and discuss it with friends, relatives and your GP if you 
wish.  Ask us if there is anything that is not clear, or if you would like more information. 
A leaflet is produced by INVOLVE (Promoting public involvement in NHS, public health and social care 
research)  - www.invo.org.uk gives information about medical research and looks at some questions you 
may want to ask.   
What is the purpose of the study? 
Aortic aneurysm is a common condition where the major blood vessel (aorta) in the tummy dilates like a 
balloon.  The vast majority of patients have no symptoms.  There is some evidence that abdominal aortic 
aneurysms (AAA) run in families and it is unclear whether this risk is due to environmental factors (e.g. 
diet, smoking, high blood pressure etc) or whether a person’s genes may contribute.  
Given time, however, the aneurysm expands and may burst. Of all the cases of ruptured AAA only 10% 
survive emergency surgery compared to 95% who survive elective surgery. The wider availability of 
ultrasound scans as a simple non-invasive method to accurately assess the presence of aneurysms and 
the National Aortic Aneurysm Screening means that in future it is likely that we will identify large numbers 
of subjects with early disease. 
At the present time patients with small Aortic Aneurysms (3.0 – 5.0cm) are followed up by routine 
ultrasound scans every 3-12 months depending upon their size. Once the Aortic Aneurysm exceeds 
5.5cms patients are referred by their consultants for more specialised scanning to assess the suitability for 
treatment. This can be either a CT or MRI/MRA scan.  A CT (Computerised Tomography) scan is a type of 
x-ray examination where a cross sectional picture of the area scanned is produced. Magnetic Resonance 
Scanning (known as MRI/MRA)) is a way of looking inside your body without the use of x-rays.  Instead it 
uses a large magnet, radiowaves and a computer to scan your body and produce a detailed picture.  
Surgery in the form of open or stenting (minimally invasive) is reserved for those patients in whom the 
abdominal aortic aneurysm exceeds 5.5cms in diameter.   
The overall aim of the LEADS project is to investigate AAA development, growth and outcomes, and thus 
identify novel treatments.   
Why have I been chosen? 
You have been chosen because you have an Abdominal Aortic Aneurysm, so called “triple A” 
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Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take part, you will be given this 
information sheet to keep and be asked to sign a consent form. If you do decide to take part, you are still 
free to withdraw at any time and without giving a reason.  This will not affect the standard of care you 
receive. 
 
What will happen if I take part? 
If you are happy to help us with this research project this is what will happen: 
You will have nothing to eat or drink after midnight before your visit. 
You should try not to smoke during this period. 
You will be asked some simple questions about your health. 
You will have cuffs placed around your arm, leg and a pad on your neck which will be used to measure the 
stiffness of your blood vessels. 
You will have a heart tracing. 
You will give a sample of blood (50mls, about 4 tablespoons).  These samples will allow us to study the 
levels of blood sugar, fat and factors in the blood, which cause it to clot. We will also look at the genes 
which are involved in the development of aortic aneurysms and the formation of new blood vessels and 
blood clotting. 
You will have a simple ultrasound test (very similar to the scans that pregnant women have) to measure 
the size of the abdominal aorta.  This is painless and takes 5-10 minutes. In those cases where it is difficult 
to see the aorta we will arrange a separate ultrasound scan at St James’ Hospital, this will be undertaken 
by Dr Michael Weston, Consultant Radiologist. 
The above tests will take place in the clinical research unit of the LIGHT laboratories of the University of 
Leeds. You will be asked to attend for an appointment with a research nurse, which will last just over one 
hour.  We will contact you to confirm a suitable day and time for the assessment. We will send you details 
of how to get to the LIGHT building. 
We will access your electronically held medical records annually. We will register your data with the NHS 
Information Centre and the NHS Central Register so that we can track your progress over the study time 
period. As such your data will be identifiable to us. With your consent, we will also access other nationally 
kept databases, such as including the Office of National Statistics (ONS), Hospital Episode Statistics 
(HES) and the National Myocardial Infarction Audit Project (MINAP), to track any other medical problems 
you may encounter over the period of the study. 
We will write to you on a yearly basis to ask if you would be prepared to return for a further a repeat 
assessment. 
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 If your aortic aneurysm is larger than 5.5cms your consultant will arrange for you to have either a CT scan 
or an MRI scan. This is part of the normal workup to assess how best to treat your aortic aneurysm. We 
would like to have your permission to store these anonymised images and use them at a later date to 
study (1) the comparison between ultrasound and CT/MRI, (2) the force and stresses upon the aortic wall, 
(3) the flow through the aorta and (4) the impact of a metal stent on the aorta. This work will be undertaken 
by Dr Peter Walker (Department of Mechanical Engineering, University of Leeds). 
If you are having an operation for your aortic aneurysm we would ask permission to collect the following 
samples 
(1) fluid between the aortic aneurysm wall and the blood clot 
(2) a blood sample (20 mls) from the aneurysm sac, 
(3) a sample of the wall of the aortic aneurysm and 
(4) the blood clot within the aneurysm. 
 All of these tissues are usually discarded at the time of surgery   
Post operation 
You will be seen in the out-patient department at approximately six weeks following surgery.  
At this stage we will ask if you would be happy for a further sample to be taken at 3 to 6 months post 
operatively.  This could be arranged as a home visit. 
You will have nothing to eat or drink after midnight before your visit. 
You should try not to smoke during this period. 
You will give a sample of blood (50mls, about 4 tablespoons).  These samples will allow us to study the 
levels of blood sugar, fat and factors in the blood, which cause it to clot.  
What are the potential risks from taking part? 
Taking a blood sample is unlikely to cause any problems, although some people experience minor 
discomfort or bruising. 
What are the potential benefits from taking part? 
There are no direct benefits to you for taking part.  In the future we hope that the information we get from 
this study may help us to improve the treatment of patients with abdominal aortic aneurysms.  We will be 
able to assess whether life-style changes and or new drug treatments may help those patients with small 
abdominal aortic aneurysms and relatives at highest risk of developing abdominal aortic aneurysms. 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes available.  In your case this 
may be an increase in the size of your abdominal aorta.  If this happens, your research nurse will tell you 
about it and discuss with you whether you want to continue in the study.  If you decide to withdraw, 
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arrangements will be made for your care to continue.  If you decide to continue in the study you will be 
asked to sign an updated consent form and the necessary information passed onto your consultant 
surgeon and general practitioner. 
What if something goes wrong? 
If taking part in this research project harms you, there are no special compensation arrangements.  If you 
are harmed due to someone’s clinical negligence, then you may have grounds for a legal action but you 
may have to pay for legal advice. Regardless of this, if you wish to complain about any aspect of the way 
you have been approached or treated during the course of this study, the normal National Health Service 
complaints mechanisms should be available to you. 
Will my taking part in this study be kept confidential? 
All information, which is collected, about you during the course of this research will be kept strictly 
confidential.  Any information that leaves the laboratory will have your name and address removed so that 
you cannot be recognised from it.   The blood, fluid and tissue samples taken to look at the proteins and 
genes will be given a study number so that it is impossible in any way to identify you from them. 
You should be aware that the samples of blood, fluid and tissue will be stored in a freezer and may be 
used for future studies at a later date. 
Any abnormalities detected in your blood sugar or fat will be forwarded to you and your general 
practitioner. 
What will happen to the results of the study? 
The results of the study will be published in a variety of surgical journals and discussed at surgical 
meetings. Please note that you will not be identified in any report or publication. 
Who is organising and funding the research? 
The study is based in the Division of Cardiovascular and Diabetes Research at the Leeds Institute of 
Genetics, Therapeutics and Health at the University of Leeds. The study is currently funded by The 
Garfield Weston Trust, Circulation Foundation and the British Heart Foundation. 
Who has reviewed the study? 
Leeds (East) Research Ethics Committee has reviewed the study. 
Contact for further information   
Any further questions regarding the study can be easily answered by calling Anne Johnson Vascular 
Research Nurse 0113 343 7702 or by writing to Professor Julian Scott, Leeds Vascular Institute, Leeds 
General Infirmary, Leeds LS1 3EX   
Thank you for considering whether to take part in this research 
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Appendix 3 - Patient Consent Form  
 
 
Subject Identification Number:  Name of researcher: Prof D J A Scott        
        Anne Johnson                      
                  
1. I confirm that I have read and understand the study information sheet dated  
__/__/__ and have had the opportunity to discuss it with relatives and friends, 
and ask any questions.  
2. I understand and accept that if I take part in the study I may not gain any direct 
personal benefit from it. 
3. I understand that all information collected in the study will be held in confidence 
and that, if it is presented or published, all my personal details will be removed 
from it.  
4. I understand that any blood and tissue samples collected as part of the study are 
given freely as a gift. I consent to my samples being examined for genetic factors 
which are thought to influence the formation of aneurysms. I agree to transfer any 
property rights to the samples I provide to the University of Leeds on the 
understanding that it is only used for research.  
5. I confirm that I will be taking part in this study of my own free will.  I understand 
that I may withdraw from it, at any time and for any reason, without my medical 
care or my legal rights being affected. I understand that if I later decide to 
withdraw from the study, any samples or information already collected from me 
may continue to be used for the purposes of the study, unless I specifically 
withdraw consent for this to happen.  
6. I agree to my electronically held medical records being accessed by the research 
nurses assigned to the study. 
7. I agree to information held about me by other registered databases, including the 
National Office of Statistics (ONS), Hospital Episode Statistics (HES) and the 
National Myocardial Infarction Audit Project (MINAP),being accessed by the 
study team for the purposes of the study. 
8. I agree to participate in this study. 
Name    Signature   Date 
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Appendix 4 - DNA extraction from whole blood using the QIAGEN Maxi-Column 
Kit  
Before starting 
1. Prepare a 70°C water bath 
2. Buffer AW1 should be prepared (mixed with ethanol as indicated on the 
bottle) 
a. Stored at room temp 
3. Buffer AW2 should be prepared (mixed with ethanol as indicated on the 
bottle) 
a. Stored at room temp 
4. QIAGEN protease should be prepared (Add 5.5mls of distilled water) 
5. Blood should be defrosted in a room temperature water bath 
Procedure 
1. Pipette 500µL QIAGEN protease into the bottom of a 50ml centrifuge 
tube (each vial of protease will be enough for 11 blood samples)  
2. Add 6ml of blood (one full pink topped tube) 
3. Add 4ml of PBS 
4. Mix briefly 
5. Add 12ml of Buffer AL (provided in kit), mix thoroughly by inverting the 
tube 15 times then shaking vigorously for a minute.  
6. Incubate at 70°C for 10minutes (incubating for longer will not adversely 
affect the DNA yield) 
7. Add 10ml of ethanol (96-100%) to each sample 
8. Mix by inverting 10 times and then shaking vigorously again 
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9. Transfer half of the solution into the QIAamp maxi column within a 50ml 
centrifuge tube. 
10. Ensure the rim is dry and close the cap 
11. Centrifuge at 1850xg or 3000rpm for 3 minutes 
12. Remove the maxi-column from the centrifuge tube, discard the filtrate, 
ensure the tube is dry and replace the column 
13. Transfer the remaining solution into the maxi-column 
14. Centrifuge again at 1850xg or 3000rpm for 3 minutes 
15. Remove the maxi-column from the centrifuge tube, discard the filtrate, 
ensure the tube is dry and replace the column 
16. Add 5ml of Buffer AW1 to the QIAamp maxi column. Pipette carefully, 
without moistening the rim. Pipette to the side of the column (not directly 
onto the membrane) 
17. Centrifuge at 4500xg or 5000rpm for 1 minute. 
18. Without discarding the filtrate, add 5ml of buffer AW2 to the QIAamp 
maxi column. 
19. Centrifuge at 4500xg or 5000rpm for 15minutes 
20. Place the QIAamp maxi column in a clean 50ml centrifuge tube. 
21. Discard the collection tube containing the filtrate 
22. Pipette 1ml  of Buffer AE directly onto the membrane of the QIAamp 
maxi-column. 
23. Incubate at room temperature for 5 minutes. 
24. Centrifuge at 4500xg or 5000rpm for 2minutes. 
25. Two final steps: 
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a. For maximum concentration of DNA – reload the eluate containing 
the DNA onto the maxi column. Incubate for 5 mins at room 
temperature. Centrifuge at 4500xg or 5000rpm for 5minutes. 
b. For maximum yield of DNA – Pipette 1 ml of fresh AE buffer onto 
the membrane of the QIAamp maxi column. Incubate for 5 mins at 
room temperature. Centrifuge at 4500xg or 5000rpm for 5minutes. 
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Appendix 5 - Angiotensin II Dosing Schedule  
 
1004 
pump
Ang II (750 
ng/kg/min)
Mouse 
Weight 
(g)
Concentration 
for pump (µg/µl) 
angII 
(µg) 
needed 
to make 
120 (µl) 
volume
Stock 
required 
µl 
water 
require
d µl 
20 6.43 771.43 30.86 89.14
21 6.75 810.00 32.40 87.60
22 7.07 848.57 33.94 86.06
23 7.39 887.14 35.49 84.51
24 7.71 925.71 37.03 82.97
25 8.04 964.29 38.57 81.43
26 8.36 1002.86 40.11 79.89
27 8.68 1041.43 41.66 78.34
28 9.00 1080.00 43.20 76.80
29 9.32 1118.57 44.74 75.26
30 9.64 1157.14 46.29 73.71
31 9.96 1195.71 47.83 72.17
32 10.29 1234.29 49.37 70.63
33 10.61 1272.86 50.91 69.09
34 10.93 1311.43 52.46 67.54
35 11.25 1350.00 54.00 66.00
36 11.57 1388.57 55.54 64.46
37 11.89 1427.14 57.09 62.91
38 12.21 1465.71 58.63 61.37
39 12.54 1504.29 60.17 59.83
40 12.86 1542.86 61.71 58.29
to make 120 µl - 
stock 25 µg/µl
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Appendix 6 - Mouse Identification Code 
Mice within the CEU at the University of Leeds undergo ear notching to allow for 
identification of individual subjects housed within the same cage/undergoing the 
same experimental protocol at the same time. 
Represents a site of ear notching 
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Appendix 7 - Histology Processing Protocol 
17 hour processing programme for the dehydration of samples for 
histology 
 
1 70% ethanol 30minutes 
2 70% ethanol 30minutes 
3 70% ethanol 30minutes 
4 90% ethanol 1 hour 
5 100% ethanol 2 hours 
6 100% ethanol 2 hours 
7 100% ethanol 2 hours 30minutes 
8 Histoclear 30minutes 
9 Histoclear 1 hour 30 minutes 
10 Histoclear 1 hour 30 minutes 
11 Paraffin 1 hour 30 minutes 
12 Paraffin 2 hours 
 
 
